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Background: Motivational interviewing (MI) enhanced with behaviour change techniques (BCTs) and
deployed by health trainers targeting multiple risk factors for cardiovascular disease (CVD) may be more
effective than interventions targeting a single risk factor.
Objectives: The clinical effectiveness and cost-effectiveness of an enhanced lifestyle motivational
interviewing intervention for patients at high risk of CVD in group settings versus individual settings
and usual care (UC) in reducing weight and increasing physical activity (PA) were tested.
Design: This was a three-arm, single-blind, parallel randomised controlled trial.
Setting: A total of 135 general practices across all 12 South London Clinical Commissioning Groups were
recruited.
Participants: A total of 1742 participants aged 40–74 years with a ≥ 20.0% risk of a CVD event in the
following 10 years were randomised.
Interventions: The intervention was designed to integrate MI and cognitive–behavioural therapy (CBT),
delivered by trained healthy lifestyle facilitators in 10 sessions over 1 year, in group or individual format.
The control group received UC.
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Randomisation: Simple randomisation was used with computer-generated randomisation blocks. In each
block, 10 participants were randomised to the group, individual or UC arm in a 4 : 3 : 3 ratio. Researchers
were blind to the allocation.
Main outcome measures: The primary outcomes are change in weight (kg) from baseline and change in
PA (average number of steps per day over 1 week) from baseline at the 24-month follow-up, with an
interim follow-up at 12 months. An economic evaluation estimates the relative cost-effectiveness of each
intervention. Secondary outcomes include changes in low-density lipoprotein cholesterol and CVD risk score.
Results: The mean age of participants was 69.75 years (standard deviation 4.11 years), 85.5% were male
and 89.4% were white. At the 24-month follow-up, the group and individual intervention arms were not
more effective than UC in increasing PA [mean 70.05 steps, 95% confidence interval (CI) –288 to 147.9
steps, and mean 7.24 steps, 95% CI –224.01 to 238.5 steps, respectively] or in reducing weight (mean
–0.03 kg, 95% CI –0.49 to 0.44 kg, and mean –0.42 kg, 95% CI –0.93 to 0.09 kg, respectively). At the
12-month follow-up, the group and individual intervention arms were not more effective than UC in
increasing PA (mean 131.1 steps, 95% CI –85.28 to 347.48 steps, and mean 210.22 steps, 95% CI
–19.46 to 439.91 steps, respectively), but there were reductions in weight for the group and individual
intervention arms compared with UC (mean –0.52 kg, 95% CI –0.90 to –0.13 kg, and mean –0.55 kg,
95% CI –0.95 to –0.14 kg, respectively). The group intervention arm was not more effective than the
individual intervention arm in improving outcomes at either follow-up point. The group and individual
interventions were not cost-effective.
Conclusions: Enhanced MI, in group or individual formats, targeted at members of the general population
with high CVD risk is not effective in reducing weight or increasing PA compared with UC. Future work
should focus on ensuring objective evidence of high competency in BCTs, identifying those with modifiable
factors for CVD risk and improving engagement of patients and primary care.
Trial registration: Current Controlled Trials ISRCTN84864870.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 69.
See the NIHR Journals Library website for further project information. This research was part-funded by
the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s
College London.
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Plain English summary
People who have a high risk of heart disease can reduce this risk by changing their lifestyles, such as byimproving their diets and increasing their physical activity levels. However, there is no good evidence on
how best to support people to change and then maintain healthier lifestyles. It is thought that support
from others might be helpful. An intervention based on two talking therapies, called motivational
interviewing and cognitive–behavioural therapy, to help people make a commitment to living healthier
lives was developed. People from the local community with a health-related background were recruited
and trained in these skills. Then general practitioners invited patients on their register who were at high
risk of heart disease to participate. Those patients who replied and met the study criteria were randomly
allocated to one of three arms. Participants received either group- or individual-based intensive lifestyle
sessions or usual care. Those who were randomised to the lifestyle course were offered 10 sessions of
therapy over 12 months by lifestyle trainers. Two years later, it was found that there were no differences in
weight or physical activity levels between the three arms. The lifestyle interventions were not cost-effective
compared with usual care. When the possible explanations were studied, it was found that those who
could have benefited the most from the therapy (such as those who were most overweight, those from
poorer backgrounds and those who were of African Caribbean ethnicity) were less likely to participate.
Whether or not the skills of the therapists made a difference could not be properly assessed. Sometimes,
patients and their doctors were not sure why they were invited. Future research should focus on people
who have lifestyles that can be changed (e.g. more overweight individuals with unhealthy diets), on finding
ways of improving the quality of the intervention and on ensuring that patients have more information.
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Scientific summary
Background
Interventions targeting multiple risk factors for cardiovascular disease (CVD) are more effective than
interventions targeting a single risk factor. Most lifestyle interventions lead to early improvements but are
difficult to maintain longer term. Motivational interviewing (MI) is associated with modest short-term
improvements in diet and physical activity (PA) and is a brief intervention. Adding behaviour change
techniques (BCTs) using cognitive–behavioural therapy (CBT) skills may support maintenance long term.
Deployment of health trainers to deliver lifestyle interventions is a potentially cost-effective method to
reduce health inequalities. The importance of peer learning to support lifestyle change compared with
individual support to reduce CVD risk is understudied.
Objectives
The overall purpose was to design and evaluate an intensive lifestyle intervention based on psychological
theory using BCTs, to reduce the risk of CVD. This would be delivered by a healthy lifestyle facilitator (HLF)
employed from the local community.
Primary objectives
To assess whether or not MOVE IT (enhanced MOtiVational intErviewing InTervention), delivered in either
(1) a group or (2) an individual format, is more effective than usual care (UC) in reducing weight and
increasing PA 24 months later.
Secondary objectives
l To assess whether or not group MOVE IT is more effective than the individual format in reducing
weight and increasing PA 24 months later.
l To assess whether or not MOVE IT, delivered in either (1) a group or (2) an individual format, is more
effective than UC in reducing low-density lipoprotein (LDL) cholesterol and reducing CVD risk score
24 months later.
l To compare the number of fatal or non-fatal cardiovascular events, and other recorded adverse events
(AEs), per treatment allocation.
l Cost-effectiveness: to assess whether or not MOVE IT, delivered in either (1) a group or (2) an individual
format, is more cost-effective than UC, in terms of quality-adjusted life-years (QALYs) gained over the
24-month follow-up period.
l To conduct a process evaluation to understand the mechanisms of action of the intervention by
assessing mediation, participation bias, competency and fidelity of the intervention, and participant and
therapist experience.
Methods
Setting
The study was set in 12 South London Clinical Commissioning Groups aiming to capture socioeconomic
and ethnic diversity. General practices with list sizes of > 5000 patients were invited to participate.
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Study criteria
The case definition includes adults aged 40–74 years who screen as positive for high CVD risk and who
are not known to have CVD or to be on the diabetes mellitus, kidney, atrial fibrillation or stroke registers.
The QRISK®2 score (QResearch, Nottingham, UK) was used to identify those with a CVD risk score of
≥ 20%, indicating the chance of having a fatal or non-fatal cardiovascular event over the next 10 years.
The inclusion criteria were being fluent in conversational English, having permanent residency and
planning to stay in the UK for at least three-quarters of the year.
The exclusion criteria were having established CVD; having a pacemaker; being on a register for diabetes
mellitus, kidney disease, atrial fibrillation or stroke; having chronic obstructive pulmonary disease; having
a disabling neurological disorder; having a severe mental illness; being registered blind; being housebound
or resident in a nursing home; not being ambulatory; having more than three falls in the previous year;
pregnancy; having advanced cancer; having morbid obesity (body mass index of ≥ 50 kg/m2); or currently
participating in a weight-loss programme.
Sample size
A conservative effect size of 0.25 was selected, which translates to a difference between two arms of
675 steps per day (PA), 1.25 kg of weight and total cholesterol of 0.25 mmol/l at the 24-month follow-up.
Clustering effect within the arm was taken into account. A sample size of 1420 participants was needed to
detect these differences with a two-tailed alpha of 0.025. Assuming an approximate dropout rate of 20%,
1704 participants (648 in the group intervention arm and 528 each in the individual intervention and UC
arms, accounting for the dropout rate) were needed.
Baseline measures
Sociodemographic data, family history of CVD, biomedical data, QRISK2 score, smoking status, alcohol
intake, PA [measured objectively using the ActiGraph GT3X accelerometer (ActiGraph, Pensacola, FL, USA)
and using self-report scales], diet (measured using a standardised multiple-pass 24-hour dietary recall
questionnaire), depressive symptoms (measured using the nine-item Patient Health Questionnaire), illness
perceptions, and self-efficacy for changing PA and dietary habits were collected.
Randomisation and allocation concealment
Participant randomisation was conducted by the data manager from an independent clinical trials unit
(King’s College London) using computer-generated randomisation blocks. In each block, 10 participants
were randomised to the group intervention arm, individual intervention arm or UC in a 4 : 3 : 3 ratio. It was
not possible to conceal the allocation to the participants or the HLFs post randomisation, but assessors
were blind to the allocation for the primary and secondary outcomes.
Planned interventions
Arm 1 received UC only. General practitioners participating in the study were expected to follow their local
NHS Health Check pathway for those who have a CVD risk score of ≥ 20%.
Arm 2 received UC and enhanced MI in a group format. The intervention was based on the theory of
planned behaviour and delivered using principles and techniques from MI, CBT and social cognitive theory.
A training manual, an intervention curriculum and a participant workbook were developed. The intervention
consisted of 10 sessions, plus an introductory session, over 12 months. The intensive phase consists of
six weekly sessions at the beginning of the first quarter. The maintenance phase consists of four sessions
delivered at 3, 6, 9 and 12 months. Abraham and Michie’s BCT taxonomy was used to classify the specific
techniques.
Arm 3 received UC and enhanced MI in an individual format. This was the same as arm 2 except that the
components were delivered individually (one to one).
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Measurement of outcomes
The primary outcomes are change in weight (kg) and PA (average number of steps per day assessed by
accelerometry) between arms. Secondary outcomes are change in LDL cholesterol and CVD risk score,
dietary habits, health beliefs and depression.
The EuroQol-5 Dimensions was used to generate QALYs for use in the economic analyses. Intervention
costs were calculated and service use was measured at baseline and at the 12- and 24-month follow-up
assessments using an adapted Client Service Receipt Inventory.
Statistical analysis plan
Analysis and reporting was in line with the Consolidated Standards of Reporting Trials (CONSORT) guidelines.
Primary analyses were on an intention-to-treat basis. The differences in treatment effect between the three
arms at 12 and 24 months of this partially nested design were analysed using mixed-effects models with
pre-randomisation values as a covariate. Sensitivity analysis included adjusting for potential baseline variables
of age, sex, Index of Multiple Deprivation, education, marital status, smoking status and missing data. There
are no formal stopping rules.
Health-care costs were compared between the three arms using bootstrapping methods to estimate 95%
confidence intervals (CIs) around the mean cost differences.
Process evaluation
The main outcome measures were a quantitative assessment of participation bias (reach), quantitative
assessment of the competency (and also fidelity) of the intervention and patient and therapist experiences
of the process of change.
Adverse events
Participants receiving the intervention were able to report AEs at any time during the intervention period to
the HLF and this information was routinely collected at 12 and 24 months.
Results
This three-arm parallel randomised controlled trial tested the effectiveness of an enhanced MI intervention,
delivered by specially trained health trainers (HLFs), in a group format versus an individual format, and
versus UC, for reducing weight and increasing PA in adults at high risk (≥ 20.0%) of developing CVD in
the next 10 years. The mean age of participants was 69.75 years (4.11 years), 85.5% were male and
89.4% were white, with baseline characteristics being similar between the three arms.
There were only minor and non-significant differences between treatment arms in PA at 12 or 24 months.
Participants in the individual intervention arm walked a mean of 210 steps (95% CI –19.5 to 439.9 steps)
more at 12 months than UC participants and those in the group intervention arm walked a mean of 131
steps (95% CI –85.3 to 347.5 steps) more at 12 months than UC participants. All differences (including limits
of the 95% CIs) were less than the minimum clinically significant difference (MCD) of 675 steps as defined
in the study protocol. Similarly, at the 12-month follow-up and using 97.5% CIs, minor and non-significant
differences in the mean number of steps between the individual and UC arms (210.22 steps, 97.5% CI
–52.44 to 472.89 steps) and the group and UC arms (131.10 steps, 97.5% CI –116.35 to 378.55 steps)
were observed.
For weight, there was a small but significant mean difference between the individual and UC arms of
–0.55 kg (95% CI –0.95 to –0.14 kg) and between the group and UC arms of –0.52 kg (95% CI –0.90 to
–0.13 kg). However, the mean differences (including the 95% CI limits) are below the MCD of 1.25 kg.
There was no mean difference between the group and individual intervention arms (–0.03 kg, 95% CI
–0.43 to 0.37 kg). At 24 months, no significant mean differences were observed. Similarly, at the 12-month
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follow-up and using 97.5% CIs, minor mean differences between the individual and UC arms (–0.55 kg,
97.5% CI –1.01 to –0.08 kg) and the group and UC arms (–0.52 kg, 97.5% CI –0.96 to –0.08 kg) were
observed.
It was found that there was no treatment effect for any of the secondary outcomes at either follow-up
point. There were no differences in the number of fatal or non-fatal cardiovascular events and other
recorded AEs between the three treatment arms.
The health economic results revealed that there was little difference in terms of service use and costs between
the three arms other than those resulting from the interventions themselves. Total service costs over the
follow-up period were highest for the individual intervention arm, followed by the group intervention arm,
and then followed by the UC arm. Differences were not statistically significant. QALYs were very similar
for each arm. The group intervention was dominated by UC, which had lower costs and produced more
QALYs. The individual intervention did produce more QALYs than UC but the incremental cost-effectiveness
ratio indicated a cost per QALY far in excess of the threshold commonly used by NICE. For this reason,
neither form of the intervention was cost-effective. There was much uncertainty around the cost and
outcome differences but the conclusion of a lack of cost-effectiveness holds.
Process evaluation results
Mediators
It was found that dietary changes did not mediate any treatment effects on the primary outcomes. Further
mediational analyses were not conducted, as there was no change in the primary or secondary outcomes.
Participation bias
It was found there was significant evidence of reduced reach, in that those patients with higher CVD risk,
higher levels of deprivation status and of African Caribbean ethnicity were less likely to reply to invitations
from their general practice to participate in this trial.
Fidelity analysis
There were significant methodological limitations of conducting a fidelity analysis because of internet
outage resulting in the loss of all audio data. From data retrieved from elsewhere, consisting of a highly
selected sample, there was evidence that nearly all of the HLFs had sufficient competencies in at least one
MI skillset.
Patient experience
The main themes that emerged were (1) perceived benefits of the study (benefits of increased health
awareness, positive lifestyle changes and the opportunity to learn from others); (2) factors enhancing
behaviour change (continuity of sessions over a longer period and having continuity of the same HLF);
and (3) perceived risk of CVD (this was lower than was expected). One further theme that emerged
solely for the non-completers was (4) potential barriers to change, such as lack of feedback, and
overcoming these barriers.
Therapist experience
The overall view was that the formal training period could have been shortened, with more exposure
to training cases, and that the HLFs had not been prepared for the real-world challenges once in the
clinical setting. They perceived themselves as competent in the MI approach and BCT. They observed
the importance of working with patients towards their goals but there were some common challenges,
such as patients not engaging and some of the intervention materials not being deemed age-appropriate.
The HLFs felt that support from supervisors, and administrative support, was insufficient but that they
could problem-solve by supporting each other.
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Conclusions
This study suggests that an intensive lifestyle intervention using BCTs based on MI and CBT is not effective
in reducing weight and increasing PA in a population-based sample of people at high risk of CVD. The
reason may be that the study did not reach those with modifiable CVD risk factors as this sample consisted
of predominantly older males. This suggests that the QRISK2 engine on its own is not suitable for identifying
those patients most likely to benefit from intensive lifestyle interventions. Further research should focus on
interventions for those subgroups most at risk who are less likely to participate in lifestyle interventions
(people of African Caribbean ethnicity or in low socioeconomic settings) or who have a higher proportion
of modifiable CVD risk factors (evidence of being overweight or having high lipids levels).
Trial registration
This trial is registered as ISRCTN84864870.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research (NIHR). This research was part-funded by the NIHR Biomedical Research
Centre at South London and Maudsley NHS Foundation Trust and King’s College London.
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Chapter 1 Introduction
Epidemiology of cardiovascular disease and its risk factors
Cardiovascular disease (CVD) is the leading cause of mortality, morbidity and disability in the UK and in
other developed countries.1 However, many of the major determinants of CVD are modifiable, including
tobacco smoking, a diet high in saturated fat, high low-density lipoprotein (LDL) cholesterol, obesity,
a sedentary lifestyle, hypertension and diabetes mellitus.2–6 Lower educational attainment and lower
socioeconomic status are associated with a greater risk of CVD, and this association is strongest for
females.7 The risk of CVD varies markedly between ethnic groups, with a higher rate of ischaemic heart
disease in those of South Asian ethnicity and a higher rate of cerebrovascular disease in those of African
ethnicity among those living in England and Wales.8
Although CVD remains the most common cause of death in developed nations, mortality rates have
been falling. Between 1981 and 2000, CVD mortality in the UK fell by 62% in men and 45% in women.9
Cohort studies and prediction models suggested that a fall in the prevalence of tobacco smoking, a
decline in population blood pressure levels and changes in cholesterol levels were important contributors.9,10
Population-wide changes in modifiable risk factors, such as dietary intake, can bring about substantial
benefits and further changes in blood lipids, particularly reductions in levels of non-high-density lipoprotein
(HDL) cholesterol.10 However, limited changes in physical activity (PA) and rising levels of obesity have
limited the decline in CVD mortality.10 Further efforts are therefore needed to bring about positive changes,
particularly in diet, obesity and PA.
Cardiovascular risk identification
The NHS in England introduced the Health Check programme in 2009 as part of the Department of Health
and Social Care (DHSC)’s long-term vision for the future of public health in England.11 In offering Health
Checks to all those aged 40–74 years without a known diagnosis of CVD, the aim is to prevent heart
disease, stroke, diabetes mellitus and kidney disease and to reduce health inequalities. The risk assessment
includes collection of demographic data, smoking status, cholesterol level, blood pressure and diabetes
mellitus status. An individualised risk management plan is given in accordance with the assessment to
support lifestyle changes, such as referral to smoking cessation sessions, exercise prescriptions, lifestyle
advice and signposting to local resources.
A lower-than-anticipated coverage of NHS Health Checks has been reported,12 with regional variations in
attendance ranging from 27% to 52%,12 with greater uptake in patients of older age and in regions of
lower deprivation.13 Reductions in CVD risk have been reported for those attending Health Checks;14
however, a systematic review of the implementation of Health Checks found no reduction in mortality or
morbidity.15 The programme has attracted criticism owing to a lack of an up-to-date evidence base and
Clinical Commissioning Groups (CCGs) lacking the resources to implement them.16
Several risk algorithms have been developed and validated to estimate the risk of developing CVD based
on known risk factors; these risk algorithms include the Framingham Risk Score,17 the ASSIGN score,18
QRISK®19 and QRISK®220 (both QResearch, Nottingham, UK). The latter is now recommended by the
National Institute for Health and Care Excellence (NICE) for the identification of people at risk of CVD
up to the age of 84 years in England.21 The QRISK2 algorithm takes into account self-report ethnicity,
deprivation and other relevant clinical conditions, and is updated annually to reflect changes in clinical
evidence, data recording and population demographics. Once a high CVD risk is ascertained, the primary
prevention of CVD is recommended via lifestyle advice and interventions.
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The evidence for increasing physical activity
Physical inactivity increases mortality and the risk of diseases such as CVD and diabetes mellitus.22 The
DHSC advises adults to perform ≥ 30 minutes of at least moderate-intensity PA on ≥ 5 days per week,
in ≥ 10-minute bouts, for optimum health benefits.23 Walking is the most common form of PA in adults
and is associated with reductions in CVD and all-cause mortality, and walking pace is a stronger predictor
of improved outcomes than walking duration.24 Walking is promoted as a near-perfect exercise as it has
the lowest risk of harm and is now included in UK public health policy.25,26
However, the proportion of those achieving PA recommendations is low, particularly when objective
measures are used to assess PA. In England, 39% of men and 29% of women self-report achieving
the recommended PA levels, but objective assessment of PA using accelerometers in a subsample of the
Health Survey for England found that only 5% of men and 4% of women aged 35–64 years achieved the
recommended levels.27
Systematic reviews and meta-analyses report moderate positive short-term increases in PA following
lifestyle interventions, in either a group or an individual format, but findings are limited because most
studies used self-report measures.28,29 Evidence for brief PA interventions suggests improvement in PA in
the short term, but there is limited evidence for the long-term impact, cost-effectiveness and deliverability
in a primary care setting.30,31 A review of 32 trials reported that walking interventions led to improvement
in a number of cardiovascular risk factors, including blood pressure and weight, but not in lipids.32 The
majority of the reviewed intervention trials recruit motivated volunteers and report low response rates,
which may limit the representativeness of observed findings.
The contents of assessed interventions to promote PA differ significantly, but social support and
cognitive–behavioural therapy (CBT) strategies, rather than health education alone, are recommended
in older adults.33 The use of pedometers as a method of self-monitoring can increase PA and improve
health in the short term.34 Compared with usual care (UC), the use of pedometers and a brief walking
intervention in primary care led to improvements in 12-month PA in a sample of adults not achieving the
recommended activity levels at baseline.35 The intervention was as effective when delivered by post as
when delivered by nurses in primary care, suggesting that PA can be improved in physically inactive
patients with minimal resources. Details of the components used in trials of interventions to promote PA,
including information on the behaviour change techniques (BCTs) used, are recommended to improve
implementation and evidence syntheses.29,36
The evidence for dietary interventions
Modest beneficial changes to dietary intake, specifically changes to fat, fibre, fruit and vegetable intake,
are found following healthy diet interventions in primary care, but there is variability in intervention design
and delivery as well as the methodological quality of previous studies.37 Based on the limited evidence
available, estimates of the cost-effectiveness of dietary interventions in primary care suggest that interventions
need to be targeted towards the older population at greatest risk of disease to be cost-effective.38
A systematic review of randomised controlled trials (RCTs) assessing generic dietary advice for reducing
CVD risk found modest beneficial effects on mean total and LDL cholesterol levels and small reductions in
blood pressure up to 12 months later, suggesting that dietary advice may contribute to an improved CVD
risk profile.39 However, the longer-term effects of dietary interventions are unknown owing to limited
follow-up periods of reviewed studies. Compared with UC, dietary interventions produce modest weight
losses that diminish over time.40 Further work is needed to understand how the modest benefits of dietary
interventions may be maintained.
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The evidence for motivational interviewing
Motivational interviewing (MI) is a common approach to behaviour change in health care, defined as a
collaborative, goal-oriented style of communication with particular emphasis on the language of change.41
It is designed to strengthen motivation for and commitment to a specific behavioural goal by eliciting and
exploring personal reasons for change within an atmosphere of acceptance and compassion.42 The appeal
of MI is that it is brief, can be delivered by a range of health-care providers, has a competency framework
and can be applied to a range of health-care settings, with evidence of benefits to health outcomes when
compared with other interventions.43
Systematic reviews and meta-analyses have demonstrated significant, moderate effects of MI on diet and
exercise behaviours,44 as well as on health outcomes such as reduced weight, cholesterol and blood
pressure, although the number of trials is small.45,46 However, a systematic review of MI used in lifestyle
interventions for people at risk or with a diagnosis of CVD found little evidence of the benefits of MI,
noting the considerable variability between interventions and the outcomes measured and that few have
included a long-term follow-up to assess whether or not any observed benefits are sustained.47 A 14-month
follow-up of diabetic patients who had received a MI lifestyle intervention found no benefits in lifestyle,
biomedical or psychological outcomes compared with UC.48 A RCT with a 12-month postintervention
follow-up period found that the benefits of up to five MI sessions delivered over a period of 6 months on
walking and cholesterol levels were maintained in a sample of overweight or obese patients, but other
CVD risk factor outcomes were not maintained.49 Effects were stronger for those found to be at higher
risk at baseline, suggesting that interventions should target high-risk patients to achieve the best results.
A taxonomy of behaviour change techniques
The limitations of current models of lifestyle interventions, particularly their short-term effects, have led to
a search for more sophisticated and targeted behavioural interventions.50 A Cochrane Database Systematic
Review of multiple risk factor interventions for the primary prevention of coronary heart disease observed
that techniques based on instruction and information were associated with small improvements in lipid
levels and blood pressure, especially when embedded in a theoretical framework related to behaviour
change.51 A systematic review of behavioural interventions found that the techniques most effective in
improving diet and PA were based on self-regulatory behaviours, such as goal-setting, self-monitoring,
giving feedback, utilising social support and MI.52 Interventions based on a psychological theory, such as
the theory of planned behaviour,53 were more effective, as were those for high-risk populations. There is
less evidence to support the case for any minimum threshold of intensity, mode of delivery, intervention
provider and setting;50–52 therefore, further study is required to understand how the benefits of behavioural
interventions on lifestyle and health outcomes can be maintained. Evaluating interventions in the context
of a taxonomy of BCTs and an intervention map offers a framework that is easier to teach, test, replicate
and translate.52–54
In a pilot RCT, a group intervention developed in line with evidence of the most effective BCTs52 led to
reductions in weight, when co-interventions and comorbidities were controlled for, but did not increase
PA at the 12-month follow-up in people at high risk of CVD, compared with UC.55 As this was a pilot RCT,
the authors note that the intervention was acceptable to participants and that outcomes could be
improved by adapting the intervention accordingly. The effects of the group-based setting were not
compared with a one-to-one setting, and there is little evidence in the literature on the differences
between group and individual approaches. It has been found that the benefits of group sessions outweigh
individual sessions even when it is not preferred by participants,56 and that group sessions are highly
valued by participants.57 However, it is also reported that at least one individual session is critical to the
success of interventions and in ameliorating disengagement in some participants.57,58 The variability in
patient samples involved in these studies, the intervention delivered and the methodology of each study
limit the generalisability of the findings.
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By enhancing a MI approach with effective BCTs, the modest effect sizes of each may lead to improvement
in outcomes. In people with type 1 diabetes mellitus, four sessions of MI alone was not associated with
improved glycaemic control, but four sessions of MI followed by eight sessions of CBT was associated
with improved glycaemic control, compared with UC.59 However, the effects were not maintained after
12 months,60 and participants stated that MI helped them to become more ready to change their behaviour
but that further support was needed to implement the change.61 The evidence for enhancing MI with CBT is
not consistent, as the landmark COMBINE (Combined Pharmacotherapies and Behavioural Interventions for
Alcohol Dependence) study did not demonstrate increased abstinence from alcohol in those receiving the
psychological intervention.62
The role of health trainers
The DHSC recommended the deployment of health trainers into the most deprived areas of the UK in
a White Paper published in 2004.63 A health trainer is employed by the NHS from the local community
in which they serve to provide lifestyle advice to those at risk of disease, with the overall aim of the
programme being to address health inequalities, an important issue within multi-ethnic and variably
deprived settings.64 The role involves identifying clients from hard-to-reach and disadvantaged groups,
providing one-to-one support in identifying potential problems in lifestyles, setting goals, supporting
behaviour change and reviewing client progress.65 The health trainer programme has been found to
increase uptake of NHS Health Checks, particularly in men, younger age groups and those from less
affluent areas.66
A comprehensive review of interventions delivered by lifestyle advisors found little evidence of the benefits
of interventions promoting healthy diet and/or increased PA in North American trials; there was no effect
on weight and little evidence of improvement in PA levels, but the intervention contents, delivery and
goals varied considerably.67 A review of the available evidence on the NHS health trainer programme
thus far indicates positive outcomes and acceptability, but critics argue that the models of service provision
are varied, evaluations have included no comparator group and there is a lack of evidence for the
maintenance of behaviour change.68 A health trainer programme for CVD risk reduction in patients with
at least one CVD risk factor found significant reductions in CVD risk after 12 months for only those who
were identified as being at high risk of CVD (a Framingham Risk Score for CVD of ≥ 20.0%) at baseline.69
The service also led to high levels of behavioural goal achievement and small, but significant, increases in
quality of life. However, as this was a service evaluation there was no comparator group and achievement
of behavioural goals was self-reported and unrelated to changes in CVD risk. Further work is needed
to assess the potential for health trainers to deliver complex behavioural interventions, including the
employment of objective outcome measures, the assessment of maintenance of behavioural change and
clinical benefits, and comparison of outcomes with a control group.
The case for an enhanced motivational interviewing intervention
At the population level, the potential benefits of reducing weight and increasing PA in those who are at risk
of CVD are considerable. Modest, short-term beneficial effects of various behaviour change interventions
for the primary prevention of CVD emphasise the need for more complex, targeted interventions and
RCTs that assess long-term benefits. MI provides broad appeal for its collaborative patient-centred style,
evidence base and deliverability, and by enhancing a MI approach with the specific BCTs that have the
strongest evidence, and incorporating techniques designed to enhance maintenance, observed outcomes
may be improved. The relative effectiveness of a group intervention versus an individual intervention
remains uncertain, but the former offers social support and may be more cost-effective, if it is acceptable
to participants. Health trainers may improve the acceptability of interventions to harder-to-reach populations
and positive outcomes have been reported in health trainer programmes thus far. The investigation of the
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
4
potential for a health trainer to deliver more sophisticated interventions, and for the effects to be compared
with UC in a RCT setting, is yet to be undertaken.
The overall aim was to compare the effectiveness of MOVE IT (enhanced MOtiVational intErviewing
InTervention), which integrates MI with CBT BCTs, in reducing weight and increasing PA in those at high
risk of CVD over 24 months across three arms: (1) enhanced MI in a group format versus (2) in an
individual format versus (3) UC. The primary interest was whether or not MOVE IT in a group format was
more effective and cost-effective than the individual format or UC because of its potential for social support.
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Chapter 2 Research objectives
The following material has been primarily reproduced from our published study protocol, Bayley et al.70This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided he original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/. The text below includes minor additions and formatting changes to the original text.
The purpose of this study was to design and evaluate MOVE IT for people at high risk of CVD, to be
delivered by a healthy lifestyle facilitator (HLF) employed from the local community and trained in the
intervention. We opted for the job title of HLF, rather than health trainer or lifestyle advisor, as this was
thought to better reflect the principles of collaborative work underpinning MI.
Primary objective
To assess whether or not MOVE IT delivered in either a (1) group or (2) individual format is more effective
than UC in reducing weight (kg) and increasing PA (average number of steps per day assessed via
accelerometry) 24 months later.
Secondary objectives
l To assess whether or not group MOVE IT is more effective than the individual format in reducing weight
and increasing PA 24 months later.
l To assess whether or not MOVE IT, delivered in either (1) a group format or (2) an individual format,
is more effective than UC in reducing LDL cholesterol and in reducing CVD risk score 24 months later.
l To compare the number of fatal or non-fatal cardiovascular events, and other recorded adverse events
(AEs), per treatment allocation.
l Cost-effectiveness: to assess whether or not MOVE IT delivered in either (1) a group format or (2) an
individual format is more cost-effective than UC, in terms of quality-adjusted life-years (QALYs) gained
over the 24-month follow-up period.
l Process evaluation: using mixed methods, we conducted the following –
¢ Mediational analysis: to examine whether or not changes in behavioural and psychological factors,
such as dietary intake, health beliefs, depressive symptoms and self-efficacy, mediate the association
between the intervention and outcomes.
¢ Participation bias: to assess whether or not the RCT recruited those it intended, we assessed the
participation bias by comparing the sociodemographic characteristics and QRISK2 scores of those
who responded to the invitation to participate and those who did not.
¢ Fidelity analysis: to assess whether or not MOVE IT was delivered in accordance with the manual
and to compare whether or not the levels of competencies among the HLFs were associated with
variations in outcomes using thematic contents analysis of sessions.
¢ Participant and therapist experience: using qualitative methods, we describe the perceived
expectations, benefits, strengths and limitations of the intervention from the patient and
intervention provider perspective.
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Chapter 3 Methods
The following material has been primarily reproduced from our published study protocol, Bayley et al.70This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided he original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/. The text below includes minor additions and formatting changes to the original text. The revised
protocol was published before recruitment ended.70
Trial design
This was a three-arm parallel RCT for individuals at high risk of CVD. The three arms were (1) UC and enhanced
MI in a group format, (2) UC and enhanced MI in an individual format and (3) UC. As participants in the group
intervention arm, but not in the other two arms, were clustered within groups, this trial has a partially clustered
(or nested) design. Interventions were delivered in 10 sessions across a period of 12 months. Participants were
followed up at 12 and 24 months from baseline.
Ethics approval and research governance
The Dulwich Research Ethics Committee (REC) (reference number 12/LO/0917) granted ethics approval.
The trial was registered with an International Standard Randomised Controlled Trial Number
(ISRCTN84864870).
Setting
The study was set in 12 South London CCGs (Bexley, Bromley, Croydon, Greenwich, Kingston, Lambeth,
Lewisham, Merton, Richmond, Southwark, Sutton and Wandsworth) that are linked to each other by the
South London Health Innovation and Education Cluster (SLHIEC) and inherent in this infrastructure is an
efficient method for recruitment. South London has additional advantages: the population is approximately
3 million;71 nearly one-quarter of the population is African, Caribbean or South Asian; it spans the range
of population densities, urbanisation and socioeconomic profiling; the development of a Health Innovation
Network in South London can allow for rapid dissemination of research findings; and research resources
can be shared across adjacent CCGs during periods of varying workload. General practices with list sizes
of > 5000 patients were invited to take part, representing approximately 60% of all practices within the
SLHIEC.
Eligibility criteria
The following eligibility criteria were used by general practitioners (GPs) during the initial search for eligible
patients. In addition, exclusions were made following patient response to the invitation when the research
assistant found that the patient did not meet the following criteria. When in any doubt, the opinion and
approval of the patient’s GP was sought.
The inclusion criteria were:
l being aged ≥ 40 years and ≤ 74 years
l having a CVD risk score of ≥ 20.0%, calculated using QRISK2, a validated predictive tool for identifying
the percentage risk of having a fatal or non-fatal cardiovascular event in the next 10 years72
l being fluent in conversational English
l being permanently resident and planning to stay in the UK at least three-quarters of a year.
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The exclusion criteria were:
l having established CVD (including congenital heart disease, angina, myocardial infarction,
coronary revascularisation procedures, peripheral artery disease, coronary artery bypass graft
or angioplasty)
l having a pacemaker
l being on a register for diabetes mellitus, kidney disease, atrial fibrillation or stroke (either ischaemic or
haemorrhagic, including transient ischaemic attacks)
l having chronic obstructive pulmonary disease
l having a disabling neurological disorder
l having a severe mental illness such as psychosis, a learning disability, dementia or cognitive
impairment
l being registered blind
l being housebound or resident in a nursing home
l being unable to move about independently or not being ambulatory
l having more than three falls in the previous year
l being pregnant
l having advanced cancer
l being morbidly obese [body mass index (BMI) of > 50 kg/m2]
l currently participating in a weight-loss programme
l living in the same household as another participant who was already randomised.
Sample size
The power calculation of our main outcome variables is based on the findings of previous research.34,73
We selected a very conservative effect size of 0.25, expressed as the difference in units of pooled standard
deviations (SDs), which translates to an ability to detect differences between two arms of 675 steps per
day, 1.25 kg of weight and total cholesterol of 0.25 mmol/l. Our study was powered to detect changes
that may be modest at the individual level but that would have an important impact if occurring at the
population level.74
We took into account clustering effect within the group intervention [intraclass correlation coefficient (ICC)
of 0.05] by calculating the optimal sample size in presence of differential clustering effects.75 A sample
size of 1420 participants in total was needed to detect these differences in our primary hypotheses, and
a two-tailed alpha of 0.025 was used to take account of multiple comparisons for ‘individual versus UC’,
‘group versus UC’ and ‘group versus individual’. Assuming an approximate 17% loss to follow-up, a total
sample size of 1704 was calculated.
Recruitment
Invitation procedure
Participating general practices screened primary care databases for eligible patients using either EMIS
(EMIS Health, Leeds, UK) or Vision (In Practice Systems, London, UK) medical records systems, two of
the clinical software programmes most commonly used in UK primary care. Patients who met the
eligibility criteria were invited to participate via a standardised letter from their general practice, which
was posted along with a participant information sheet. A prepaid return envelope was included for
the return of a reply slip, for the patient to express interest to take part, to the main study centre. After
the patient had given permission to be contacted, a research assistant made telephone contact with the
patient to confirm that they met all eligibility criteria and to schedule a first appointment.
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Consenting participants
As participants attended a first appointment with the research assistant, they were asked to read and
complete a consent form. Participants were given the opportunity to ask any questions regarding the study
or the consent statements.
Calculation of cardiovascular disease risk score
Once consented, data collection began with CVD risk screening; a summary is given in Table 1. High CVD
risk was calculated using QRISK2, a validated predictive tool for identifying those at a ≥ 20.0% chance of
TABLE 1 Data collection schedule summary
Data collection
Time point
CVD risk
screening Baseline
Post baseline
and pre
randomisation
12
months
Post 12
monthsa
24
months
Post 24
monthsa
Eligibility form ✓
Consent form ✓
Sociodemographic
characteristics
✓ ✓
Changes to sociodemographic
characteristics
✓ ✓
7-day accelerometer data
returned
✓ ✓ ✓
Biomedical data ✓ ✓ ✓
Blood results analysed ✓ ✓ ✓
Record of past interventions ✓ ✓ ✓
AUDIT ✓ ✓ ✓
Smoking status ✓ ✓ ✓
PHQ-9 ✓ ✓ ✓
GPPAQ ✓ ✓ ✓ ✓ ✓ ✓
IPAQ ✓ ✓ ✓ ✓ ✓ ✓
BIPQ ✓ ✓ ✓
Self-efficacy scale ✓ ✓ ✓
EQ-5D ✓ ✓ ✓
24-hour dietary recall ✓ ✓ ✓ ✓ ✓ ✓
CSRI ✓ ✓ ✓
Medication data ✓ ✓ ✓
AE questionnaire ✓
Participant feedback
questionnaire
✓
AUDIT, Alcohol Use Disorders Identification Test; BIPQ, Brief Illness Perception Questionnaire; CSRI, Client Service Receipt
Inventory; EQ-5D, EuroQol-5 Dimensions; GPPAQ, General Practice Physical Activity Questionnaire; IPAQ, International
Physical Activity Questionnaire; PHQ-9, Patient Health Questionnaire – 9 items.
a Post 12 months and post 24 months refer to accelerometer wear conducted after the respective follow-up appointment.
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having a fatal or non-fatal cardiovascular event over the next 10 years.72 The measures required for the
calculation of QRISK2 score are:
l Age (years).
l Sex.
l Self-report ethnicity.
l Postcode.
l Smoking status – current (if current, how many cigarettes or equivalent per day), ex-smoker or
non-smoker. We also collected the number of years smoking for current and ex-smokers.
l Diabetes mellitus status (none, type 1 or type 2).
l Rheumatoid arthritis status.
l Chronic kidney disease status.
l Atrial fibrillation status.
l Hypertensive treatment status.
l Family history of CVD (a first-degree relative diagnosed with angina or heart attack when < 60 years
of age).
l Height (cm) and weight (kg) were taken for a calculation of BMI (kg/m2).
l Systolic blood pressure (mmHg) – the third of three measurements taken.
l The ratio of HDL cholesterol (mmol/l) to total cholesterol (mmol/l).
Postcode data were collected for the calculation of Index of Multiple Deprivation (IMD) 2010 scores76
(based on lower-layer super output area).77 The IMD incorporates seven domains: income deprivation,
employment deprivation, health deprivation and disability, education deprivation, crime, barriers to housing
and services and living environment.
Levels of LDL cholesterol (mmol/l), triglycerides (mmol/l), plasma glucose (mmol/l) and glycated
haemoglobin (HbA1c) (mmol/mol) were also taken at this time point, and patients with a HbA1c level of
> 47 mmol/mol were subsequently excluded.
Baseline measures
If QRISK2 score was calculated as ≥ 20.0%, participants were subsequently invited to a second
appointment for the collection of the following data prior to randomisation.
Sociodemographic data
These were age, sex, self-report ethnicity and family history of CVD collected for the QRISK2 calculation,
occupational status, educational attainment, marital status, literacy [using the Rapid Estimate of Adult
Literacy in Medicine (REALM)78] and place of residence.
Biomedical data
These were weight, height, BMI, blood pressure, plasma glucose level, lipids and HbA1c level, which were
collected for the QRISK2 calculation. Data collection included a full-body composition analysis and
measurement of waist, hip and arm circumferences.
Weight and body composition were measured in light clothing without shoes on the Class 3 Tanita®
SC-240 digital scale (Tanita, Amsterdam, the Netherlands) to 0.1 units for weight (kg), fat range (%),
fat mass (kg), fat-free mass (kg), body water (kg), muscle mass (kg), bone mass (kg) and to the nearest
1 unit for visceral fat (level) and impedance (ohm) and basal metabolic rate (kcal). Height was measured to
0.1 cm using stadiometers with the supported stretch stature method and weight and height measurements
were used to calculate BMI (kg/m2).
Waist circumference (cm) was measured horizontally halfway between the lowest rib and the upper
prominence of the pelvis using a non-extensible steel tape against the bare abdomen. Hip circumference
(cm) was measured at the widest part of the hip. Arm circumference (cm) was taken from the mid-upper
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arm, at the midpoint between the top of the shoulder and the point of the elbow. Two measurements
were taken for each circumference, with a third taken if the first two measurements differed by > 0.5 cm.
Blood pressure (mmHg/mmHg) and resting heart rate (beats per minute) were measured with digital
Omron blood pressure monitors [Omron Healthcare (UK) Ltd, Milton Keynes, UK) using standardised
procedures of three readings taken 1 minute apart while seated.
Lifestyle data
These were smoking status collected for QRISK2 calculation, PA, alcohol intake and dietary intake.
Physical activity was measured objectively using the ActiGraph GT3X accelerometer (ActiGraph, Pensacola,
FL, USA), a validated tri-axial movement sensor that also records step count.79 The research assistant
explained to the participant how to wear the accelerometer: on a belt over the hip for 7 days, from
waking in the morning until going to bed at night and removing only for bathing. Participants were asked
to keep a log of activities, including sedentary activity, to assist with the qualitative interpretation of the
data. The output from the accelerometer includes number of steps taken and time spent doing PA using
standard cut-off points for sedentary activity and light, moderate, vigorous and very vigorous PA. The
research assistant ensured that, on the participant returning the accelerometer, it had been worn for
≥ 540 minutes on each of ≥ 5 days, and, if not, the participant was asked to wear the accelerometer for
another 7 days. Step count per day and a measurement of PA at an at least moderate level [moderate to
vigorous PA (MVPA)] in > 10-minute bouts were extracted from the collected data. Standardised vertical
axis cut-off points for PA were used to classify sedentary (0–99 counts per minute), light (100–1951 counts
per minute), moderate (1952–5724 counts per minute), vigorous (5725–9498 counts per minute) and
very vigorous (≥ 9499 counts per minute) activity, with MVPA equating to ≥ 1952 counts per minute.80
Self-report PA was also measured using the General Practice Physical Activity Questionnaire and the
International Physical Activity Questionnaire81 at both the baseline appointment and after 1 week of
accelerometer wear.
Alcohol intake was measured using the Alcohol Use Disorders Identification Test (AUDIT),82 which has a
range of scores values from 0 to 40. Participants were categorised as abstainers (score 0), low-risk drinkers
(score 1–7) or possibly harmful drinkers (score ≥ 8).
Dietary intake was assessed using a standardised multiple-pass 24-hour dietary recall, which provides a
more objective and reliable measure of change in intervention studies, at both the baseline appointment
with the research assistant and independently after 1 week of accelerometer wear. Research assistants
were trained to follow a standardised protocol and ask neutral probing questions to encourage recall
of food items, and were taught about different methods of food preparations and brands in different
cultures. Portion size was assessed using food photographs to estimate daily calorie intake.83,84 Dietplan7
software (Forestfield Software Ltd, Horsham, UK) was used for coding the 24-hour recall diaries and
deriving nutrient intake. For food not listed in the software’s database, we created new food codes and
inputted the available nutritional information. If nutritional information was unavailable for an unlisted
type of food, we selected the most similar type of food already in the database.
Psychological data
These included depressive symptoms, health beliefs and health state. Depressive symptoms were collected
using the Patient Health Questionnaire-9 items (PHQ-9),85 as depression is associated with worse outcomes
in CVD.86 Each of the nine items are scored from 0 to 3 depending on frequency of occurrence of symptoms,
for a score in the range of 0–27. One or two missing items can be substituted with the average score of
non-missing items. When there are more than two missing values, the questionnaire is not scored. The
questionnaire is followed by a functioning question, and the questionnaire results are provided to the
patient’s GP.
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The Brief Illness Perception Questionnaire was adapted to be used for ‘high risk of CVD’ rather than for an
illness.87 The questionnaire asks the participant to rate their beliefs of the causes of their high risk of CVD
and how being at high risk affects them. A total score is calculated by summing together all items, with
items 3, 4 and 7 reverse-scored, a higher score reflecting a more serious view of the high risk of CVD.
We also used a validated self-efficacy questionnaire for exercise,88 and adapted this to assess self-efficacy
in keeping to a healthy diet as well as psychological processes we were seeking to change through the
intervention. Average scores for both exercise and diet self-efficacy were calculated by summing together
the score of each answered item and dividing by the number of items answered.
The EuroQol-5 Dimensions (EQ-5D) was used to measure the health state of the participant on the
dimensions of mobility, self-care, usual activities, pain or discomfort and anxiety or depression using three
levels: no problems, some problems or extreme problems.89 Participants are asked to rate their current
health state within the 0–100 range.
Health-care usage data
Health-care usage was assessed using the Client Service Receipt Inventory (CSRI),90 which included usage
of hospital services, community-based services and support received from friends or relatives for any health
reasons for the 12-month period leading up to the appointment. Data on current prescription medication
were also collected from medical records.
Randomisation and allocation concealment
Simple randomisation was used, with general practice included as a random factor in the model and
emphasis being on more practices and fewer patients per practice. Randomisation of participants was
conducted by the data manager from an independent clinical trials unit (King’s College London) using
computer-generated randomisation blocks with block sizes of 10. In each block, 10 participants were
randomised to the group intervention arm, the individual intervention arm or the UC arm in a 4 : 3 : 3
ratio. The unequal allocation ratio ensured that the group intervention arm had approximately 33% more
participants, allowing the group sessions to run with enough participants.
As this is a complex psychological intervention, it was not possible to conceal the allocation to the
participants or the HLFs post randomisation. Research assistants, statisticians and technicians were blind to
the allocation. Participants were reminded in advance of and during the follow-up appointments not to
reveal their allocation.
Outcome measures
At the 12- and 24-month follow-up assessments, participants were asked if there had been any change
to their sociodemographic status, such as accommodation, relationship status and educational attainment.
AE and participant feedback questionnaires were administered. All other baseline measures were repeated
at the 12- and 24-month follow-ups (see Table 1).
Trial arms and intervention details
Arm 1: usual care and enhanced motivational interviewing in a group format
Theoretical framework
The intervention is based on the theory of planned behaviour for initiation of behaviour change: to change
behaviour, people need to form an intention.53 Intention formation is influenced by three constructs:
(1) expected value or positive attitude (people see the value in making the change), (2) subjective norm
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(significant others and peers also value the change) and (3) self-efficacy (people believe that they are
capable of making the change).
Our intervention taps into all three constructs using principles and techniques from MI,41 CBT91 and social
cognitive theory92 (Figure 1). MI is used to support participants in forming healthy intentions. MI is a
collaborative conversation style for strengthening a person’s own motivation for, belief in and commitment
to change. Hobbis and Sutton91 highlight the gap between translating intention into action and illustrate
how CBT can be applied to bridge this gap. For this intervention, techniques from CBT are used to support
the transition from intention to action, and action to maintenance.93 Identifying and challenging unhelpful
thoughts or thinking styles can promote more positive emotions and behaviours, for example ‘When I get
breathless after some exercise (bodily sensation), this means that I am going to damage my heart (incorrect
cognition)’ or ‘I have eaten one doughnut (behaviour), I might as well eat the whole bag (all or nothing
cognition)’.
Social cognitive theory emphasises the importance of significant others in shaping people’s behaviours.
The theory of planned behaviour also highlights this aspect through the ‘subjective norm’ construct.
In our intervention, social networks from the participants’ own lives and/or group members (in the group
intervention arm) were actively utilised to provide practical and emotional support and opportunities for
modelling health behaviours during all phases of the intervention.
Intervention development
We conducted a scoping study to identify manuals published in English in the previous 5 years to improve
diet and/or PA in the peer-reviewed and grey literature. The aim was to map the quality, contents and
cultural diversity of these manuals to inform the content of our intervention. The clinical psychologist (CP)
devised the intervention based on this synthesis and on our expertise in developing lifestyle interventions.
Social
support
Subjective
norms
Attitude/
expected
value
Perceived
behavioural
control
IntentionMI skills CBT skills
Initiation of
behaviour(s)
Maintenance
of
behaviour(s)
FIGURE 1 Theoretical framework and intervention map. White background indicates psychological process;
green background indicates behaviour change technique.
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We used an iterative process to draft the manual and refine it over 2–3 cycles. There are two manualised
outputs from the trial:
1. An intervention curriculum. This provides an outline of each intervention session, including key learning
points, interactive activities and action planning.
2. A participant workbook. This includes key learning points from each session, action planning
worksheets, case studies and a self-monitoring diary for each participant.
The participants also received a pedometer, with guidance on how to use it effectively, and access to
online, DVD (digital versatile disc) and paper resources on CVD risk.
The programme consisted of 10 sessions, plus an introductory telephone session, spread over 12 months.
The outline of each session is given in Table 2. Each participant allocated to a treatment arm had a ‘session 0’
telephone call as an introduction to the intervention, to receive their intervention packs and to become
familiar with the HLF. The intensive phase consisted of six weekly sessions at the beginning of the first quarter.
The first three sessions focused on PA and the second three sessions focused on diet. The maintenance phase
consisted of four sessions delivered at 3, 6, 9 and 12 months after intervention commencement.
Those randomised to the group intervention arm were encouraged to use peer learning and the peer
support environment to facilitate change during both the intensive phase and the maintenance phase.
Each group had a maximum of 11 participants and sessions lasted for 120 minutes. The intervention
was delivered in local venues, such as community halls and health centres. Between sessions and during
follow-up, participants were encouraged to communicate with each other and the HLF. Novel methods
and teaching aids were used to supplement the delivery of BCTs, such as visual aids (food labels)/cue
cards, exercise demonstrations, video/audio material of patient testimonials, activity-based learning around
meal planning, and text/e-mail reminders. HLFs were expected to offer sessions between 08.00 and 21.00,
enabling flexibility for participants in full-time work or with carer roles. Cultural and religious awareness
was built in to the intervention.
For ease of translation, the key components of the programme have been defined in accordance with
Abraham and Michie’s BCT taxonomy:54
i. provide information on consequences
ii. prompt intention formation
iii. prompt barrier identification
iv. prompt specific goal-setting
v. prompt review of behavioural goals
vi. prompt self-monitoring of behaviour
vii. teach to use prompts or cues
viii. agree on behavioural contract
ix. use follow-up prompts
x. plan social support or social change
xi. relapse prevention
xii. MI.
Training the healthy lifestyle facilitators
The HLFs were employed at NHS band 3 level by King’s College Hospital and seconded as appropriate to
the CCG. The training programme lasted for 8 weeks and involved a standardised package of training
materials. The teaching was a combination of didactic learning, role playing and feedback, group exercises,
reading and case study discussion. The HLFs used rating scales for self-monitoring of skill progression
during role playing.
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TABLE 2 Intervention session contents
Session (time from intervention
commencement) Content
Intensive phase
Session 0 Focus: introduce the intervention
Examples of delivery: structure of the programme, ice breaker, rapport building with
HLF, give out pedometers and baseline measures
Session 1: PA (week 1) Focus: increasing routine activity
Examples of delivery: elicit views regarding walking more and sitting less and
instruction on use of pedometer. Support individual goal-setting
Session 2: PA (week 2) Focus: increasing non-routine activity
Examples of delivery: elicit views on recommended activity levels and reflect on
previously enjoyed exercise and its benefits. Provide information/demonstration/
leaflets regarding local exercise options. Support individual goal-setting
Session 3: PA (week 3) Focus: to maintain PA changes
Examples of delivery: elicit views regarding lapse vs. relapse using case studies.
Discuss lapse triggers and strategies to manage them. Support individual
relapse-prevention plans (including implementation intentions)
Session 4: diet (week 4) Focus: increasing health food choices
Examples of delivery: elicit views on healthy eating principles. Interactive games
regarding healthy snacks. Support individual goal-setting
Session 5: diet (week 5) Focus: decreasing unhealthy food choices
Examples of delivery: elicit views on foods to avoid in excess. Interactive games
regarding food labelling and high-fat and high-salt foods. Support individual
goal-setting
Session 6: diet (week 6) Focus: to maintain dietary changes
Examples of delivery: elicit views regarding lapse vs. relapse using case studies.
Discuss lapse triggers and strategies to manage them. Support individual
relapse-prevention plans (including implementation intentions)
Maintenance phase
Session 7 (3 months) Focus: review progress and problem-solve setbacks
Examples of delivery: highlight positive changes in review session, discuss setbacks
and potential ways forward. Support individual relapse-prevention plans
Session 8 (6 months) Focus: review progress and problem-solve setbacks
Examples of delivery: highlight positive changes in review session, discuss setbacks
and potential ways forward. Support individual relapse-prevention plans
Session 9 (9 months) Focus: review progress and problem-solve setbacks
Examples of delivery: highlight positive changes in review session, discuss setbacks
and potential ways forward. Support individual relapse-prevention plans
Session 10 (12 months) Focus: review progress and problem-solve setbacks
Examples of delivery: highlight positive changes in review session, discuss setbacks
and potential ways forward. Support individual relapse-prevention plans
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Each HLF’s competency was assessed at the end of training via a knowledge test and through observing
delivery of two sessions (one intensive, one maintenance). Four domains were assessed: MI, BCTs, group
skills and time management, utilising relevant coding frameworks (see Appendix 1). The competency
thresholds were adapted for the study,94–96 requiring each HLF to demonstrate ‘moderate proficiency’ in
each of the domains before delivering the intervention, meaning that they delivered 70% of BCTs, were
90% MI-adherent and scored in the moderate range in at least two of the other Motivational Interviewing
Treatment Integrity (MITI)97 categories, in at least three of the group skills categories and in time management.
HLFs that were not competent on initial assessment received further training and reassessment to reach the
required competency level.
Healthy lifestyle facilitator competency was monitored throughout the intervention by the CP, who
facilitated fortnightly group supervision and weekly e-mail supervision (based on the HLFs completing
reflective practice logs). The CP also conducted quality assurance of the intervention administration by
regularly reviewing audiotaped sessions (one individual session per month and two group sessions every
8 months) and providing feedback, as needed.
Arm 2: usual care and enhanced motivational interviewing in an individual format
This had the same components as the group intervention arm but was delivered individually (i.e. one to one).
There was no opportunity/expectation/guidance for participants to form groups with each other between
sessions. The number, content and spread of sessions was the same and sessions lasted for 40 minutes;
we reduced the duration of each session to approximately control for attention in the two treatment arms.
Arm 3: usual care only
General practitioners participating in the study were expected to follow their local Health Check pathway
for those patients who had a CVD risk score of ≥ 20.0%.
Clinical effectiveness
Primary outcomes
The primary outcomes were change in weight (kg) and PA (average number of steps per day) between arms.
Secondary outcomes
Changes in LDL cholesterol and CVD risk score were assessed. The QRISK2 measurement of CVD risk
is sensitive to changes in weight, cholesterol level, blood pressure, HbA1c level and smoking status.
The number of fatal and non-fatal CVD events and hospital admissions were recorded using an AE
questionnaire and by recording hospital services usage using the CSRI. Changes in dietary habits were
measured via analysis of dietary recall data. Health beliefs and depression at 12 and 24 months were
assessed as measures of mediating processes.
Cost-effectiveness
The main perspective for the economic evaluation is that of the health-care system. The EuroQol-5
Dimensions, three-level version (EQ-5D-3L) is used to generate QALYs for use in economic analyses.98
Intervention costs were calculated taking into account staff time for delivering the sessions and the unit
costs include elements for overheads and oncosts and account for the ratio of direct-to-indirect contact
time. We assumed that the clinician would be grade 3 and that the unit cost per hour was £32.40. For the
group intervention, the costs are apportioned over the number of attendees, which averaged 5.5. Other
service use was measured at baseline, 12 months and 24 months using the CSRI. EQ-5D instruments were
developed in the 1980s and have been subsequently adapted for use in around 500 studies. Service costs
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were calculated by combining service use data with information on unit costs.99,100 We had originally
planned to explore the cost of lost employment. However, these data were not adequately recorded and
so this was omitted.
Process evaluation
The overall aim of the qualitative analysis is to identify and describe factors and processes that affect the
delivery, receipt and outcome of the study to aid interpretation and translation of the observed findings.
Process data are analysed before outcome data wherever possible to reduce bias in interpretation. The
main themes are described in the following sections.
Participation bias
The extent to which the intervention reached out to eligible participants is assessed by (1) the makeup of
general practices that agreed and declined to participate, (2) participation biases and (3) attrition biases.
We also invited participants who did not complete the intervention to attend a focus group to give
feedback on the programme.
Fidelity analysis
We measured adherence and competence of the trained HLF team in delivering the manualised
intervention. See Chapter 8 for a full description.
Processes of change
The HLFs would record if targets were met (not at all, partially or fully) at the beginning of each session as
a measure of participant adherence to the intervention. Supervision and interviews with the HLFs were used
to assess which BCTs were popular, why and for which lifestyle behaviour. We administered a process
questionnaire at the end of the study that required all randomised participants to discuss, in open-ended
and standardised structured questions, which techniques they had found most useful, their appraisal of
the techniques and their level of satisfaction with the interventions of their allocated arms. We included the
UC arm to assess the similarity and differences with the intervention arms as there may have been some
overlap. In addition to the questionnaire, we conducted focus groups with a small number of participants
to elicit more detailed feedback (see Chapter 4).
Statistical analysis
Analysis and reporting is aligned with Consolidated Standards of Reporting Trials (CONSORT) guidelines,101
with primary analyses being on an intention-to-treat (ITT) basis. A description of the sample will be presented
using mean (SD) or count (percentage). The baseline characteristics of those who withdrew and those who
did not complete the intervention are compared with those of participants who completed follow-up.
Descriptive data also include maximum values, minimum values, medians and interquartile ranges (IQRs)
when appropriate. Significance is reported to a two-tailed alpha level of 0.05 as appropriate for comparisons.
The differences in treatment effect between the three arms at 12 and 24 months of this partially nested
design are analysed using mixed-effects models, with pre-randomisation values as a covariate.102 In the
linear mixed model, ‘treatment arm’, ‘time’ (as a categorical variable with two levels: 12 and 24 months),
the ‘interaction between treatment group and time’, ‘borough’, ‘ethnicity’ and the ‘baseline values’ of the
outcome variable are the fixed part of the model. The random parts of the models are ‘general practice’
(participants are nested in practices) and ‘therapy group’. The design of the study is complex because we
have a partially clustered cross-classified design. In the previous version of the analysis plan, we planned to
account for the partially nested design of ‘therapy group’ in an approach that matches the non-parallel
data structure.103 However, preliminary analyses with blinded data revealed that this complex model of a
partially nested, cross-classified design did not converge. Thus, in agreement with the Trial Steering
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Committee (TSC) and Data Monitoring and Ethics Committee (DMEC) (on 6 July 2017), we decided to
drop the random effect for therapist from the primary analyses. We are aware that we may underestimate
standard errors of treatment effects; however, health intervention therapist effects in similar studies
[e.g. the National Institute for Health Research (NIHR)-funded IMPACT104 and Diabetes-6105 RCTs] ranged
between negligible and small (ICC range 0 to 0.02).
The dependency of the repeated observations of the same participants at 12 and 24 months and the
covariance between the residuals within the lowest-level group ‘patients’ are correlated by using an
unstructured covariance pattern model. For the final model, the group difference estimates and associated
confidence intervals (CIs) are reported for 12 (for secondary analyses) and 24 months after randomisation.
In a sensitivity analysis, the random effect of borough was replaced by a partially nested random effect for
therapist group, as described previously, and results compared.
The described analysis approach provides valid inferences under the assumption that the missing data
mechanism can be ignored (missing at random). Sensitivity of results to missing data was further assessed
by including covariates predictive of missingness in the analyses model.
The significance level was 2.5% (two-sided) for the two main comparisons of (1) group format versus UC
and (2) individual format versus UC. The (secondary) comparison (group format vs. individual format) was
assessed on a 5% significance level as our research hypotheses is a null hypothesis of no difference.
The large sample size should have ensured that all possible confounding variables are equally distributed
between treatment arms. However, in the sensitivity analysis, we extended the model of the primary analysis
by including baseline variables with substantial imbalance, thought to be important in determining outcome.
The potential baseline variables were age, sex, IMD, education, marital status and smoking status.
The following further sensitivity analyses were conducted and, for all analyses, changes in predicted
treatment outcome differences are presented in the analysis plan – available on the project webpage
[see www.journalslibrary.nihr.ac.uk/programmes/hta/106203/#/ (accessed 29 April 2019)].
Sensitivity analysis adjusting for delay in intervention start
Participants allocated to the intervention arms began intervention sessions at different time points relative
to randomisation. Therefore, we conducted a sensitivity analysis to include time between randomisation
and session 0 of the intervention in the model.
Sensitivity analysis adjusting for unblinding of research assistants at follow-up
Every effort was made to avoid participants revealing their treatment allocation to the research assistant at
follow-up. Research assistants recorded whether or not they were unblinded to treatment allocation at
either the 12- or the 24-month follow-up. We conducted a sensitivity analysis to include unblinding (yes/no)
at follow-up time into the model.
Sensitivity analysis adjusting for insufficient accelerometer wear at baseline
We conducted a sensitivity analysis to include the number of valid days (≥ 540 minutes) of accelerometer
wear at baseline in the model.
Sensitivity analysis adjusting for insufficient accelerometer wear at follow-up
We conducted a sensitivity analysis to include the number of valid days (≥ 540 minutes) of accelerometer
wear at 12 and 24 months in the model.
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Sensitivity analysis adjusting for the recruitment of participants with a
body mass index of < 25 kg/m2
Although BMI was not included in the eligibility criteria, an aim of the study was to assess reduction in
weight, which would be inappropriate for participants who were of healthy weight or underweight at
baseline. We conducted a sensitivity analysis to include a BMI of < 25 kg/m2 (yes/no) at baseline in the model.
Sensitivity analysis adjusting for the recruitment of participants with a
QRISK2 score of < 20.0%
We conducted a sensitivity analysis to include a QRISK2 score of ≥ 20.0% (yes/no) at baseline in the model.
Dietary intake analysis
When available, the dietary recall diary from the appointment (or, if missing, the later diary) was used.
Owing to resource constraints, we a priori elected to analyse a random sample of 602 participants who
had a recall diary available for each time point (baseline and 12- and 24-month follow-ups). The random
selection of the 602 participants approximately followed the treatment allocation ratio used for the study
(4 : 3 : 3). Thus, the arm sizes for the group, individual and UC arms were 240, 180 and 182, respectively.
Food quantities and nutrient intake were checked for outliers, indicating possible data entry errors. Eight
nutrients (water, protein, fat, carbohydrates, total sugar, fibre, saturated fat and sodium) and total energy
intake (kcal) were selected as variables of interest. These variables were selected based on their relevance
to the intervention (i.e. its emphasis on reducing fat/sugar/salt intake and increasing water/fibre intake).
Dietary intake data are summarised at each time point using means (SDs). A linear mixed-effects model,
accounting for the partially nested design, tested if there were any effects of treatment arm and time or
their interaction on nutrient intake. The model controlled for participant age, sex, ethnicity, IMD 2010
baseline score76 and if the day recalled was Saturday/Sunday (binary yes/no variable).
A series of mediation analyses were conducted to test if dietary intake measured at the 12-month follow-up
mediated the effect of the intervention on the primary outcomes (weight and PA) or QRISK2 score at
the 24-month follow-up. Owing to the limitations of the software used – R version 3.4.2 (The R Foundation
for Statistical Computing, Vienna, Austria) and the mediation package [URL: https://cran.r-project.org/web/
packages/mediation/mediation.pdf (accessed 29 April 2019)] – each mediation analysis was constrained to
testing differences between two of the treatment arms. Thus, a total of 81 mediation analyses were run
[three outcomes × nine diet variables × three treatment arm comparisons (UC vs. group, UC vs. individual,
group vs. individual)]. The mediation models controlled for participant age, sex, ethnicity, IMD 2010
baseline score,76 if the day recalled was Saturday/Sunday (binary yes/no variable), baseline diet and baseline
value for the respective outcome.
Although many statistical tests were carried out for the dietary intake analysis, these tests were largely
exploratory. Therefore, a two-tailed alpha level of 0.01 was used to determine statistical significance.
For the linear mixed-effects models, the fixed-effect estimates for the effects of time and treatment arm
and their interaction were bootstrapped with 1000 replicates and their 95% CIs calculated.
Cost-effectiveness analysis
Health-care costs are compared between the two treatment arms and UC. Given that the data are likely to
be skewed, we use bootstrapping methods to estimate 95% CIs around the mean cost differences. QALYs
are calculated from the EQ-5D-3L administered at baseline, 12 months and 24 months. Area under the
curve methods allow us to calculate the QALY gain over the entire follow-up period and QALY differences
are analysed controlling for baseline EQ-5D-3L score in a regression model. If costs were higher for one
arm than for another and QALY gains are greater, we then constructed an incremental cost-effectiveness
ratio (ICER) to show the cost per extra QALY gained. There will be uncertainty around cost and QALY
estimates and this is explored using cost-effectiveness planes generated from 1000 bootstrapped resamples
of the data for each of the comparisons. Bootstrapping was carried out using the bsample routine in Stata®
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Version 15 (StataCorp LP, College Station, TX, USA), with the strata option used so resampling was by
arm. Separate regressions of costs and QALYs were performed on each bootstrapped sample and results
retrieved and plotted on the plane. Finally, we generated cost-effectiveness acceptability curves, using the
net-benefit approach and bootstrapping, to indicate the probability that any of the three approaches is the
most cost-effective for different values placed on a QALY gain. The range of values used is £0 to £100,000.
This includes the threshold that is used by the NICE: £20,000–30,000. Sensitivity analyses are carried out
around key costs, particularly those for the interventions themselves. We did not impute for missing values
and a complete-case analysis was instead conducted.
Ethics issues
The trial was reviewed by the Dulwich REC and has been approved (reference 12/LO/0917). The TSC
provided overall trial supervision, supported by the DMEC. The main ethics consideration was to ensure
that the risk of harm to participants was minimised and that they were fully informed of any risks. We
considered literacy and cultural sensitivities in obtaining informed consent. Other ethics considerations
were in ensuring that recruitment and informed consent were handled in such a way that potential
participants were not put under pressure to take part and that confidentiality was preserved. All participant
data are stored using a unique study identifier and electronic data are password protected.
In general, regular PA is associated with improved health outcomes and this outweighs the risk of
sedentary lifestyles. However, sudden increases in vigorous PA for otherwise sedentary individuals is
associated with a higher risk of myocardial infarction and of musculoskeletal injuries, which may be
pertinent as we were intervening in a group that is at high risk of CVD. However, one of the components
of BCTs is to deliver the message that PA should be increased in a graded manner rather than suddenly.
The intervention discouraged excessive and/or sudden changes to lifestyles. Weight loss could worsen
frailty by accelerating the usual age-related loss of muscle that leads to sarcopenia, but combining weight
loss with increased PA can actually ameliorate frailty.106 Importantly, our intervention is based on healthier
diets and gradual and sustainable weight loss as opposed to commercial weight-loss programmes. We
considered risks to be small and minimal owing to the exclusion of patients with existing CVD and the use
of GP advice when CVD events occurred during participation.
Adverse events
An AE, which may be classed as serious, was defined as any untoward occurrence during the study that
should be reported to the REC and TSC within an agreed time frame. A suspected unexpected serious AE
was defined as an untoward occurrence that is related to the intervention and is unexpected. Participants
had the opportunity to report AEs at 12-month and 24-month study appointments with the research
assistant as an AE questionnaire was administered, and participants receiving the intervention were able to
report at any time during the intervention period to the HLF. All serious AEs and laboratory values were
reviewed by the principal investigator (PI) and a co-investigator, and the PI was responsible for determining
causality and reporting any AE related to the study to the REC using the National Research Ethics Service
guidance.
The AE questionnaire included asking specifically about physical injuries, which were coded as one of the
following types of injury: (1) dislocation, (2) fracture, (3) sprain/strain, (4) other injury to a muscle/tendon
or (5) other. Details were also collected of how the injury occurred (context, e.g. if the participant fell) and
whether or not any treatment was administered. Cardiovascular events were similarly coded, with the
following categories used: (1) angina, (2) atrial fibrillation, (3) coronary heart disease, (4) coronary bypass,
(5) myocardial infarction, (6) stroke or transient ischaemic attack, or (7) other. Details were also added and
verified by checking the participant’s medical records, as necessary.
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Obtaining informed consent
General practice staff conducted the searches using our guidance and invited potential participants to give
permission for research assistants to contact them. Research assistants invited potential participants to
meet them in the general practice, and they were given verbal and written information about the study
and at least 1 week to think about participating. We invited patients who were eligible but declined
participation to give informed consent for the collection of baseline data to assess the generalisability of
our findings.
Withdrawal and stopping rules
Participants were free to withdraw from the study at any time. If the participant withdrew from the
intervention, they were asked if they were happy to attend follow-up study appointments and for further
data to be collected. If they withdrew from the study without consent to follow-up, no further data were
collected.
There were no formal stopping rules. This is because the intervention did not ask participants to do
anything more than follow usual GP advice regarding diet and PA. However, the PI evaluated the causality
of any AE and advised withdrawal if necessary.
Time period for retention of trial documentation
Copies of patient consent forms were kept for 12 months after the study ended. Personal data that are
identifiable by patient name or address will be destroyed 3 years after the study ended. Other trial records
will be archived for 7 years after the trial ended before being destroyed.
Patient and public involvement
Before the trial began, we held a focus group with 10 patients from a general practice in Peckham,
London. All patients were of African, Caribbean or South Asian ethnicity, first generation migrants and
at high risk of CVD, and were distributed equally between sexes. The group understood the rationale of
the MOVE IT trial. They recognised that daily stressors affect lifestyle choices and welcomed the chance
to talk about this and think differently. The preference was for interventions in an individual format, but
they could see the potential benefits of learning from others in a group. Flexible appointment times were
stressed as being important, so that the intervention could fit around other activities. The patients felt that
it was necessary to provide more information about individual health status rather than just telling patients
that they are at high risk of heart disease. They also gave tips on how to recruit; they thought that by
getting some patients on board, these patients could network in the local community. These comments
were incorporated into the intervention.
We invited this group of patients to form a patient and public involvement (PPI) group to help with the
development of study documentation, including the patient information sheet and consent form. A PPI
group of five patients was formed, and two members remained involved until the end of the trial. Their
role during recruitment involved advertising the trial to both general practices and potential participants,
advising on the development of poster and leaflet campaigns to increase public awareness and actively
recruiting general practice sites across four of the CCGs. As part of the process evaluation, we sought PPI
in the development of topic guides to be used in focus groups to gain feedback from participants who
attended the intervention.
Throughout the trial, the trial team updated PPI members with progress and welcomed feedback. The PPI
members attended all TSC meetings throughout the trial to gain more detailed feedback and discuss
points of interest with the trial manager, PI and co-investigators.
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Chapter 4 Protocol changes
I t was necessary to make amendments to the original protocol for a number of unforeseen reasons andto enable improvement in our study methodology and the collected data.
Low uptake of NHS Health Checks
In parallel to setting up MOVE IT, there were increasing numbers of reports and concerns that there was a
lower-than-anticipated uptake of NHS Health Checks,12 with regional variations in attendance ranging
from 27% to 52% and greater uptake among older patients and in regions of lower deprivation.13 We
also observed this when we started recruiting and that this was delaying the project.
It was necessary to amend the protocol to detail that the researcher would repeat all CVD risk algorithm
measures at screening. General practice searches for eligible participants could therefore not rely on recent
Health Check data but instead on estimates of CVD risk using outdated data or inaccurate substitutions for
missing data.
This change to the protocol led to the exclusion of a large number of patients whose medical record data
suggested that they were at a ≥ 20.0% QRISK2 score but on screening were found to have a score of
< 20.0% (see Chapter 5). Consequently, more resources were required to complete recruitment to target
(substantial amendment; approved in July 2013).
Change to recruitment and study time frame
As research assistants were screening a larger proportion of ineligible patients who could not be
randomised, the recruitment period had to be extended from 12 months to 21 months to allow the target
sample size to be reached. This required an increase in funding to support a greater number of research
assistants and for a longer period of time to support the recruitment procedures at a greater number of
research sites. As a result, the end-of-study follow-ups were also extended by a further 9 months (minor
amendment; approved on 16 March 2015).
Research sites
We initially invited general practice sites with list sizes of > 8000 patients. We extended invitations to
smaller practices with > 5000 patients, as we required an increase in the number of sites owing to the
high number of responses from ineligible patients (substantial amendment; approved in July 2013).
Randomisation
Randomisation was not stratified by general practice and ethnicity as planned, as the numbers of patients
in many practices are not large enough to stratify by both factors. Simple randomisation was agreed to be
the best method, with surgery included as a random factor in the model, and emphasis being on more
practices and fewer patients per practice (substantial amendment; approved in July 2013).
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Research measures
Three blood pressure measures were taken. The third, rather than the mean, systolic blood pressure is used
in the QRISK2 algorithm and will be reported in this final report (substantial amendment; approved on
9 June 2015).
Intervention details
The proposed health trainer job title was changed to HLF to better incorporate the MI aspect of the
intervention whereby the participant was ‘facilitated’ rather than ‘trained’ to make healthy lifestyle changes.
We revised the definition and description of MI to that used in the third edition of the MI textbook.42
The intervention was updated to include a session 0, which was an introductory session via telephone.
The length of group intervention sessions was increased to 120 minutes, rather than 90 minutes, to better
match for attention with the individual intervention sessions (substantial amendment; approved in July 2013).
Further to the above changes, we changed the protocol to state that participants would be seen for
intervention sessions within 6 months from randomisation, as this time period was not initially stated
and the start of intervention sessions was presumed to be immediate. The time period varied greatly owing
to (1) large numbers of participants randomised and waiting to be seen, as a result of the accelerated
recruitment rate to meet the target, and (2) HLF staff turnover and the subsequent recruitment and training
of new staff members, which created delays. When this time period was exceeded, we made every effort
to still engage participants in the intervention and continued to follow-up for the ITT analysis (substantial
amendment; approved on 9 June 2015).
Additional consent procedures
Participants were given the opportunity to consent to the following additional items post randomisation:
l Once participants had completed all research measures, they were asked if we could link their data to
other collaborating research studies in which they also participated (substantial amendment; approved
on 21 September 2015).
l We requested access to Hospital Episodes Statistics data,107 information on all hospital appointments for
up to a 6-year period beginning 12 months before participating in the study. However, as this was
requested after participants completed the study, we did not gain consent from all participants for this
and thus did not seek the Hospital Episodes Statistics data and used only CSRI information on hospital
services usage (substantial amendment; approved on 21 September 2015). We requested that
participants provided consent to these points remotely, via a letter to and a telephone call with the
participant, to avoid unnecessary appointment scheduling (minor amendment; approved on
13 January 2016).
l A small number of participants who received the intervention (group or individual) were randomly
selected to be invited to a focus group to provide feedback. They were asked to provide written
informed consent to take part in an audiotaped focus group (substantial amendment; approved on
7 March 2016).
l A small number of participants were asked to consent to a video recording or photograph of an
intervention session to be used to promote the study for educational and training purposes only
(substantial amendment; approved on 7 March 2016).
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Elaboration of process evaluation: participation bias
We gained ethics approval to collect anonymised demographic data on all patients who were identified as
potentially eligible and invited to participate when screening the GP medical records. These data enabled
an estimation of participation bias through examining differences in age, sex, ethnicity, deprivation and
QRISK2 score between responders and non-responders to the study invitation (substantial amendment;
approved on 8 January 2016).
King’s College London network outage and impact on the fidelity analysis
On 18 October 2016, a university-wide information technology (IT) network outage occurred as a result
of an infrastructure fault, restricting us from accessing the shared network drives in which various trial
data were stored (as per university protocol) and resulting in some data being lost. Although King’s College
London IT services made an extensive effort to forensically retrieve data from backup sources, all audiotaped
intervention session data were lost from the university-managed shared network drive. We estimated this
to be almost 2000 hours of intervention delivery. In addition, we lost data from approximately 200 dietary
recall diaries (which could be re-inputted from their paper copies) and 95 accelerometry data files from the
24-month follow-up. For the accelerometry data, we asked the 95 participants to rewear the accelerometer;
of those, eight declined and consequently had missing data for the PA outcome. We conducted a sensitivity
analysis adjusting for participant rewear of the accelerometer.
The loss of the intervention session data was reported to the TSC. At the subsequent TSC meeting
(on 6 July 2017), its members recommended that we attempt to recover the session recordings from other
sources and conduct the fidelity analysis in accordance with the original plan as closely as possible. Of the
data lost, we were able to recover approximately 400 hours from local backups and physical audiotapes,
with the co-operation of university IT services and previous HLF staff. This precluded us from conducting
the a priori fidelity analysis and randomly selecting coding data from a larger sample of tapes in the
database. Instead, we adapted our analysis plan to code and analyse all of the limited, non-random data
that were available. Furthermore, we had planned to use the data from the fidelity assessment to determine
whether or not the levels of competencies between the HLFs were associated with variations in patient
outcomes or mediated the treatment effect. However, the quality of the data recovered precluded us
from conducting this analysis as well. See Chapter 8 for further details on our adapted fidelity analysis.
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Chapter 5 Main clinical results of the trial
Practice recruitment
Of the 310 general practices with a list size of > 5000 in the 12 South London CCGs that were invited,
126 (40.6%) agreed to participate. A further nine (out of 145) general practice sites with a list size of
< 5000 were recruited. Therefore, a total of 135 (29.7%) of the 455 general practices within the 12 South
London CCGs participated.108 The list of participating general practices is provided in Appendix 2. The
distribution of practices participating in each CCG and the differences in IMD 2010 scores of participating
and non-participating practices are given in Table 3. There were no differences in general practices’
participation by IMD 2010 score.
There was greater initial interest from practices in outer-London CCGs, such as Bromley, Bexley and
Merton, and feedback from inner-London CCGs, such as Lambeth and Wandsworth, was that practices
are overexposed to research studies and may not have the resources to participate. No formal process of
collecting reasons for non-participation of general practices was conducted.
TABLE 3 General practice participation in the MOVE IT trial and practice deprivation by each South London CCG
CCG
General practices
Participating in MOVE IT Not participating in MOVE IT
n (% of all
CCG practices)
IMD 201076 score,
mean (SD)
n (% of all
CCG practices)
IMD 201076 score,
mean (SD)
Bromley 22 (48.9) 16.65 (8.93) 23 (51.1) 15.95 (8.42)
Merton 10 (40.0) 16.40 (5.16) 15 (60.0) 15.62 (7.09)
Lewisham 16 (39.0) 30.32 (4.26) 25 (61.0) 31.28 (3.62)
Southwark 16 (36.4) 31.36 (6.45) 28 (63.6) 30.72 (5.71)
Greenwich 14 (33.3) 30.40 (6.89) 28 (66.7) 30.80 (6.59)
Bexley 9 (33.3) 18.19 (9.98) 18 (66.7) 16.94 (4.68)
Sutton 8 (29.6) 13.00 (4.52) 19 (70.4) 17.44 (6.34)
Croydon 14 (24.1) 22.02 (6.52) 44 (75.9) 25.02 (7.97)
Kingston 6 (23.1) 10.42 (1.09) 20 (76.9) 11.39 (1.35)
Lambeth 9 (18.8) 32.19 (4.58) 39 (81.3) 30.84 (3.72)
Richmond 5 (17.2) 9.69 (1.21) 24 (82.8) 11.28 (3.12)
Wandsworth 6 (14.0) 20.67 (6.24) 37 (86.0) 22.60 (5.38)
Total 135 (29.7) 22.42 (9.85) 320 (70.3) 23.14 (9.20)
Data source: Public Health England [https://fingertips.phe.org.uk/profile/general-practice/data (accessed 1 November 2017)].
Note
t-test comparisons of practice deprivation between participating and non-participating practices in each CCG and, overall,
were non-significant (p > 0.05).
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Participant recruitment and flow through the trial
An electronic search for eligible patients was conducted by each general practice using inclusion and
exclusion criteria as Read codes109 and including a calculated estimate of QRISK2 value based on values for
risk factors already recorded. Participants were recruited between June 2013 and February 2015; recruitment
per CCG is given in Table 4. Figure 2 is the CONSORT flow diagram showing participant progression through
the trial. Screening eligible participants at general practices led to invitations being sent to 17,775 patients.
An expression of interest to take part was received from 3515 patients (a response rate of 19.8%).
Participation biases (the differences between those who responded to the invitation and those who did not)
are explored in Chapter 7 as part of the process evaluation. Following a brief telephone screening questionnaire,
3183 patients attended for a first appointment with a researcher and provided consent.
In the first appointment, eligibility was assessed using all measures required for QRISK2 score calculation.
This led to the exclusion of 1332 participants as they did not meet the eligibility criteria. The main reason
for this (1105 participants; 83.0% of all exclusions) was that the QRISK2 score was < 20.0% on recalculation
at face-to-face screening. For 71 participants, blood test results indicated a raised HbA1c level (> 47mmol/mol)
and they were directed to their GP for further advice and informed that they were not eligible to participate.
Eighty-eight participants did not complete all screening measures and, therefore, QRISK2 could not be
calculated (see Figure 2 for further details of exclusions).
Of the 1851 participants eligible to be randomised, 1742 were randomised and the remaining 109
declined to participate further. Of the randomised sample, 697 were allocated to the group intervention
arm, 523 to the individual intervention arm and 522 to the UC arm.
TABLE 4 Participant recruitment by CCG
CCG Date first participant recruited to trial
Participants, n (%)
Consented (N= 3183) Randomised (N= 1742)
Sutton 7 June 2013 265 (8.3) 151 (8.7)
Merton 10 June 2013 149 (4.7) 79 (4.5)
Kingston 20 June 2013 107 (3.4) 59 (3.4)
Croydon 21 June 2013 472 (14.8) 259 (14.9)
Bexley 3 July 2013 177 (5.6) 103 (5.9)
Richmond 5 July 2013 98 (3.1) 54 (3.1)
Bromley 9 July 2013 885 (27.8) 510 (29.3)
Lewisham 11 September 2013 350 (11.0) 182 (10.4)
Southwark 10 October 2013 134 (4.2) 82 (4.7)
Wandsworth 22 October 2013 139 (4.4) 61 (3.5)
Lambeth 11 November 2013 219 (6.9) 97 (5.6)
Greenwich 6 March 2014 188 (5.9) 105 (6.0)
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Excluded
(n=1332)
• QRISK2 score of < 20%, n =1105
• Did not complete screening, n =88
• HbA1c  > 47 mmol/mol and/or 
   diagnosed with diabetes mellitus, n = 71
• CVD event/heart condition, n =31
• Chronic kidney disease, n =8
• Not fluent in conversational English, n = 4
• Aged >74 years, n =3
• BMI of > 50 kg/m², n=3
• COPD, n =3
• Unable to exercise/immobile, n =3
• Severe mental health condition, n =5
• Another participant in same household – 
   random deselection, n =3
• Taking part in a lifestyle intervention, n=2
• Aged <  40 years, n=1
• Not permanently resident in UK, n =1
• Advanced cancer, n =1
Allocated to group
intervention
(n=697)
• Received group intervention,
n =437
 Completed, n =342
 Did not complete, n =95
• Did not receive group
   intervention, n =260
Allocated to individual
intervention
(n=523)
• Received individual
   intervention, n =406
 Completed, n =290
 Did not complete, n =116
• Did not receive individual
   intervention, n =117
Allocated to usual care
(n=522)
• Received usual care, n=522
Loss by 12-month follow-up
• Withdrawn, n =69
• Died, n =3
• Non-contactable, n =34
• No PA data, n =35
Loss by 24-month follow-up
• Withdrawn, n =94
• Died, n =3
• Non-contactable, n =31
• No PA data, n =26
Primary analysis at 12 months
• Analysed – weight, n = 591, 
   84.8%
• Analysed – PA, n = 557, 79.9%
• Analysed – weight, n = 568, 
   81.5%
• Analysed – PA, n = 543, 77.9%
Primary analysis at 24 months
Consented
(n=3183)
Eligible
(n=1851)
Invited
(n=17,775)
Did not respond 
(n = 14,260) 
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(n=1742)
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Loss by 12-month follow-up
• Withdrawn, n =33 
• Died, n=2
• Non-contactable, n =27
• No PA data, n =43
Loss by 24-month follow-up
• Withdrawn, n =66
• Died, n=2
• Non-contactable, n =35
• No PA data, n =21
Loss by 12-month follow-up
• Withdrawn, n =11
• Died, n =3
• Non-contactable, n =24
• No PA data, n =41
Loss by 24-month follow-up
• Withdrawn, n =32
• Died, n =4
• Non-contactable, n =26
• No PA data, n =21
Primary analysis at 12 months
• Analysed – weight, n = 461, 
   88.1%
• Analysed – PA, n = 418, 
   79.9%
• Analysed – weight, n = 419, 
   80.1%
• Analysed – PA, n =  401, 76.7%
Primary analysis at 24 months
Primary analysis at 12 months  
• Analysed – weight, n = 482, 
   92.3%
• Analysed – PA, n = 443, 
   84.9%
• Analysed – weight, n =  460, 
   88.1%
• Analysed – PA, n = 439, 84.1%
Primary analysis at 24 months
level of
FIGURE 2 The CONSORT flow diagram. COPD, chronic obstructive pulmonary disease. Reproduced from Ismail
et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open
access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license,
which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided
the original work is properly cited, a link to the licence is given, and indication of whether changes were made.
See: https://creativecommons.org/licenses/by/4.0/.
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Intervention delivery
Sessions received
A summary of the intervention received by participants randomised to either of the intervention arms
is presented in Table 5. Overall, 665 participants (54.5%) completed the intervention, whereas
344 participants (28.2%) did not start the intervention sessions and 211 participants (17.3%) started but
did not complete the intervention sessions. Differences in intervention receipt were significantly different
between the intervention arms [χ2(2) = 38.30; p < 0.001].
For all participants who started the intervention (n = 843), a mean of 8.2 (SD 3.2) sessions (median
9 sessions, IQR 7–11 sessions), including the introductory session 0, were received. The differences in
attendance between treatment arms is given in Table 6, with the individual intervention arm attending
significantly more sessions (U = 55,388; p < 0.001).
TABLE 5 Summary of intervention receipt
Intervention received
Participants randomised to intervention arms, n (%)
Group (N= 697) Individual (N= 523) Total (N= 1220)
Did not start intervention 260 (37.3) 117 (22.4) 377 (30.9)
Completed intervention 342 (49.1) 290 (55.4) 632 (51.8)
Did not complete intervention
Attended 1/11 sessions 34 (4.9) 33 (6.3) 67 (5.5)
Attended 2/11 sessions 11 (1.6) 14 (2.7) 25 (2.0)
Attended 3/11 sessions 9 (1.3) 13 (2.5) 22 (1.8)
Attended 4/11 sessions 5 (0.7) 5 (1.0) 10 (0.8)
Attended 5/11 sessions 6 (0.9) 4 (0.8) 10 (0.8)
Attended 6/11 sessions 10 (1.4) 12 (2.3) 22 (1.8)
Attended 7/11 sessions 11 (1.6) 15 (2.9) 26 (2.1)
Attended 8/11 sessions 5 (0.7) 11 (2.1) 16 (1.3)
Attended 9/11 sessions 3 (0.4) 7 (1.3) 10 (0.8)
Attended 10/11 sessions 1 (0.1) 2 (0.4) 3 (0.2)
Reproduced from Ismail et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0)
license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided
the original work is properly cited, a link to the licence is given, and indication of whether changes were made.
See: https://creativecommons.org/licenses/by/4.0/.
TABLE 6 Number of sessions attended, by participants in the intervention arms who started the intervention and
by session type
Sessions
Intervention arm
Group (n= 437) Individual (n= 406)
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
All session types
Including session 0 7.62 (2.96) 8 (6–10) 8.82 (3.38) 11 (8–11)
Excluding session 0 6.72 (2.93) 7 (5–9) 7.83 (3.39) 10 (7–10)
Intensive sessions (n = 6) 4.58 (1.80) 5 (4–6) 5.07 (1.93) 6 (6–6)
Maintenance sessions (n = 4) 2.14 (1.56) 3 (0–4) 2.76 (1.70) 4 (1–4)
Reproduced from Ismail et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0)
license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided
the original work is properly cited, a link to the licence is given, and indication of whether changes were made.
See: https://creativecommons.org/licenses/by/4.0/.
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Participants attended a mean of 4.8 sessions (SD 1.9, median 6, IQR 4–6 sessions) out of the six intensive
sessions and a mean of 2.4 sessions (SD 1.7, median 3, IQR 0.5–4 sessions) out of the four maintenance
sessions. Participants in the individual intervention arm attended significantly more intensive sessions
(U = 62,806; p < 0.001) and maintenance sessions (U = 65,424; p < 0.001) than participants in the group
intervention arm. A comparison of attendance between the arms and session types is presented in Table 6.
Delays to intervention commencement
There were unexpected delays to intervention commencement, due to factors mentioned in Chapter 4. The
date of intervention commencement was missing for 35 participants (2.9%). We endeavoured to start the
intervention within 6 months of randomisation, and this was possible for 986 out of 1185 participants
(83.2%): 561 out of 682 (82.3%) in the group intervention arm and 425 out of 503 (84.5%) in the individual
intervention arm. The time between randomisation and the start of the intervention for participants randomised
to each intervention arm is illustrated in Figure 3.
Participants who were randomised to receive the intervention (in either the group intervention arm or
the individual intervention arm) waited a mean of 3.12 ± 2.70 months (minimum 0.16, maximum 15.21,
median 2.07, IQR 0.92–4.99 months) from randomisation to their scheduled session 0. The wait time did
not differ between the group (3.17 ± 2.78 months; n = 682) and individual (3.04 ± 2.59 months; n = 503)
arms [t(1120.5) = 0.83; p = 0.41].
Intervention duration
For those participants attending at least one of sessions 1–10 (n = 782), we calculated the time between
session 0 and the final session attended. Across the intervention arms, the mean time between session 0
and the final session was 330.6 ± 173.8 days [minimum 6, maximum 808, median 366, IQR 231–440 days;
dates were unavailable for one participant (0.1%)]. The time between session 0 and the final session was
significantly longer in the individual intervention arm (355.6 ± 173.1 days; n = 373) than in the group
intervention arm (307.8 ± 171.4 days; n = 408) [t(771.4) = 3.87; p < 0.001].
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FIGURE 3 Time between randomisation and intervention start date (session 0), by intervention arm. Reproduced
from Ismail et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This
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Reasons for not starting or not completing the intervention
When participants decided not to start the intervention that they had been randomly allocated to, they
were invited to provide a reason for this. When participants decided to stop attending intervention sessions
before the course finished, they were also asked for a reason. Table 7 presents the reasons given for not
starting or not completing the intervention by participants in each intervention arm.
We qualitatively explore the reasons for non-completers withdrawing from treatment, as part of the
process evaluation, in Chapter 9.
Participant adherence to the intervention
After the completion of each intervention session, the HLF was responsible for recording (1) if the
participant set a target for that session (yes/no) and (2) if that target was achieved (coded as no/partially/
fully). Session 0 was not included as participants were not asked to set goals for that session.
Of the 1220 participants randomised to the intervention arms, 774 (63.44%) had available adherence
data. Of those, 407 (58.39% of those randomised) were in the group intervention arm and 367 (70.17%
of those randomised) were in the individual intervention arm.
The 774 participants attended a total of 5932 sessions. Table 8 shows the rate of targets set overall and by
intervention arm and Figure 4 shows the number of targets set at each session. The overall rate of targets
set differed significantly between arms [χ2(1) = 6.12; p = 0.01] but the distribution of targets set at each
session did not differ significantly between arms [χ2(9) = 16.18; p = 0.06].
For each target set, the HLF also recorded if the participant achieved it; achievement was rated as
‘not at all’, ‘partially’ or ‘fully’. Table 9 shows the number of targets achieved by intervention arm and
in total; the distribution of targets achieved (excluding missing data) differed significantly between arms
[χ2(2) = 7.25; p = 0.03]. Figure 5 shows the distribution of target achievement at each session number.
TABLE 7 Reason given for not starting or not completing the intervention, by participants in each intervention arm
Reason
Intervention arm, n (%)
Group Individual
Did not start
intervention
(N= 103)
Did not complete
intervention
(N= 116)
Did not start
intervention
(N= 241)
Did not complete
intervention
(N= 95)
Delay to start of intervention 3 (1.2) 1 (1.1) 2 (1.7) 4 (3.4)
Ill health 12 (4.6) 7 (7.4) 6 (5.1) 10 (8.6)
Location of sessions 24 (9.2) 3 (3.2) 2 (1.7) 1 (0.9)
Multiple reasons 9 (3.5) 3 (3.2) 3 (2.6) 2 (1.7)
No benefit 6 (2.3) 11 (11.6) 5 (4.3) 4 (3.4)
No longer interested 41 (15.8) 13 (13.7) 14 (12.0) 18 (15.5)
Other 7 (2.7) 6 (6.3) 2 (1.7) 6 (5.2)
Too busy 68 (26.2) 20 (21.1) 26 (22.2) 38 (32.8)
Unable to contact 31 (11.9) 13 (13.7) 25 (21.4) 20 (17.2)
Unhappy with intervention design 7 (2.7) 9 (9.5) 6 (5.1) 10 (8.6)
Unknown 52 (20.0) 9 (9.5) 26 (22.2) 3 (2.6)
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FIGURE 4 Number of targets set, by each session and intervention arm.
TABLE 9 Summary of targets achieved for intervention adherence
Target achieved?
Targets set by trial arm, n (%)
Group intervention Individual intervention Total
Not at all 143 (5.54) 158 (5.54) 301 (5.54)
Partially 664 (25.72) 679 (23.81) 1343 (24.71)
Fully 1376 (53.29) 1676 (58.77) 3052 (56.16)
Missing rating 399 (15.45) 339 (11.89) 738 (13.58)
Total 2582 2852 5434
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TABLE 8 Summary of intervention adherence: target set by intervention arm
Target set?
Participants randomised to intervention arms with available data, n (%)
Group (N= 407) Individual (N= 367) Total (N= 774)
Target set at session 2582 (90.66) 2852 (92.48) 5434 (91.60)
No target set 266 (9.34) 232 (7.52) 498 (8.40)
Total 2848 3084 5932
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The rate of target achievement differed by session number [χ2(18) = 116.99; p < 0.0001]. When looking
within each session number, the rate of target achievement differed significantly between the intervention
arms at sessions 1 [χ2(2) = 6.40; p = 0.04] and 6 [χ2(2) = 6.75; p = 0.03] only.
Loss to follow-up
Participants were not seen at follow-up for one of three reasons: (1) they had withdrawn from the study,
(2) they had died or (3) they were non-contactable at the follow-up due date (attempts were made to
contact the participant up to 6 months after the due date). Participants who were randomised to either of
the intervention arms but who did not take part in the intervention did not necessarily withdraw from the
study, and their data are included at follow-up to carry out the ITT analysis. Table 10 shows loss to follow-up
at both the 12-month follow-up and the 24-month follow-up, with the reasons for withdrawal given.
Those who were permanently lost to follow-up at 12 months (withdrawn/died) were not contacted again
at 24 months, whereas those who were non-contactable at 12 months were contacted again at 24 months.
We exceeded the target follow-up of 83% of participants required by the original sample size calculation.
The total loss to follow-up across all arms of the study at 12 months was 11.8%; it was 15.2% in the
group intervention arm, 11.9% in the individual intervention arm and 7.3% in the UC arm. The total loss
to follow-up across all arms of the study at 24 months was 16.8%; it was 18.4% in the group intervention
arm, 19.7% in the individual intervention arm and 11.9% in the UC arm. Data were collected for 91.6%
of all participants for at least one of the 12- and 24-month follow-ups, and for 79.7% of participants at
both 12 and 24 months. The differences in loss to follow-up between the treatment arms were significant
at the 12-month follow-up [χ2(2) = 17.99; p < 0.001] and the 24-month follow-up [χ2(2) = 13.39; p = 0.001].
Withdrawal rates differed significantly between treatment arms at both the 12-month follow-up [χ2(2) = 27.08;
p < 0.001] and the 24-month follow-up [χ2(2) = 15.98; p < 0.001].
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FIGURE 5 Distribution of target achievement, by intervention arm and session number.
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Accelerometer data completeness
The remaining participants did attend follow-up appointments but did not necessarily complete accelerometer
wear for the collection of PA outcomes. Table 11 provides details of the number of accelerometer data
collected by trial arm at each time point. The required PA data at baseline was ≥ 5 days of ≥ 540 minutes of
accelerometer wear. A number of participants did not wear the accelerometer for the sufficient amount of
time at baseline and, therefore, were randomised in error. In the original analysis plan, we stated that we
included those with ≥ 4 days of data in the primary analysis to limit exclusions; however, after discussions
with the statistician of the TSC (James Carpenter) we included all participants to minimise loss of power
and to avoid inducing a potential bias. In agreement with the TSC, for all time points we used the wearable
data points if participants wore the accelerometer for at least 1 full day (≥ 540 minutes). Otherwise, the
data were considered missing.
TABLE 10 Reasons for loss to follow-up, by arm at 12 and 24 months
Reason
Trial arm, n (%)
Group intervention Individual intervention UC
By 12-month follow-up
Death 3 (2.8) 2 (3.2) 3 (7.9)
Withdrawal
Ill health 11 (10.4) 5 (8.1) 3 (7.9)
Too busy 9 (8.5) 10 (16.1) 1 (2.6)
Unhappy with study 6 (5.7) 5 (8.1) 1 (2.6)
No perceived benefit 6 (5.7) 6 (9.7) 1 (2.6)
No longer interested 11 (10.5) 2 (3.2) 3 (7.9)
Relocated 8 (7.5) 2 (3.2) 2 (5.3)
Unknown 18 (17.0) 3 (4.8) 0 (0.0)
Non-contactable 34 (32.1) 27 (43.5) 24 (63.2)
Total 106 (100.0) 62 (100.0) 38 (100.0)
By 24-month follow-up
Death 3 (2.3) 2 (1.9) 4 (6.5)
Withdrawal
Ill health 22 (17.2) 13 (12.6) 15 (24.2)
Too busy 12 (9.4) 15 (14.6) 2 (3.2)
Unhappy with study 8 (6.3) 9 (8.7) 5 (8.1)
No perceived benefit 8 (6.3) 8 (7.8) 1 (1.6)
No longer interested 14 (10.9) 10 (9.7) 6 (9.7)
Relocated 12 (9.4) 3 (2.9) 3 (4.8)
Unknown 18 (14.1) 8 (7.8) 0 (0.0)
Non-contactable 31 (24.2) 35 (34.0) 26 (41.9)
Total 128 (100.0) 103 (100.0) 62 (100.0)
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TABLE 11 Summary of accelerometer data collection at each time point and by trial arm
Accelerometer data collection
Time point (n)
Baseline 12-month follow-up 24-month follow-upa
Trial arm
Group
intervention
Individual
intervention UC
Group
intervention
Individual
intervention UC
Group
intervention
Individual
intervention UC
No accelerometer issued
Withdrawn – – – 69 33 11 94 66 32
Died – – – 3 2 3 3 2 4
Non-contactable – – – 34 27 24 31 35 26
Number of valid days (≥ 540 minutes) that the accelerometer was worn
0 9 7 5 35 43 41 26 21 21
1 4 3 4 2 4 3 2 3 5
2 6 7 8 8 5 7 10 8 8
3 12 3 8 12 4 9 11 8 9
4 21 16 25 20 13 17 20 10 18
5 63 46 28 47 31 40 44 40 43
6 122 87 94 115 65 84 98 70 77
7 460 354 350 353 296 283 358 262 279
a Owing to the IT outage, 95 accelerometer data files were lost: 33 in the group intervention arm, 34 in the individual intervention arm and 28 in the UC arm. A total of 87 participants
rewore the accelerometer: 29 in the group intervention arm, 31 in the individual intervention arm and 27 in the UC arm.
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The total percentage of missing activity data across all arms of the study at baseline was 0.5%
(n = 8 participants) and at 12 months it was 18.6%: 20.1% in the group intervention arm, 20.1% in the
individual intervention arm and 15.1% in the UC arm [χ2(2) = 5.9; p = 0.052]. The total percentage of
missing activity data across all arms of the study at 24 months was 20.6%: 22.1% in the group intervention
arm, 23.3% in the individual intervention arm and 15.9% in the UC arm [χ2(2) = 10.4; p = 0.006]. At least
one activity follow-up measurement was available for 88.1% of the study participants: 86.4% in the group
intervention arm, 86.6% in the individual intervention arm and 91.8% in the UC arm [χ2(2) = 9.7; p = 0.008].
Baseline characteristics
Tables 12 and 13 present the baseline characteristics and secondary outcome measures, respectively, of
participants by treatment arm for baseline comparability. [For baseline values of the primary outcomes, see
Tables 16 (PA) and 18 (weight).] A comparison of baseline characteristics between arms did not reveal any
major imbalance, including all prespecified variables that may affect primary outcome (age, sex, ethnicity,
IMD 2015 score, education status, marital status and smoking status).
TABLE 12 Baseline characteristics of participants, by trial arm
Characteristic
Trial arm
Total (N= 1742)
Group
intervention
(N= 697)
Individual
intervention
(N= 523) UC (N= 522)
Age (years)
Mean (SD) 69.59 (4.16) 69.76 (4.11) 69.96 (4.05) 69.75 (4.11)
Median (minimum,
maximum)
70.34 (48.94, 75.83) 70.77 (48.27, 75.83) 70.61 (54.02, 75.51) 70.56 (48.27, 75.83)
IQR (lower quartile–
upper quartile)
5.24 (67.44–72.68) 5.20 (67.66–72.86) 5.54 (67.6–73.14) 5.33 (67.55–72.88)
Sex, n (%)
Male 593 (85.1) 457 (87.4) 440 (84.3) 1490 (85.5)
Female 104 (14.9) 66 (12.6) 82 (15.7) 252 (14.5)
Ethnicity,a n (%)
White 614 (88.1) 471 (90.1) 473 (90.6) 1558 (89.4)
Asian or Asian mixed 75 (10.8) 45 (8.6) 41 (7.9) 161 (9.2)
Black or black mixed 8 (1.1) 7 (1.3) 8 (1.5) 23 (1.3)
Current employment?, n (%)
Yes 166 (23.8) 114 (21.8) 99 (19.0) 379 (21.8)
No 531 (76.2) 409 (78.2) 423 (81.0) 1363 (78.2)
Qualifications, n (%)
No formal qualifications 186 (27.2) 126 (24.4) 122 (23.8) 434 (25.3)
O level/GCSE/CSE/NVQ 188 (27.4) 141 (27.3) 143 (27.9) 472 (27.6)
A level or higher 311 (45.4) 249 (48.3) 247 (48.2) 807 (47.1)
Relationship status, n (%)
Married/cohabiting 521 (74.7) 412 (78.8) 371 (71.1) 1304 (74.9)
Divorced/separated/
widowed
100 (14.3) 62 (11.9) 82 (15.7) 244 (14.0)
Single 76 (10.9) 49 (9.4) 69 (13.2) 194 (11.1)
continued
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TABLE 12 Baseline characteristics of participants, by trial arm (continued )
Characteristic
Trial arm
Total (N= 1742)
Group
intervention
(N= 697)
Individual
intervention
(N= 523) UC (N= 522)
IMD 2015 score111
n 695 522 522 1739
Mean (SD) 15.52 (10.75) 16.26 (10.82) 16.43 (11.17) 16.02 (10.90)
IMD 2015 quintile, n (%)
First (least affluent) 63 (9.1) 46 (8.8) 52 (10.0) 161 (9.3)
Second 122 (17.6) 125 (23.9) 108 (20.7) 355 (20.4)
Third 136 (19.6) 88 (16.9) 93 (17.8) 317 (18.2)
Fourth 166 (23.9) 116 (22.2) 124 (23.8) 406 (23.3)
Fifth (most affluent) 208 (29.9) 147 (28.2) 145 (27.8) 500 (28.8)
Smoking status, n (%)
Current smoker 112 (16.1) 75 (14.3) 81 (15.5) 268 (15.4)
Ex-smoker 380 (54.5) 315 (60.2) 290 (55.6) 985 (56.5)
Non-smoker 205 (29.4) 133 (25.4) 151 (28.9) 489 (28.1)
Number of cigarettes per day if current smoker
Mean (SD) 11.60 (8.36) 11.04 (8.12) 11.15 (9.15) 12.70 (10.88)
Median (minimum,
maximum)
10 (0, 50) 10 (1, 45) 9 (1, 40) 10 (0, 100)
IQR (lower quartile–
upper quartile)
13 (5–18) 10 (5–15) 14 (4–18) 13 (5–8)
Alcohol intake (AUDIT score), n (%)
Abstainer (0) 73 (10.5) 54 (10.3) 55 (10.5) 182 (10.4)
Low risk (1–7) 506 (72.6) 397 (75.9) 383 (73.4) 1286 (73.8)
Possibly harmful (≥ 8) 118 (16.9) 72 (13.8) 84 (16.1) 274 (15.7)
Depressive symptoms (PHQ-9 score)
Mean (SD) 2.07 (3.38) 1.98 (3.05) 1.88 (3.13) 1.99 (3.21)
Median (minimum,
maximum)
0 (0, 26) 0 (0, 18) 0 (0, 21) 0 (0, 26)
IQR (lower quartile–
upper quartile)
3 (0–3) 3 (0–3) 3 (0–3) 3 (0–3)
Severity of depressive symptoms (PHQ-9 score), n (%)
None (0–4) 583 (83.6) 436 (83.4) 448 (85.8) 1467 (84.2)
Mild (5–9) 82 (11.8) 72 (13.8) 51 (9.8) 205 (11.8)
Moderate (10–14) 23 (3.3) 10 (1.9) 18 (3.4) 51 (2.9)
Moderately severe
(15–19)
7 (1.0) 5 (1.0) 4 (0.8) 16 (0.9)
Severe (20–27) 2 (0.3) 0 (0.0) 1 (0.2) 3 (0.2)
Rheumatoid arthritis?, n (%)
Yes 17 (2.9) 18 (3.9) 17 (3.5) 52 (3.4)
No 574 (97.1) 443 (96.1) 465 (96.5) 1482 (96.6)
Prescribed blood pressure medication?, n (%)
Yes 385 (55.2) 280 (53.5) 276 (53.0) 941 (54.0)
No 312 (44.8) 243 (46.5) 245 (47.0) 800 (46.0)
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TABLE 12 Baseline characteristics of participants, by trial arm (continued )
Characteristic
Trial arm
Total (N= 1742)
Group
intervention
(N= 697)
Individual
intervention
(N= 523) UC (N= 522)
Family history of angina or myocardial infarction?, n (%)
Yes 192 (27.5) 140 (26.8) 148 (28.4) 480 (27.6)
No 505 (72.5) 383 (73.2) 374 (71.6) 1262 (72.4)
A level, Advanced level; CSE, Certificate of Secondary Education; GCSE, General Certificate of Secondary Education;
NVQ, National Vocational Qualification; O level, Ordinary level.
a The number of categories of ethnicity data was reduced from 17 to 3. One participant born in Chile was initially coded
as ‘other ethnicity’ and recoded to ‘white ethnicity’.
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TABLE 13 Secondary outcome measures at baseline, by trial arm
Measure
Trial arm
Total
Group
intervention
Individual
intervention UC
QRISK2 score (%)
n 697 523 522 1742
Mean (SD) 24.95 (4.79) 25.26 (5.27) 24.93 (4.81) 25.04 (4.94)
BMI (kg/m2)
n 697 523 522 1742
Mean (SD) 28.17 (4.11) 28.31 (4.28) 28.37 (4.59) 28.27 (4.31)
Total cholesterol (mmol/l)
n 697 522 522 1741
Mean (SD) 5.09 (1) 5.10 (1.01) 5.05 (1.00) 5.08 (1.00)
LDL cholesterol (mmol/l)
n 694 515 517 1726
Mean (SD) 3.11 (0.85) 3.14 (0.89) 3.07 (0.88) 3.11 (0.87)
Total cholesterol/HDL ratio
n 697 523 522 1742
Mean (SD) 4.17 (1.13) 4.20 (1.16) 4.11 (1.13) 4.16 (1.14)
HbA1c level (mmol/mol)
n 684 515 515 1714
Mean (SD) 37.58 (3.39) 37.55 (3.48) 37.56 (3.45) 37.56 (3.43)
Waist circumference (cm)
n 692 520 520 1732
Mean (SD) 102.37 (11.64) 103.24 (11.83) 102.54 (12.29) 102.68 (11.89)
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Missing data
Patterns of missing follow-up data for the primary outcome were investigated by comparing the baseline
data of those with missing primary outcome data at follow-up with the data of those who provided
follow-up data. Participants missing 12-month follow-up assessment data walked significantly less at
baseline (6509.0 vs. 6802.6 steps per day; t = 1.99; p = 0.048) and were significantly more likely to be
current smokers [23.1% vs. 14.3%; χ2(2) = 13.6; p = 0.001]. Participants with missing 24-month follow-up
assessment data walked significantly less at baseline (6376.9 vs. 6833.1 steps per day; t = –2.78; p = 0.006),
were significantly more likely to be current smokers [22.0% vs. 14.4%; χ2(2) = 6.4; p = 0.041], were
significantly more likely to have no formal qualifications [23.8% vs. 33.2%; χ2(2) = 12.3; p = 0.002] and
were significantly more likely to be more depressed (PHQ-9 score of 1.89 vs. 2.47; t = 244; p = 0.015).
There were no differences between numbers of participants missing at either follow-up point compared
with participants who were present in age, sex, weight, BMI, QRISK2 score, relationship status, ethnicity,
IMD 2015 score111 or alcohol consumption (AUDIT score).
Predictors of missing outcome data at 12 and 24 months
In addition to participants missing the follow-up assessment, activity data were also missing because
accelerometers were not worn for sufficiently long enough. Two participants did not provide weight data
at 24 months. An analysis of missing outcome data was therefore carried out in addition to an analysis of
missing attendance data. A stepwise logistic regression with baseline variables, treatment arm, borough
at baseline and potential predictors of missing outcome data at 12 and 24 months for weight and PA
separately revealed that education, smoking status, PHQ-9 depression score and treatment arm were the
most important predictors. However, only little variation was explained by the models (< 2.5% pseudo-R2).
Education, smoking status and PHQ-9 depression score were included as predictors of missingness in a
sensitivity analysis to assess potential bias due to missing outcome data.
Table 14 presents a summary of baseline comparisons between participants with missing data at the
12-month follow-up and those who attended the 12-month follow-up. Table 15 presents a summary of
the baseline comparison between participants with missing data at the 24-month follow-up and those
who attended the 24-month follow-up.
TABLE 14 Summary of baseline characteristics of participants with present vs. missing primary outcome data at the
12-month follow-up
Missing/present
data
Characteristic
Weight (kg) BMI (kg/m2)
PA (number
of steps) Age (years)
QRISK2
score (%)
PHQ-9 total
score
Missing
Mean 84.07 28.89 6509.043 68.94 24.82 2.63
SD 18.45 5.47 2024.38 4.10 5.67 3.79
n 208 208 202 208 208 208
Present
Mean 83.61 28.32 6802.64 70.04 24.94 1.82
SD 14.91 4.51 2755.58 4.04 4.74 3.07
n 1534 1534 1532 1534 1534 1534
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Primary outcomes
Physical activity
Table 16 presents a descriptive summary of the PA (number of steps) outcome by trial arm and time point.
These are the imputed data (methods are described in Chapter 3) and are used for the analyses. Report
Supplementary Material 1 presents a descriptive summary of the original (non-imputed) data, which are
simply the means of all wearable data points per participant. We observed a near-perfect correlation
(r’s > 0.98) between the imputed and original data at each time point. Figure 6 shows the mean PA level
with 95% CIs for each arm over time.
TABLE 15 Summary of baseline characteristics of participants with present vs. missing primary outcome data at the
24-month follow-up
Missing/present
data
Characteristic
Weight (kg) BMI (kg/m2)
PA (number
of steps) Age (years)
QRISK2
score (%)
PHQ-9 total
score
Missing
Mean 84.43 28.63 6376.94 69.71 25.32 2.47
SD 15.35 4.44 2497.19 4.32 5.12 3.87
n 293 293 287 293 293 293
Present
Mean 83.43 28.20 6833.13 69.76 24.98 1.89
SD 15.00 4.28 2752.55 4.07 4.91 3.05
n 1449 1449 1447 1449 1449 1449
TABLE 16 Summary of PA (number of steps) outcome, by trial arm
Time point
Trial arm
Total (N= 1742)
Group intervention
(N= 697)
Individual intervention
(N= 523) UC (N= 522)
Baseline
n (%) 695 (99.71) 519 (99.24) 520 (99.62) 1734 (99.54)
Mean (SD) 6692.78 (2702.08) 6820.87 (2747.26) 6781.18 (2708.37) 6757.63 (2716.55)
12-month follow-up
n (%) 557 (79.91) 418 (79.92) 443 (84.87) 1418 (81.40)
Mean (SD) 6847.70 (2921.44) 6918.56 (2867.54) 6738.29 (2872.85) 6834.41 (2889.32)
24-month follow-up
n (%) 543 (77.91) 401 (76.67) 439 (84.10) 1383 (79.39)
Mean (SD) 6412.51 (2716.39) 6584.61 (2729.06) 6520.21 (2861.38) 6496.60 (2765.79)
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Assessment of assumptions
Distribution of data
Box plots, Q–Q plots and histograms reveal unimodal distribution with some positive skew for PA (see
Report Supplementary Material 1); however, the skew is similar in all groups at all time measurements.
Furthermore, there are no serious outliers. This suggests that the distribution of the outcome measures
does not seriously violate the assumption of being normally distributed and that there is no need for
transformations.
Assessment of standard deviations between arms and over time
Assessments of SDs reveal only small differences in variances between groups or over time for PA (see
Table 16), which further justifies the use of a mixed-effects model with continuous outcome data assuming
a multivariate normal distribution for the analysis of PA.
The primary analysis (mixed-effects regression) of the treatment effect on PA was conducted on 2801
observations. There were 133 unique general practices, with a mean of 21.1 observations for each (range
1–99 observations). There were 1534 unique participant identifiers, with a mean of 1.8 observations for
each (range 1–2 observations). Table 17 presents the pairwise comparisons. The fixed and random-effects
outputs can be found in Report Supplementary Material 1.
There were only minor and non-significant differences between treatment arms in PA levels at 12 or
24 months. At 12 months, compared with participants in the UC arm, participants in the individual
intervention arm walked, on average, 210 steps (95% CI –19.5 to 439.9 steps) more and those in the
group intervention arm walked, on average, 131 steps (95% CI –85.3 to 347.5 steps) more. All differences
(including limits of the 95% CIs) were less than the minimum clinically significant difference (MCD) of
675 steps as defined in the study protocol. Similarly, at the 12-month follow-up and using 97.5% CIs,
we observed minor and non-significant differences between the individual and UC arms (mean difference
210.22 steps, 97.5% CI –52.44 to 472.89 steps) and the group and UC arms (mean difference 131.10 steps,
97.5% CI –116.35 to 378.55 steps).
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Weight
Table 18 presents a descriptive summary of weight by trial arm and at each time point. Figure 7 shows the
mean weight with 95% CIs for each arm over time.
Assessment of assumptions
Distribution of data
Box plots, Q–Q plots and histograms reveal unimodal distribution with only minor positive skew for weight
(see Report Supplementary Material 1). The skew is similar in all groups at all time points. Furthermore,
there are no serious outliers. This suggests that the distribution of the outcome measures could be treated
as normally distributed without the need for transformations.
TABLE 17 Pairwise comparisons of trial arms of treatment effect on the primary outcomes
Comparisons
Outcome
PA (number of steps) Weight (kg)
Mean difference (95% CI) p-value Mean difference (95% CI) p-value
12-month follow-up
Individual and UC 210.22 (–19.46 to 439.91) 0.073 –0.55 (–0.95 to –0.14) 0.008
Group and UC 131.1 (–85.28 to 347.48) 0.24 –0.52 (–0.90 to –0.13) 0.009
Individual and group 79.12 (–157.73 to 315.98) 0.51 –0.03 (–0.43 to 0.37) 0.89
24-month follow-up
Individual and UC 7.24 (–224.01 to 238.5) 0.95 –0.42 (–0.93 to 0.09) 0.104
Group and UC 70.05 (–288 to 147.9) 0.53 –0.03 (–0.49 to 0.44) 0.91
Individual and group 77.29 (–153.37 to 307.95) 0.51 –0.40 (–0.86 to 0.07) 0.096
TABLE 18 Summary of weight (kg) outcome by trial arm
Time point
Trial arm
Total (N= 1742)
Group intervention
(N= 697)
Individual intervention
(N= 523) UC (N= 522)
Baseline
n (%) 697 (100) 523 (100) 522 (100) 1742 (100)
Weight (kg), mean (SD) 83.15 (14.75) 84.15 (15.35) 83.65 (15.19) 83.60 (15.06)
12-month follow-up
n (%) 591 (84.79) 461 (88.15) 482 (92.34) 1534 (88.06)
Weight (kg), mean (SD) 82.59 (15.19) 83.31 (15.13) 83.43 (15.07) 83.07 (15.13)
24-month follow-up
n (%) 568 (81.49) 419 (80.11) 460 (88.12) 1447 (83.07)
Weight (kg), mean (SD) 82.72 (15.29) 82.98 (15.40) 83.10 (15.13) 82.92 (15.26)
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Assessment of standard deviations between arms and over time
Assessments of SDs reveal little differences in variances between groups or over time for each scale
(see Table 18), which further justifies the use of a mixed-effects model with continuous outcome data,
assuming a multivariate normal distribution for the analysis of weight.
The primary analysis (mixed-effects regression) of the treatment effect on weight was conducted on 2981
observations. There were 133 unique general practices, with a mean of 22.4 observations for each (range
2–104 observations). There were 1595 unique participant identifiers, with a mean of 1.9 observations for
each (range 1–2 observations). Table 17 presents the pairwise comparisons. The fixed and random-effects
outputs can be found in Report Supplementary Material 1.
There was a small but significant mean difference between the individual and UC arms of –0.55 kg
(95% CI –0.95 to –0.14 kg) and between the group and UC arms of –0.52 kg (95% CI –0.90 to –0.13 kg).
However, the differences (including the 95% CI limits) are below the MCD of 1.25 kg. There was no
difference between the group and individual intervention arms (mean –0.03 kg, 95% CI –0.43 to 0.37 kg).
At 24 months, no significant differences were observed. Similarly, at the 12-month follow-up and using
97.5% CIs, we observed minor differences between the individual and UC arms (mean difference
–0.55 kg, 97.5% CI –1.01 to –0.08 kg) and the group and UC arms (mean difference –0.52 kg, 97.5% CI
–0.96 to –0.08 kg).
Sensitivity analyses
Sensitivity analysis adjusting for imbalances in baseline characteristics
No imbalances were observed in any of the prespecified baseline characteristics; therefore, a sensitivity
analysis adjusting for these confounders was not carried out for either of the primary outcomes.
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A total of 15 sensitivity analyses were conducted for each (except for two instances; the weight outcome
was not completed) of the primary outcomes:
1. adjusting for partially nested random effect for therapist
2. adding therapist and general practice as random factors and exchangeable residual covariance matrix
3. removing potential outliers (removed 12 for weight and 6 for PA)
4. only including patients with a BMI of > 25 kg/m2 (analysed 2298 for weight and 2159 for PA)
5. adjusting for treatment compliance, including participants in the group or individual intervention arms
who attended at least one intervention session (analysed 2427 for weight and 2305 for PA)
6. adjusting for the delay in intervention start (continuous variable)
7. adjusting for the unblinding of the research assistant at each follow-up appointment (binary variable)
8. adjusting for the number of days of accelerometer wear at baseline (> 3 days, binary variable)
9. adjusting for the number of days of accelerometer wear at baseline (> 5 days, binary variable)
10. adjusting for the number of valid days of accelerometer wear at baseline (≥ 540 minutes, continuous
variable); not completed for weight
11. adjusting for the number of days of accelerometer wear at each follow-up appointment (continuous
variable); not completed for weight
12. adjusting for a BMI score of < 25 kg/m2 at baseline (binary variable)
13. adjusting for a QRISK2 score ≥ 20.0% at baseline (binary variable)
14. adjusting for predictors (PHQ-9, smoking status and education) of missing outcome data
15. adjusting for accelerometer rewear at the 24-month follow-up (binary variable); not completed
for weight.
Report Supplementary Material 1 presents the output of the sensitivity analyses for each of the primary
outcomes, following the numbering above. None of the above sensitivity analyses altered our conclusions
for either of the primary outcomes.
Complier-average causal effect analysis
Because there is no evidence of any clinically important treatment effect using a per-protocol analysis
(analysing only compliers in the treatment arms), we did not conduct a complier-average causal effect
(CACE) analysis. A lack of a clear binary adherence variable for all participants also prevented us from
undertaking a reliable CACE analysis.
Secondary outcomes
Table 19 presents the pairwise comparison output for each of the secondary outcomes. We did not
observe any treatment effects for any of the secondary outcomes at 12 or 24 months.
Dietary intake analysis
Table 20 shows nutrient intake at each time point and by treatment arm. The linear mixed-effects models
showed four significant effects for three of the nutrients:
1. fat: a time effect (b = –3.19, 95% CI –6.10 to –0.13)
2. fibre: a treatment-arm-by-time interaction effect for the group intervention arm versus the UC arm
(b = 1.20, 95% CI 0.15 to 2.29)
3. saturated fat: a treatment arm effect for the group intervention arm versus the UC arm (b = –3.32,
95% CI –6.37 to –0.11)
4. saturated fat: a time effect (b = –1.53, 95% CI –2.89 to –0.20).
The mediation analyses revealed that none of the nutrients of interest at the 12-month follow-up mediated
the effect of the intervention on the 24-month outcomes (p > 0.24 for all analyses).
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TABLE 19 Pairwise comparisons between trial arms of treatment effect on secondary outcomes
Comparison
Secondary outcome
QRISK2 score (%) HbA1c level (%) LDL cholesterol level (mmol/l)
Diastolic blood pressure
(mmHg)
Systolic blood pressure
(mmHg)
Mean difference
(95% CI) p-value
Mean difference
(95% CI) p-value
Mean difference
(95% CI) p-value
Mean difference
(95% CI) p-value
Mean difference
(95% CI) p-value
12-month follow-up
Individual and UC –0.14 (–0.68 to 0.40) 0.62 0 (–0.37 to 0.38) 0.99 0 (–0.07 to 0.08) 0.94 –1.12 (–2.25 to 0.01) 0.051 –1.83 (–3.96 to 0.29) 0.09
Group and UC –0.28 (–0.79 to 0.23) 0.29 0.08 (–0.27 to 0.42) 0.66 0 (–0.07 to 0.07) 0.96 –0.25 (–1.29 to 0.80) 0.64 –0.61 (–2.58 to 1.37) 0.55
Individual and
group
0.14 (–0.36 to 0.64) 0.59 –0.08 (–0.41 to 0.25) 0.65 0 (–0.07 to 0.08) 0.90 –0.88 (–1.94 to 0.19) 0.107 –1.23 (–3.23 to 0.77) 0.23
24-month follow-up
Individual and UC 0.05 (–0.63 to 0.72) 0.89 0.02 (–0.39 to 0.43) 0.91 0.05 (–0.04 to 0.14) 0.26 –1.04 (–2.20 to 0.11) 0.077 –0.29 (–2.37 to 1.79) 0.79
Group and UC 0.01 (–0.68 to 0.71) 0.97 0.19 (–0.20 to 0.59) 0.33 0.07 (–0.01 to 0.15) 0.108 –0.07 (–1.21 to 1.07) 0.90 1.74 (–0.21 to 3.68) 0.08
Individual and
group
0.03 (–0.64 to 0.71) 0.92 –0.17 (–0.50 to 0.16) 0.31 –0.02 (–0.10 to 0.07) 0.69 –0.97 (–2.09 to 0.14) 0.088 –2.03 (–4.01 to –0.04) 0.045
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Adverse events
A total of 523 AEs were reported between baseline and the 24-month follow-up. Seventy-four participants
reported experiencing multiple AEs: nine reported experiencing three AEs and 65 reported experiencing
two AEs (Table 21). The mean number of AEs experienced by each participant was 0.35 ± 0.58 and the
means did not differ across trial arms [F(2) = 0.68; p = 0.51]. The proportions of AEs by subcategories were
largely similar across the trial arms (Table 22).
TABLE 20 Summary of nutrient intake at each time point, by treatment arm
Nutrient
Trial arm, mean (SD)
Group (n= 240) Individual (n= 180) UC (n= 182) Total (N= 602)
Baseline
Water (g) 1685.90 (954.28) 1704.70 (1052.29) 1557.10 (745.33) 1652.58 (929.12)
Protein (g) 73.41 (32.03) 75.00 (31.06) 73.07 (34.89) 73.78 (32.60)
Fat (g) 66.79 (34.40) 70.51 (38.66) 70.01 (35.34) 68.87 (35.98)
Carbohydrates (g) 205.78 (80.57) 211.91 (86.02) 207.46 (79.44) 208.12 (81.81)
Energy (kcal) 1769.25 (619.96) 1828.19 (719.03) 1817.39 (647.54) 1801.43 (658.65)
Total sugar (g) 91.63 (49.53) 94.89 (56.35) 93.04 (50.68) 93.03 (51.93)
Fibre (g) 19.54 (8.54) 19.98 (9.33) 19.90 (8.77) 19.78 (8.84)
Saturated fat (g) 23.84 (14.51) 26.21 (16.99) 25.90 (14.93) 25.17 (15.43)
Sodium (mg) 2116.47 (1273.13) 2386.72 (1393.46) 2195.32 (1347.91) 2221.11 (1335.23)
12-month follow-up
Water (g) 1583.16 (808.22) 1570.28 (823.08) 1564.05 (756.09) 1573.53 (796.10)
Protein (g) 66.04 (28.50) 68.45 (28.44) 70.27 (26.28) 68.04 (27.84)
Fat (g) 58.55 (29.98) 61.82 (33.61) 66.90 (32.30) 62.05 (31.94)
Carbohydrates (g) 194.66 (76.52) 200.70 (75.91) 211.24 (77.02) 201.48 (76.67)
Energy (kcal) 1607.90 (588.22) 1673.23 (616.31) 1771.27 (567.89) 1676.83 (593.68)
Total sugar (g) 80.70 (46.11) 83.33 (41.69) 88.90 (42.59) 83.96 (43.83)
Fibre (g) 19.95 (9.42) 19.42 (8.83) 20.20 (8.30) 19.87 (8.91)
Saturated fat (g) 20.69 (13.12) 22.81 (15.20) 24.72 (14.23) 22.54 (14.18)
Sodium (mg) 1902.25 (1194.57) 1971.90 (1258.57) 2022.70 (1098.10) 1959.49 (1185.31)
24-month follow-up
Water (g) 1674.34 (814.50) 1628.88 (867.23) 1640.77 (802.37) 1650.60 (825.89)
Protein (g) 72.35 (31.53) 70.52 (28.10) 71.58 (27.00) 71.57 (29.16)
Fat (g) 66.47 (35.00) 61.53 (29.60) 63.60 (26.40) 64.13 (31.02)
Carbohydrates (g) 206.11 (74.14) 208.88 (80.67) 206.72 (73.29) 207.12 (75.78)
Energy (kcal) 1752.88 (637.69) 1706.12 (562.62) 1726.69 (528.81) 1730.98 (583.60)
Total sugar (g) 84.60 (42.88) 88.93 (47.73) 86.92 (41.14) 86.60 (43.85)
Fibre (g) 21.31 (10.11) 19.59 (9.73) 19.50 (7.73) 20.25 (9.36)
Saturated fat (g) 22.89 (14.54) 23.24 (13.61) 22.84 (11.42) 22.98 (13.36)
Sodium (mg) 1988.68 (1283.79) 2099.04 (1316.58) 2087.66 (1150.50) 2051.61 (1254.18)
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TABLE 21 Summary of AEs per participant, by trial arm
AE reporting
Trial arm
Chi-squared
test outputa
Group intervention
(N= 697)
Individual intervention
(N= 523) UC (N= 522)
Any AE reported, n (%) 212 (30.4) 151 (28.9) 160 (30.7) 0.48
Multiple AEs, n (%) 34 (4.9) 17 (3.3) 23 (4.4) 4.20
2 27 (3.9) 16 (3.1) 22 (4.2)
3 7 (1.0) 1 (0.2) 1 (0.2)
Number of AEs per participant,
mean (SD)
0.37 (0.61) 0.33 (0.54) 0.35 (0.57)
a Chi-squared tests, two degrees of freedom, p > 0.05.
Reproduced from Ismail et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0)
license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided
the original work is properly cited, a link to the licence is given, and indication of whether changes were made.
See: https://creativecommons.org/licenses/by/4.0/.
TABLE 22 Summary of AEs, by subcategory and trial arm
AE type
Trial arm, n (%)
Chi-squared
test outputa
Group intervention
(N= 697)
Individual intervention
(N= 523) UC (N= 522)
Death 3 (0.4) 2 (0.4) 4 (0.8) 0.92
Any physical injury 109 (15.6) 65 (12.4) 85 (16.3) 3.61
Dislocation 5 (0.7) 1 (0.2) 2 (0.4) 1.96
Fracture 16 (2.3) 8 (1.5) 7 (1.3) 1.82
Sprain/strain 10 (1.4) 17 (3.3) 12 (2.3) 3.90
Muscle/tendon 28 (4.0) 16 (3.1) 25 (4.8) 2.33
Other 48 (6.9) 22 (4.2) 39 (7.5) 5.72
Fall 37 (5.3) 17 (3.3) 23 (4.4) 3.00
Any cardiovascular event 42 (6.0) 22 (4.2) 22 (4.2) 2.94b
Angina 2 (0.3) 2 (0.4) 1 (0.2) 0.33
Atrial fibrillation 7 (1.0) 2 (0.4) 4 (0.8) 1.56
CHD 0 (0.0) 0 (0.0) 1 (0.2) 2.34
Coronary bypass 4 (0.6) 0 (0.0) 0 (0.0) 6.01c
Myocardial infarction 6 (0.9) 3 (0.6) 3 (0.6) 0.50
Stroke/TIA 9 (1.3) 3 (0.6) 6 (1.1) 1.60
Other 14 (2.0) 15 (2.9) 7 (1.3) 3.03
a Chi-squared test, two degrees of freedom, p > 0.05 except where indicated.
b Degrees of freedom = 8.
c p = 0.0495.
Reproduced from Ismail et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0)
license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided
the original work is properly cited, a link to the licence is given, and indication of whether changes were made.
See: https://creativecommons.org/licenses/by/4.0/.
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The PI and a clinical co-investigator evaluated whether or not any reported AE could have been related to
trial participation. It was determined that no AE was the direct consequence of participating in the study or
receiving the intervention. There were nine deaths reported during the trial: three participants in the group
intervention arm, two participants in the individual intervention arm and four participants in the UC arm.
The causes of death, when provided, were not deemed to be related to the intervention.
We asked specifically about CVD events at follow-up, as a number of these would be expected in a sample
of participants at high risk of CVD. However, there were no significant differences in numbers of CVD
events reported between trial arms [χ2(2) = 2.94; p > 0.05]. We also asked specifically about physical
injuries, as this was the only AE with the potential to be linked to an increase in PA as a result of
participating. There were also no significant differences in numbers of physical injuries reported between
trial arms [χ2(2) = 3.61; p > 0.05].
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Chapter 6 Cost-effectiveness
The number and percentage of participants using specific services or groups of services are shown inTable 23. In the 12-month period prior to baseline assessment, the use of all services was very similar
between the three treatment arms. There were relatively few people attending accident and emergency
(A&E) or day hospitals or being admitted as inpatients. About half of the participants in each arm had
outpatient contacts and nearly every participant had community contacts. This was largely due to GP visits.
In the 12 months prior to the 12-month follow-up, around two-thirds of the group intervention arm and
three-quarters of the individual intervention arm received the relevant intervention. Numbers of visits to
A&E and outpatient attendances had increased slightly from baseline but there were no clear differences
between treatment arms. These patterns were again observed in the 12-month period prior to the second
follow-up, although there was again a slight increase in the proportions having outpatient attendances.
For those with specific service contacts, the average number of contacts is shown in Table 24. At baseline,
community services were used more intensely than other services. The inpatient contacts refer to the
number of days in hospital. It can be seen that there are no major differences between arms. The data for
the 1-year follow-up show that the individual intervention arm had slightly more intervention contacts than
the group intervention arm. Those admitted to hospital from the individual intervention arm had more
days in hospital than the other two arms. There were no clear differences between arms in the period up
to the 24-month follow-up.
Service costs (including zero costs for non-users) were similar for inpatient care, outpatient attendances
and community contacts (Table 25). Costs of services did not differ markedly between arms, although
inpatient costs were somewhat higher for the individual intervention arm at the 12-month follow-up and
lower at the 24-month follow-up. The intervention cost was highest for those in the individual intervention arm.
Compared with the UC arm, the total costs at baseline were, on average, £151 more for the group
intervention arm (95% CI –£27 to £328) and £55 more for the individual intervention arm (95% CI –£96
to £203). The group intervention arm costs were, on average, £95 (95% CI –£93 to £299) more than
those for the individual intervention arm. After controlling for baseline in a regression model, the total
costs in the 12-month period prior to the first follow-up were, on average, £89 (95% CI –£274 to £390)
more for the group intervention arm than for the UC arm and £409 (95% CI –£171 to £1133) more for
the individual intervention arm than the UC arm. The individual intervention arm costs were, on average,
£320 (95% CI –£170 to £1133) more than those for the UC arm. By the second follow-up, and again
controlling for baseline, the mean costs for the group intervention arm were £82 (95% CI –£93 to £263)
more than those for UC and £39 (95% CI –£108 to £188) more for UC than for the individual intervention
arm. Costs were £121 (95% CI –£37 to £309) more for the group intervention arm than for the individual
intervention arm.
Mean total costs over the whole 24-month follow-up period with year 2 costs discounted by 3.5% were
£2071 (SD £3363) for the group intervention arm, £2230 (SD £7645) for the individual intervention arm
and £1852 (SD £3726) for the UC arm. Compared with UC and controlling for baseline, the group
intervention arm had costs that were, on average, £172 higher (95% CI –£237 to £599) and the individual
intervention arm had costs that were £352 higher (95% CI –£309 to £1271). For cases in which both cost
and QALY data were available, the group intervention arm had incremental costs of £173 compared with
the UC arm and the individual intervention arm had incremental costs of £356 compared with the UC arm.
These are the incremental costs subsequently used in the ICERs.
Mean EQ-5D tariff scores were similar for each arm and did not change markedly over time (Table 26).
Controlling for baseline utility and compared with the UC arm, the group intervention arm had 0.0150
fewer QALYs (95% CI –0.0388 to 0.0088 QALYs) and the individual intervention arm had 0.0039 more
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TABLE 23 Number of participants using services in the 12 months prior to baseline and at each follow-up
Service
Time point, n (%)
Baseline 12-month follow-up 24-month follow-up
Trial arm Trial arm Trial arm
Group
intervention
(N= 697)
Individual
intervention
(N= 523) UC (N= 522)
Group
intervention
(N= 597)
Individual
intervention
(N= 466) UC (N= 493)
Group
intervention
(N= 570)
Individual
intervention
(N= 422) UC (N= 459)
Intervention 0 (0) 0 (0) 0 (0) 437 (63) 406 (78) 0 (0) 0 (0) 0 (0) 0 (0)
A&E 59 (8) 43 (8) 40 (8) 82 (14) 54 (12) 58 (12) 80 (14) 67 (16) 64 (14)
Day hospital 55 (8) 42 (8) 42 (8) 40 (7) 36 (8) 30 (6) 26 (5) 18 (4) 12 (3)
Inpatient 43 (6) 31 (6) 20 (4) 47 (8) 27 (6) 31 (6) 37 (6) 24 (6) 29 (6)
Outpatient 355 (51) 268 (51) 266 (51) 346 (58) 280 (60) 301 (61) 383 (67) 272 (65) 302 (66)
Community 667 (96) 502 (96) 503 (96) 588 (98) 461 (99) 489 (99) 564 (99) 412 (98) 449 (98)
Reproduced from Ismail et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with
the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the
original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
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TABLE 24 Mean number of contacts, by those using services in the 12 months prior to baseline and at each follow-up
Service
Time point, mean (SD)
Baseline 12-month follow-up 24-month follow-up
Trial arm Trial arm Trial arm
Group
intervention
(n= 697)
Individual
intervention
(n= 523) UC (n= 522)
Group
intervention
(n= 597)
Individual
intervention
(n= 466) UC (n= 493)
Group
intervention
(n= 570)
Individual
intervention
(n= 422) UC (n= 459)
Intervention – – – 7.6 (3.0) 8.8 (3.4) – – – –
A&E 1.5 (1.6) 1.3 (0.6) 1.3 (0.7) 1.5 (1.4) 1.3 (1.1) 1.5 (1.0) 1.8 (3.3) 1.3 (0.8) 1.6 (1.7)
Day hospital 3.4 (4.1) 1.8 (2.3) 2.4 (2.0) 1.8 (1.4) 1.7 (1.9) 1.6 (1.2) 1.5 (1.0) 1.7 (1.5) 1.0 (0.0)
Inpatient 4.7 (10.1) 4.7 (5.0) 3.8 (5.9) 7.4 (12.4) 14.7 (47.9) 6.9 (21.1) 5.8 (9.3) 3.0 (3.1) 4.0 (3.3)
Outpatient 3.2 (4.2) 3.0 (4.1) 3.2 (4.5) 3.6 (4.2) 4.1 (4.5) 4.0 (5.4) 3.9 (4.2) 4.2 (4.6) 4.1 (4.0)
Community 7.1 (5.4) 7.5 (8.0) 7.0 (6.9) 8.8 (6.5) 9.2 (7.1) 9.1 (6.5) 9.4 (8.1) 8.9 (7.3) 9.2 (6.8)
Reproduced from Ismail et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the
original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
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TABLE 25 Mean service costs (2015/16 £) in the 12 months prior to baseline and at each follow-up
Service
Time point, mean (SD)
Baseline 12-month follow-up 24-month follow-up
Trial arm Trial arm Trial arm
Group
intervention
(n= 697)
Individual
intervention
(n= 523) UC (n= 522)
Group
intervention
(n= 697)
Individual
intervention
(n= 523) UC (n= 522)
Group
intervention
(n= 697)
Individual
intervention
(n= 523) UC (n= 522)
Intervention 0 (0) 0 (0) 0 (0) 55 (50) 136 (98) 0 (0) 0 (0) 0 (0) 0 (0)
A&E 19 (94) 16 (58) 15 (59) 30 (107) 23 (83) 27 (90) 36 (204) 32 (88) 33 (123)
Day hospital 193 (1049) 105 (573) 137 (618) 85 (405) 95 (497) 68 (341) 49 (271) 53 (328) 19 (114)
Inpatient 172 (1605) 164 (955) 85 (788) 340 (2333) 499 (6940) 256 (3207) 219 (1609) 99 (590) 149 (745)
Outpatient 222 (460) 210 (442) 221 (485) 284 (492) 327 (542) 329 (630) 355 (524) 366 (568) 361 (505)
Community 225 (260) 241 (331) 222 (187) 306 (253) 317 (233) 306 (220) 324 (253) 306 (232) 321 (279)
Total 831 (2127) 736 (1299) 680 (1132) 1107 (2520) 1407 (7067) 985 (3312) 984 (1915) 855 (1079) 884 (1114)
Reproduced from Ismail et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with the
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the
original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
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QALYs (95% CI –0.0217 to 0.0294 QALYs). For cases in which both cost and QALYs were available, the
group intervention arm produced 0.0149 fewer QALYs than the UC arm and the individual intervention arm
produced 0.0064 more QALYs than the UC arm. These figures are used as the denominators in the ICERs.
The group intervention arm was less effective and more expensive than the UC arm. For this reason, it was
dominated. The individual intervention was more expensive and more effective than UC. The ICER was
£55,625 per QALY (£356 divided by 0.0064 QALYs). Uncertainty around the estimates are shown in the
cost-effectiveness planes (Figures 8 and 9). In Figure 8, comparing the group intervention arm with the
TABLE 26 Mean EQ-5D tariff scores and QALYs, by arm and time point
Time point
Trial arm, mean (SD)
Group intervention Individual intervention UC
EQ-5D tariff scores
Baseline 0.8738 (0.1973) 0.8831 (0.1870) 0.8828 (0.1630)
12-month follow-up 0.8869 (0.1958) 0.9085 (0.1632) 0.8947 (0.1688)
24-month follow-up 0.8994 (0.1639) 0.9064 (0.1475) 0.9144 (0.1459)
QALYs 1.7717 (0.3073) 1.8123 (0.2306) 1.8014 (0.2462)
Reproduced from Ismail et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0)
license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided
the original work is properly cited, a link to the licence is given, and indication of whether changes were made.
See: https://creativecommons.org/licenses/by/4.0/.
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FIGURE 8 Cost-effectiveness plane comparing the group intervention arm and UC. Reproduced from Ismail et al.110
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UC arm, it can be clearly seen that the majority (69%) of bootstrapped replications fall in the north-west
quadrant, in which the group intervention arm has higher costs and produces fewer QALYs. In the
north-east quadrant, in which costs are still higher but more QALYs are produced, 8.5% of replications fall.
In the south-east quadrant, in which costs are lower and more QALYs are produced, 4% of replications fall.
Finally, 18.5% of replications fall in the south-west quadrant, in which the group intervention arm is less
expensive but produces fewer QALYs.
In Figure 9, comparing the individual intervention arm with the UC arm, 52.3% of replications are in the
north-east quadrant, in which the individual intervention arm has higher costs and produces more QALYs;
15.7% are in the south-east quadrant, in which costs are lower and there are more QALYs produced;
5.8% are in the south-west quadrant, in which costs are lower and there are fewer QALYs produced; and,
finally, 26.2% of replications are in the north-west quadrant, in which the individual intervention arm has
higher costs and produces fewer QALYs.
Figure 10 shows the cost-effectiveness acceptability curves in which all three arms are compared for
different values placed on a QALY gain. When a zero value is placed on a QALY, UC has by far the highest
probability of being the most cost-effective option (in this situation, only costs are relevant and UC is less
expensive). As the value placed on a QALY is increased, the probability that the individual intervention arm
is the most cost-effective option increases steadily and the other two arms see a fall in the probability that
they are the most cost-effective. This is to be expected as the individual intervention arm is more expensive
and more effective than the other options, and as the effect (i.e. increased QALYs) is valued more, it
increasingly offsets the cost. However, at a value of £30,000 (above which NICE is likely to decide an
intervention is not cost-effective) the individual intervention arm has a 37.4% likelihood of being the most
cost-effective option, compared with 58.1% for UC. At this value, the group intervention arm has a
likelihood of 4.5% of being the most cost-effective option.
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FIGURE 9 Cost-effectiveness plane comparing the individual intervention arm and UC. Reproduced from Ismail
et al.110 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ. This is an open
access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license,
which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided
the original work is properly cited, a link to the licence is given, and indication of whether changes were made.
See: https://creativecommons.org/licenses/by/4.0/.
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In sensitivity analyses, the intervention costs were increased and decreased by 25% and 50%, respectively,
to reflect different grades of staff delivering the interventions. When intervention costs were reduced by
25%, the group intervention arm had costs that were, on average, £188 more than for the UC arm,
whereas costs for the individual intervention arm were £395 more than for the UC arm; the differences
when intervention costs were increased by 50% were £204 and £434, respectively. Not surprisingly, these
increased differences mean that the interventions are even less likely to be cost-effective compared with UC.
When intervention costs are reduced by 25%, the group intervention arm has costs that are, on average,
£157 more than for UC. With fewer QALYs, UC is still dominant. The individual intervention now costs
£317 more than the cost of UC, resulting in a cost per QALY of £49,531. With a reduction of 50%, the
group intervention arm still has higher costs than UC (by £141) and so continues to be dominated,
whereas the individual intervention arm has costs that are £278 higher, resulting in a cost per QALY of
£43,438.
Summary
The health economic analyses show that the group intervention is not a cost-effective alternative to UC
as it produces fewer QALYs and results in higher health-care costs. The individual intervention is more
effective than UC in terms of QALYs produced but the higher costs result in an ICER that is in excess of the
£20,000- to £30,000-per-QALY threshold usually used in England to determine cost-effectiveness and so is
also not cost-effective. The ICER for the individual intervention arm compared with the group intervention
arm is below this threshold, but UC is still the preferred option. Sensitivity analyses did not alter the results
in a substantial way.
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FIGURE 10 Cost-effectiveness acceptability curves. Reproduced from Ismail et al.110 © Author(s) (or their employer(s))
2019. Re-use permitted under CC BY. Published by BMJ. This is an open access article distributed in accordance with
the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute,
remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the
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Chapter 7 Participation biases
Background
Lifestyle intervention trials have previously reported low response rates and do not always recruit those
most at risk, which will limit the generalisability of observed associations.112,113 Failure to recruit those
with the highest risk of CVD to the MOVE IT trial could have led to limited representativeness and
underestimated effect sizes, and could have contributed to increasing rather than reducing health
inequalities. It is important, therefore, that RCTs such as MOVE IT report on participation bias.
The factors found to increase likelihood of participation in walking and lifestyle intervention trials are
mid-life, female sex, living in more affluent areas, white ethnicity and university education.112,114 Ethnic
minorities are at higher risk of CVD and related disorders, such as type 2 diabetes mellitus.115 Regarding
the health of participants versus non-participants, some trials report that participants are more likely
to be of poorest health,112,116–118 whereas other studies report that participants are healthier or more
active.113,117,119,120
We compared the anonymised sociodemographic data and CVD risk of responders and non-responders to
the MOVE IT invitation to participate. We aim to test the hypothesis that people who are older, female,
living in more affluent areas, at lower risk of CVD and of white ethnicity are more likely to respond.
Methods
Using a cross-sectional design, we compared anonymous data from medical records of patients who
responded to the invitation to participate in MOVE IT and those of patients who did not. We gained REC
approval to extract anonymised data for all patients invited to participate unless an informed dissent code
was present on medical records.
The measures collected anonymously for all patients invited to participate included age (at time of
screening), sex, postcode data to calculate IMD 2010 score,76 QRISK2 score and ethnicity.
QRISK2 score was estimated on medical records via a batch calculator, using age- and sex-based national
averages for missing data values.
Ethnicity data from medical records were grouped into white, black African or Caribbean, South Asian,
other Asian, other/mixed or missing for this analysis. South Asian and other Asian ethnicities are coded
separately because South Asian ethnicity is associated with a higher CVD risk.72 The category of other/mixed
incorporates any ethnicity that is reported and does not fit into the previous categories, as well as including
mixed ethnic backgrounds.
Data are summarised as mean (SD) or percentages. The adjusted odds ratios (AORs) for response to
invitation by the sociodemographic and CVD risk data collected were calculated using logistic regression in
Stata version 14. General practice was included as a random effect in the model to allow for clustering by
practice. AORs for age are presented per 5-year increase, for IMD 2010 scores per 10-point increase and
for QRISK2 scores per 5-percentage-point increase to provide a better comparison of the strength of the
relationships.
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Results
Lists of patients invited to participate were not saved by general practices and we returned to practices
later to extract anonymous data. Sixty practices provided the original anonymised data. Sociodemographic
data and QRISK2 scores were extracted for 8902 patients, representing 50.5% of the 17,618 patients
originally invited to participate. Table 27 shows the CCGs from which anonymised data were collected
and the deprivation and ethnicity census data of each local authority.71 General practice deprivation scores
(IMD 2010)76 of practices from which anonymised data were extracted did not differ significantly from that
of all other practices in South London [t(440) = 0.57; p = 0.57).108
The sociodemographic and QRISK2 data of responders (n = 1489) and non-responders (n = 7413) are
presented in Table 28. The mean age of all patients at the time of invitation was 67.3 ± 5.7 years, and
20.7% were female. The mean IMD 201076 score of patients invited was 21.7, a score that falls within the
second-most-deprived quintile, and the mean QRISK2 score of invitees was 25.2%. Of all patients invited,
69.9% had a white ethnic background, 13.9% had ethnic minority backgrounds and 16.2% had no
ethnicity data recorded in their medical records.
The logistic regression analyses that were conducted to estimate the odds of response are also presented in
Table 28. Response rates were higher with increasing age (AOR 1.19, 95% CI 1.12 to 1.26); the odds of
response increased by 19% for each 5-year increase in age. The response rate was greater in male patients
(AOR 1.24, 95% CI 1.07 to 1.44) and decreased with greater levels of deprivation (AOR 0.84, 95% CI 0.79
to 0.90); for every 10-point increase in IMD 2010 score, the odds of responding decreased by 16%. Increased
CVD risk also lowered the response rate (AOR 0.83, 95% CI 0.77 to 0.88); for every 5-point increase in
QRISK2 score, the odds of responding decreased by 17%. The response rate was lower for patients of black
African or Caribbean ethnicity (AOR 0.66, 95% CI 0.45 to 0.96) and those with missing ethnicity data (AOR
0.55, 95% CI 0.46 to 0.66) than for patients of white ethnicity. The response rates of Asian and other ethnic
backgrounds were not significantly different from those of patients of white ethnicity.
Pairwise comparisons were conducted to explore differences in response between different ethnic minority
groups, but there were no significant differences. Response rates of patients with missing ethnicity data
were significantly lower than those of patients of South Asian ethnicity (p = 0.002). Owing to small numbers
of invitees from non-white ethnic backgrounds, a sensitivity analysis was undertaken to investigate predictors
of response to invitation with ethnicity removed from the model. Older age (p < 0.001), male sex (p = 0.017),
being more affluent (p < 0.001) and having a lower CVD risk (p < 0.001) remained significant predictors of
response.
Summary
In Chapter 5, we demonstrated that the trial successfully recruited general practices that did not differ
significantly from all other practices in South London in practice deprivation, and this was also true for the
smaller group of practices involved in this analysis. Therefore, the MOVE IT trial successfully recruited from
socioeconomically varied areas. For this analysis, we found evidence of participation bias towards patients
who were older, male, residing in more affluent areas and at a lower CVD risk and we found that patients
of black African or Caribbean ethnicity were less likely to respond than patients of white ethnicity. South
Asian patients were as likely to respond as patients of white ethnicity but the QRISK2 score identified a
smaller sample size of people of African Caribbean and Asian ethnicities. This could be partly because
those CCGs with the highest IMD 2010 scores and greater ethnic diversity were less likely to participate in
MOVE IT. It is noteworthy that these CCGs were the slowest to respond to participate although all CCGs
were invited at the same time. We also observed high rates of missing ethnicity data on medical records
and this group of patients with missing ethnicity data was less likely to respond than patients of white or
South Asian ethnicity. These findings suggest that there may have been a participation bias towards those
with lower CVD risk compared with those most at risk.
PARTICIPATION BIASES
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TABLE 27 South London CCG deprivation, ethnicity and anonymous data collected
Characteristics
CCG
Bexley Bromley Croydon Greenwich Kingston Lambeth Lewisham Merton Richmond Southwark Sutton Wandsworth
Borough deprivation
(IMD 2010 rank76)a (n)
180 217 99 19 252 14 16 208 286 25 193 102
Borough ethnicity (%)b
White 81.9 84.3 55.2 62.5 74.5 57.1 53.6 64.9 85.9 54.3 78.6 71.4
Black African or
Caribbean
8.5 6.0 20.2 19.1 2.4 25.9 27.2 10.4 1.5 26.8 4.8 10.6
South Asian 3.6 2.7 10.5 4.7 6.5 3.3 2.8 8.9 3.9 4.0 5.4 6.5
Other Asian 2.9 2.5 5.9 7.0 9.9 3.5 6.5 9.2 3.4 5.5 6.2 4.4
Other/mixed 3.0 4.5 8.4 6.7 6.6 10.1 10.0 6.5 5.2 9.4 5.0 7.1
Anonymous data collected (n)
General practices 1 11 11 1 1 6 11 2 0 9 3 4
Patients 328 2463 1663 255 27 845 1281 41 0 666 786 646
a Ranked from 1 (most deprived) to 326 (least deprived) from 326 local authorities.
b Based on census 2011 data.20,71
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TABLE 28 Comparison of responders and non-responders to the trial invitation
Characteristics
Patients
Response
rate (%)
OR for response to mailout (95% CI)
Test for trend
(p-value)
All invited
(N= 8902)a
Responded
to invitation
(N= 1489)
Did not respond
to invitation
(N= 7413) Unadjusted Adjusted
Age at invitation (years), mean (SD) 67.3 (5.7) 68.1 (5.1) 67.2 (5.8) 1.14 (1.08 to 1.21)b 1.19 (1.12 to 1.26)b < 0.001
Age group at invitation (years), n (%)
40–59 976 (11.0) 124 (8.4) 852 (11.6) 12.7
60–64 1462 (16.4) 200 (13.5) 1262 (17.0) 13.7
65–69 2989 (33.6) 536 (36.0) 2453 (33.1) 17.9
70–75 3475 (39.0) 629 (42.2) 2846 (38.4) 18.1
Sex, n (%)
Female 1847 (20.7) 291 (19.5) 1556 (21.0) 15.8 1.00 1.00
Male 7055 (79.3) 1198 (80.5) 5857 (79.0) 17.0 1.07 (0.93 to 1.23) 1.24 (1.07 to 1.44) 0.004
Ethnicity, n (%) < 0.001c
White 6223 (69.9) 1128 (75.8) 5095 (68.7) 18.1 1.00 1.00
Black African or Caribbean 272 (3.1) 34 (2.3) 238 (3.2) 12.5 0.74 (0.50 to 1.07) 0.66 (0.45 to 0.96) 0.032
South Asian 578 (6.5) 98 (6.6) 480 (6.5) 17.0 0.90 (0.70 to 1.14) 1.07 (0.84 to 1.37) 0.593
Other Asian 240 (2.7) 31 (2.1) 209 (2.8) 12.9 0.69 (0.47 to 1.03) 0.71 (0.48 to 1.05) 0.086
Other/Mixed 147 (1.7) 16 (1.1) 131 (1.8) 10.9 0.62 (0.36 to 1.05) 0.61 (0.36 to 1.05) 0.072
Missing 1442 (16.2) 182 (12.2) 1260 (17.0) 12.6 0.58 (0.48 to 0.69) 0.55 (0.46 to 0.66) < 0.001
IMD 2010 score,d mean (SD) 21.7 (12.0) 19.4 (11.3) 22.2 (12.1) 0.82 (0.76 to 0.87)e 0.84 (0.79 to 0.90)e < 0.001
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Characteristics
Patients
Response
rate (%)
OR for response to mailout (95% CI)
Test for trend
(p-value)
All invited
(N= 8902)a
Responded
to invitation
(N= 1489)
Did not respond
to invitation
(N= 7413) Unadjusted Adjusted
IMD 2010 quintile, n (%)
1 (least deprived) 1407 (15.8) 293 (19.7) 1114 (15.0) 20.8
2 1531 (17.2) 285 (19.1) 1246 (16.8) 18.6
3 1616 (18.2) 315 (21.2) 1301 (17.6) 19.5
4 2725 (30.6) 420 (28.2) 2305 (31.1) 15.4
5 (most deprived) 1604 (18.0) 171 (11.5) 1433 (19.3) 10.7
Unknown 19 (0.2) 5 (0.3) 14 (0.2) 26.3
QRISK2 score, mean (SD) 25.2 (5.0) 24.6 (4.5) 25.3 (5.1) 0.86 (0.81 to 0.92)f 0.83 (0.77 to 0.88)f < 0.001
QRISK2 score category, n (%)
20–24.9% 5357 (60.2) 968 (65.0) 4389 (59.2) 18.1
25–29.9% 2245 (25.2) 347 (23.3) 1898 (25.6) 15.5
≥ 30% 1300 (14.6) 174 (11.7) 1126 (15.2) 13.4
OR, odds ratio.
a All patients invited to participate in the trial from general practice sites at which it was possible to extract anonymised data.
b OR per 5-year increase in age.
c Chi-squared test for independence of ethnicity groups.
d IMD 2010 score;76 higher score is more deprived.
e OR per 10-point increase in IMD score.76
f OR per 5% increase in QRISK2 score.
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Chapter 8 Fidelity analysis
Introduction
As part of the process evaluation of the study, we assessed fidelity, here defined as delivery of the enhanced
MI intervention by the HLFs in accordance with the manual. Furthermore, we were interested in determining
if the level of HLF competency in delivering the intervention differed between the individual and group
intervention arms.
As described in Chapter 3, HLFs received extensive training and supervision before and during the
intervention to ensure that they were competent in delivering MOVE IT. HLFs were asked to audiotape
each intervention session, and these data were stored on King’s College London’s shared network drives,
as per the university protocol. Chapter 4 describes how a university-wide network outage caused the
recorded session data to be completely lost, with only a limited sample being subsequently recovered from
other sources. In this chapter, we will describe our original aims and methods and how these were
adapted following the network outage.
Aims
For the analysis, we were originally interested in answering five questions:
1. What was the degree of adherence by the HLFs to the MI and BCT elements in the group and
individual intervention arms?
2. What was the level of HLF competency in delivering the MI aspects?
3. What was the level of HLF competency in delivering the BCTs?
4. Were there any differences in competency in delivering the MI and BCT elements between the group
and individual treatment arms?
5. Were the HLF competency levels in delivering the intervention associated with patient outcomes or
mediators of any treatment effects?
Owing to the network outage and the number and quality of data that were subsequently recovered,
we were unable to address question 5. In addition, although the HLFs were trained to a certain level of
competency in two other domains (group skills and time management; see Chapter 3), we were not
interested in assessing their competency in these domains for this fidelity analysis.
Original methods
Identifying sessions to rate
Ideally, if every patient randomised to the individual or group intervention attended each of the 10
sessions, we would have obtained 6200 hours of recordings (Table 29). In addition, by assuming a 20%
dropout rate halfway through the intervention, we would have obtained 5201 hours of recordings. We
originally had 2756 tapes of the intervention sessions, comprising 1989 hours of content.
We planned to randomly select and rate 25% of the available recordings, stratified by intervention arm
(group vs. individual), ensuring that every participant in the individual intervention arm and every group in
the group intervention arm had at least one recording assessed for fidelity. Sessions lasting ≥ 20 minutes
would be selected. We planned that a 20-minute segment (randomly selected from the beginning, middle
or end) of each tape would be rated for individual sessions, and we selected a 50-minute segment of the
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group sessions, as this would allow a fairer opportunity for MI skills to be demonstrated in a group
context. During our preparation for the fidelity coding, we found that a 20-minute segment was not
suitable for group sessions, as the structure and format of group sessions meant that significant amounts
of time were devoted to group exercises that could not be coded.
Measures of competency
We assessed the MI and BCT aspects of the intervention. To assess HLF fidelity to the MI aspects of the
intervention, we used the MITI manual (version 3.1.1),97 which counts the number of MI techniques used.
The MITI tool has been validated and is viewed as the gold standard of MI fidelity, has been translated into
multiple languages121 and is used widely as a coding system, including in other large-scale studies.122,123
The MITI rating tool comprises several variables. ‘Global’ ratings are given for each of ‘spirit’ and ‘empathy’,
scored on a scale from 1 to 5 (with the coder assuming a beginning score of 3 and moving up or down based
on the HLF’s observed skill). Behaviour count scores are provided for ‘giving information’, ‘MI adherent’
behaviours, ‘MI non-adherent’ behaviours, ‘closed questions’, ‘open questions’, ‘simple reflections’ and
‘complex reflections’. The MITI guidance provides minimum scores that a practitioner must achieve to reach
proficiency and competency (Table 30).
TABLE 29 Potential and actual hours of session recordings
Scenario Number of participants/groups Average length (hours) Total number of hours
Ideal
Individual 523 (10 sessions) 0.70 3671
Group 139 (10 sessions) 1.81 2529
Total 6200
Anticipated
Individual 418 (105) (10 sessions, 5 dropouts) 0.70 3304
Group 125 (14) (10 sessions, 5 dropouts) 1.81 1897
Total 5201
Original (pre outage)a
Individual 2251 0.57 1289
Group 400 1.55 619
Total 1908b
Recovered (post outage)b
Individuals 324 0.70 227
Groups 71 1.81 129
Total 356
a Owing to the nature of how the audiotaped session data were recorded and stored, we could not determine the
number of sessions completed by each participant/group.
b 81 hours have been removed from this total, as the associated session tapes had not been coded for intervention arm.
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To assess HLF adherence to administering the 11 BCTs, each was coded as present (at least once) or
absent during a session. The 11 BCTs were:
l provide information on consequences
l prompt intention formation
l prompt barrier identification
l prompt specific goal-setting
l prompt review of behavioural goals
l prompt self-monitoring of behaviour
l teach to use prompts or cues
l agree on behavioural contract
l plan social support or social change
l self-talk
l relapse prevention.
Raters were provided with a BCT coding framework, which listed each BCT label alongside a description
and an example quotation (see Appendix 3). MI, which is considered the 12th BCT in the taxonomy,54
was removed and considered separately, as the CPs developing the intervention deemed this to be the
communication process by which the BCTs were used with participants, rather than as a BCT itself.
The BCT coding framework was developed by the authors and raters specifically for this trial, as our
review of the extant literature did not reveal an existing coding framework that would be appropriate.
The coding framework was developed through an iterative process and piloted internally; however,
it was not validated before being utilised in the study.
Interrater reliability
Two independent psychologists who had completed formal training in using the MITI tool and were
experienced in this method (having worked together on previous studies) coded the recordings. To
determine interrater reliability, the two raters initially coded the same selection of tapes. First, 40 tapes
(20 individual and 20 group sessions) were randomly selected. Then, for each tape, a segment that
was 20–50 minutes in length was randomly selected, reflecting the variability in quality and length of
the tapes.
The raters worked together extensively in adapting the MITI tool to suit the group format. They met on
several occasions to discuss discrepancies between the coding of individual and group transcripts.
Individual issues were also discussed as they arose until agreement was reached on coding principles.
To ensure that rater drifting did not happen, the raters initially met weekly. As the coding proceeded and
any raised issues were resolved, the raters and one of the CPs met regularly. The raters also engaged in
peer supervision, in which they would discuss with each other any coding issues that were raised for a
tape and how to resolve them. The raters closely followed the principles detailed in the MITI tool and
TABLE 30 Minimum values to achieve for MITI proficiency and competency
Measure Beginning proficiency Competency
Global spirit rating, mean score 3.5 4
Reflection-to-question ratio 1 2
Percentage with open questions 50 70
Percentage with complex reflections 40 50
Percentage who were MI adherent 90 100
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referred to this document on a regular basis. For example, it was necessary to identify the nature of
facilitative and structural statements compared with the utterances that constituted MITI behaviour counts,
such as complex and simple reflections or giving information.
Intraclass correlation coefficients using a two-way consistency model were calculated for global spirit and
empathy scores and absolute agreement percentages for each BCT. For the individual sessions, the two
raters achieved ICCs of 0.89 (95% CI 0.75 to 0.96) and 0.84 (95% CI 0.65 to 0.94) for the global ratings
of empathy and spirit, respectively; both ICCs are considered good to excellent.124 The mean absolute
agreement was 94.09% (range 85–100%) for the 11 BCTs.
For the group sessions, the two raters achieved ICCs of 0.69 (95% CI 0.37 to 0.87) and 0.71 (95% CI
0.41 to 0.88) for the global ratings of empathy and spirit, respectively; both ICCs are considered good.
The mean absolute agreement was 86.82% (range 70–100%) for the 11 BCTs.
Revised methods
Identifying sessions to rate
The network outage at King’s College London resulted in all tapes being lost, with 84.22% of them
irretrievably lost. We were able to recover 435 tapes that could be coded. Table 31 summarises the
characteristics of the recovered tapes, excluding the 40 used for determining interrater reliability (described
in the previous section). When comparing the characteristics of the original and recovered tapes, we found
that there were significant differences with regards to the distribution of session number and which HLF
administered the session, but no difference in session type (see Table 31). Furthermore one HLF was
missing from the recovered tapes (HLF13).
TABLE 31 Comparison of session characteristics of original and recovered recordings
Characteristics
Recordings, n (%)
Statistical test outputOriginal (N= 2651)a Recovered (N= 395)
Session number
0 40 (1.87) 17 (4.30) χ2(10) = 86.31; p < 0.0001
1 255 (11.93) 49 (12.41)
2 237 (11.09) 54 (13.67)
3 233 (10.90) 46 (11.65)
4 232 (10.86) 57 (14.43)
5 197 (9.22) 61 (15.44)
6 190 (8.89) 50 (12.66)
7 199 (9.31) 33 (8.35)
8 180 (8.42) 9 (2.28)
9 189 (8.84) 4 (1.01)
10 185 (8.66) 15 (3.80)
Session type
Individual 2251 (84.91) 324 (82.03) χ2(1) = 1.98; p = 0.16
Group 400 (15.09) 71 (17.97)
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We also adapted the protocol and decided that the entirety of each recovered tape, as opposed to a
20- or 50-minute segment, would be coded and its data used in the fidelity analysis. This protocol change
was discussed with and approved by the TSC. The initial 5 minutes of each tape were not coded, as we
found this time to be devoted to content other than delivering the intervention (e.g. introductions and
housekeeping from previous sessions). Approximately 50% of available tapes were randomly allocated to
each rater using minimisation to ensure balance with respect to session type, session number and HLF.
Association between healthy lifestyle facilitator competencies and patient outcomes
We were unable to conduct this analysis (question 5) because the competency data had unacceptable
levels of measurement error. Namely, the quality of the recovered data prevented us from matching
session-level HLF competencies to patient-level outcomes.
Results
Fidelity to the intervention
A total of 395 sessions were coded for fidelity (324 individual sessions, 82.03%). We observed treatment
arm differences in several of the MITI domains, generally favouring the group sessions (Table 32).
None of the HLFs achieved proficiency across the five necessary MITI domains, based on the MITI guidance
(Table 33). Two HLFs were at least proficient in four domains and two were at least proficient in three
domains. Using our adapted competency framework, three HLFs met the competency criteria. Table 34
shows the MITI scores for each HLF by session type.
TABLE 31 Comparison of session characteristics of original and recovered recordings (continued )
Characteristics
Recordings, n (%)
Statistical test outputOriginal (N= 2651)a Recovered (N= 395)
HLF
1 571 (20.72) 200 (50.63) χ2(12) = 398.05; p < 0.0001
2 472 (17.13) 64 (16.20)
3 140 (5.08) 55 (13.92)
4 30 (1.09) 30 (7.59)
5 97 (3.52) 15 (3.80)
6 109 (3.96) 7 (1.77)
7 194 (7.04) 5 (1.27)
8 86 (3.12) 5 (1.27)
9 455 (16.51) 4 (1.01)
10 155 (5.62) 4 (1.01)
11 66 (2.39) 3 (0.76)
12 341 (12.37) 3 (0.76)
13 40 (1.45) 0 (0.00)
a 105 sessions were excluded, as they had not been assessed for their characteristics prior to the outage.
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The 11 BCTs were generally coded as present in most of the group (median 45/71, range 20–58) and
individual (median 179/324, range 69–267) sessions (Table 35). The distributions of each BCT being coded
present were similar between session types, except for BCT 1 (‘provide information on consequences’).
Table 36 shows mean BCT adherence by HLF and session type, aggregated over the 11 BCTs, with ≥ 70%
indicating competency.
TABLE 32 Summary of MITI domain scores
MITI domains
Intervention arm, mean (SD)
Total (n= 395),
mean (SD)
Statistical test
output
Group
(n= 71)
Individual
(n= 324)
Global ratings
Empathy 3.07 (0.82) 3.03 (0.92) 3.04 (0.90) t(112.67) = 0.39;
p = 0.70
Spirita 3.44 (0.63) 3.52 (0.74) 3.51 (0.72) t(115.48) = –1.00;
p = 0.32
Behaviour counts
Giving information 25.54 (18.45) 12.54 (10.04) 14.88 (12.97) t(79.32) = 5.75;
p < 0.0001
MI adherent 6.83 (4.49) 6.35 (4.27) 6.44 (4.31) t(99.72) = 0.83;
p = 0.41
MI non-adherent 1.30 (2.19) 1.15 (1.88) 1.17 (1.94) t(94.01) = 0.54;
p = 0.59
Percentage who were MI adherenta 83.74 (27.30) 84.68 (21.61) 84.51 (22.71) t(88.91) = –0.27;
p = 0.79
Closed questions 22.48 (13.29) 14.44 (8.76) 15.89 (10.19) t(83.8) = 4.87;
p < 0.0001
Open questions 21.21 (10.65) 10.81 (6.63) 12.68 (8.50) t(82.27) = 7.90;
p < 0.0001
Total questions 43.69 (20.80) 25.26 (13.63) 28.57 (16.72) t(83.63) = 7.14;
p < 0.0001
Percentage with open questionsa 49.35 (14.01) 43.32 (14.74) 44.40 (14.78) t(106.74) = 3.26;
p < 0.0001
Simple reflections 30.73 (18.86) 18.35 (12.20) 20.57 (14.42) t(83.28) = 5.30;
p < 0.0001
Complex reflections 15.31 (6.88) 10.31 (6.01) 11.21 (6.46) t(94.84) = 5.66;
p < 0.0001
Total reflections 46.04 (22.07) 28.71 (15.12) 31.83 (17.85) t(85) = 6.30;
p < 0.0001
Percentage with complex reflectionsa 36.28 (14.17) 37.26 (16.98) 37.08 (16.50) t(118.63) = –0.51;
p = 0.61
Reflection-to-question ratioa 1.17 (0.57) 1.37 (0.95) 1.33 (0.90) t(168.66) = –2.28;
p = 0.024
a Domains used by the MITI tool to determine proficiency/competency.
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TABLE 33 The MITI scores, by HLF, combining session types
HLF
Number
of tapes
coded
MITI domains, mean (SD)
Global spirit
Percentage with
complex reflections
Percentage with
open questions
Reflection-to-
question ratio
Percentage who
were MI adherent
1 200 3.71 (0.61) 39.80 (16.42) 43.28 (13.15) 1.58 (0.80) 90.34 (18.74)
2 64 3.25 (0.66) 37.55 (15.68) 41.74 (16.10) 1.15 (0.73) 83.33 (23.58)
3 55 3.20 (0.77) 30.27 (15.78) 54.51 (15.32) 0.82 (0.75) 68.13 (25.57)
4 30 3.36 (1.11) 32.39 (18.10) 41.48 (11.67) 0.68 (0.30) 81.05 (23.59)
5 15 3.33 (0.50) 30.70 (12.45) 47.66 (15.27) 2.39 (2.05) 83.60 (20.09)
6 7 4.00 (0.00) 48.12 (13.11) 51.31 (15.63) 1.10 (0.32) 87.43 (18.66)
7 5 3.93 (0.49) 40.02 (6.91) 45.85 (6.24) 0.82 (0.12) 94.18 (8.85)
8 5 3.33 (0.47) 48.81 (18.31) 24.43 (19.31) 0.99 (0.77) 80.00 (44.72)
9 4 3.42 (0.42) 34.38 (8.90) 39.59 (16.27) 1.33 (0.41) 78.98 (21.91)
10 4 2.92 (0.68) 22.65 (22.06) 23.28 (5.69) 1.00 (0.29) 71.39 (23.10)
11 3 3.67 (0.58) 23.46 (13.10) 50.46 (10.48) 1.12 (0.77) 94.44 (9.62)
12 3 2.77 (0.84) 33.58 (3.49) 46.76 (7.58) 1.51 (0.19) 54.26 (26.85)
Note
Bold values indicate proficiency for that domain.
TABLE 34 The MITI scores, by HLF and session type
HLF
Number
of tapes
coded
MITI domains, mean (SD)
Global spirit
Percentage with
complex reflections
Percentage with
open questions
Reflection-to-
question ratio
Percentage who
were MI adherent
Individual sessions
1 152 3.76 (0.61) 41.00 (17.36) 42.11 (13.41) 1.64 (0.87) 91.88 (13.97)
2 50 3.25 (0.67) 37.32 (15.58) 39.14 (16.08) 1.28 (0.76) 82.76 (24.58)
3 47 3.22 (0.80) 29.69 (14.94) 53.47 (13.54) 0.85 (0.80) 67.98 (25.41)
4 30 3.36 (1.11) 32.39 (18.10) 41.48 (11.67) 0.68 (0.30) 81.05 (23.59)
5 15 3.33 (0.50) 30.70 (12.45) 47.66 (15.27) 2.39 (2.05) 83.60 (20.09)
6 7 4.00 (0.00) 48.12 (13.11) 51.31 (15.63) 1.10 (0.32) 87.43 (18.66)
7 4 4.00 (0.54) 39.31 (7.77) 45.08 (6.92) 0.83 (0.14) 92.73 (9.51)
8 5 3.33 (0.47) 48.81 (18.31) 24.43 (19.31) 0.99 (0.77) 80.00 (44.72)
9 4 2.92 (0.68) 22.65 (22.06) 23.28 (5.69) 1.00 (0.29) 71.39 (23.10)
10 4 3.42 (0.42) 34.38 (8.90) 39.59 (16.27) 1.33 (0.41) 78.98 (21.91)
11 3 2.77 (0.84) 33.58 (3.49) 46.76 (7.58) 1.51 (0.19) 54.26 (26.85)
12 3 3.67 (0.58) 23.46 (13.10) 50.46 (10.48) 1.12 (0.77) 94.44 (9.62)
Group sessions
1 48 3.55 (0.62) 35.97 (12.42) 46.98 (11.67) 1.41 (0.52) 85.44 (28.85)
2 14 3.26 (0.63) 38.38 (16.59) 51.05 (12.76) 0.68 (0.28) 85.34 (20.39)
3 8 3.04 (0.60) 33.59 (20.89) 60.65 (23.58) 0.66 (0.31) 68.93 (28.20)
7 1 3.66 (–) 42.86 (–) 48.94 (–) 0.74 (–) 100 (–)
Note
SDs could not be calculated for HLFs with only one session available; only four HLFs have group sessions available.
Bold values indicate proficiency for that domain.
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TABLE 36 Behaviour change technique adherence, by HLF and session type
HLF
Session type, % (n)
Group Individual
1 62.12 (48) 66.75 (152)
2 62.99 (14) 37.64 (50)
3 35.23 (8) 47.97 (47)
4 – 50.61 (30)
5 – 32.73 (15)
6 – 66.23 (7)
7 72.73 (1) 81.82 (4)
8 – 56.36 (5)
9 – 68.18 (4)
10 – 54.55 (4)
11 – 66.67 (3)
12 – 72.73 (3)
Note
Cell values indicate mean percentage of BCTs delivered (number of sessions).
Only four HLFs have at least one taped group session.
Bold indicates competency.
TABLE 35 Summary of BCT adherence
BCT
Intervention arm, n (%)
Total (N= 395), n (%) Statistical test outputGroup (N= 71) Individual (N= 324)
1 48 (67.61) 169 (52.16) 217 (54.94) χ2(1)= 5.01; p= 0.025
2 57 (80.28) 267 (82.41) 324 (82.03) χ2(1) = 0.09; p = 0.76
3 45 (63.38) 224 (69.14) 269 (68.10) χ2(1) = 0.70; p = 0.40
4 53 (74.65) 239 (73.77) 292 (73.92) χ2(1) = 0.00; p = 1.00
5 54 (76.06) 216 (66.67) 270 (68.35) χ2(1) = 1.87; p = 0.17
6 40 (56.34) 147 (45.37) 187 (47.34) χ2(1) = 2.32; p = 0.13
7 35 (49.30) 179 (55.25) 214 (54.18) χ2(1) = 0.65; p = 0.42
8 58 (81.69) 241 (74.38) 299 (75.70) χ2(1) = 1.23; p = 0.27
9 33 (46.48) 160 (49.38) 193 (48.86) χ2(1) = 0.11; p = 0.74
10 20 (28.17) 69 (21.30) 89 (22.53) χ2(1) = 1.18; p = 0.28
11 21 (29.58) 99 (30.56) 120 (30.38) χ2(1) = 0.00; p = 0.97
Overall 464 (59.41) 2010 (56.40) 2474 (56.94) χ2(1) = 2.02; p = 0.16
Note
n (%) indicates the number and percentage of sessions in which the BCT was coded present.
Bold indicates competency.
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Discussion
We coded 395 recorded intervention sessions for fidelity. We observed that nearly all (11/13) of the HLFs
achieved high levels of competency on at least one dimension of MI but fewer did so with the BCT, in
which only 2 out of 13 HLFs achieved competency. The HLFs received extensive training in delivering the
MI and BCT elements of MOVE IT and were supervised throughout the trial; our analysis of a non-random
and probably underpowered sample of tapes indicates that the intervention was administered with
acceptable levels of competencies in MI but the competency of HLFs in delivering the BCTs is not known.
When combining MITI scores across HLFs, we found that the MI aspects of the intervention were not
delivered at the desired competency level. At the HLF level, none of the HLFs reached the minimum
MITI-based proficiency level and only three met the competency criteria adapted for the study. By further
stratifying by session type, however, we found that two HLFs delivered the MI elements in individual
sessions at a level deemed competent for our study.
We observed treatment arm differences in several of the MITI domains. Most of these differences were in
domains with count scores, hence these were expected given the longer length of the group session
format (i.e. HLFs had more opportunity to use the technique repeatedly). Of particular interest, HLFs in
group sessions demonstrated a greater percentage of open questions, whereas in individual sessions they
made more reflections relative to questions. This may be because in group sessions a large proportion of
time was spent facilitating group discussion, which lends to repeated use of open questions. In addition,
in group sessions there may have been less opportunity for HLFs to ask closed questions, which naturally
follow open questions in individual sessions (e.g. to clarify what the individual has just said or encourage
further conversation). In terms of the reflection-to-question ratio, this could be explained by the fact that
reflections require a deeper level of listening and understanding, which the group session format does not
lend itself to as easily as individual sessions do.
Most HLFs were ‘partially proficient’ in delivering BCTs. Only three BCTs (‘prompt intention formation’,
‘prompt specific goal-setting’ and ‘agree on behavioural contract’) were administered in > 70% of sessions.
Furthermore, two BCTs (‘self-talk’ and ‘relapse prevention’) were delivered in approximately < 30% of
sessions. Across the BCTs defined for the trial, we observed treatment arm differences in only one (‘provide
information on consequences’); however, this is possibly a false positive owing to the number of tests
conducted. Finally, only two HLFs delivered, on average, ≥ 70% of the BCTs across the sessions assessed
(however, this was only five sessions for one HLF and three individual sessions for the other). These results
should be interpreted cautiously as we used an unvalidated BCT coding framework developed for this
study; thus, we may have underestimated HLFs’ competency in delivering the BCTs.
Limitations
Owing to the network outage and loss of recorded sessions, the characteristics of the recovered tapes
are based on a non-random subsample of the original tapes. Thus, it is highly likely that our findings are
biased and probably an underestimation of the HLFs’ competency. We are uncertain when these sessions
were recorded. For instance, if the sessions were recorded earlier in the study, the HLFs may have had
less competency than later in the study. We do not know why these specific tapes were saved. As part of
supervision, the HLFs were required to identify sessions in which they had had difficulties and, therefore,
these may be tapes representing lower competencies.
As the data loss occurred while we were preparing our database of recorded sessions, some session details
were left incomplete. When comparing the characteristics of the sessions in our original (pre-IT outage)
and recovered databases, we found that distributions of session numbers and HLFs were different. In
particular, the recovered sessions contained fewer maintenance sessions. The majority were retained by
one HLF and another HLF had no sessions recovered at all. Thus, it is likely that this fidelity analysis of the
recovered sessions is biased towards an underestimation.
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We did not observe any pattern concerning the number of sessions delivered by each HLF and their MI
skills. The HLF who also supervised and trained other HLFs had the largest number of sessions recovered.
Furthermore, the fidelity analysis that we conducted was possibly unsuited to the content of the
intervention. For instance, although the MITI tool was the optimum coding system for assessing fidelity in
the individual sessions, it has not been previously validated for MI delivered in a group format. Thus, the
raters faced challenges in using this to code the group sessions. For example, as the structure of the group
sessions contained more group exercises and more didactic interactions, it was difficult to detect sufficient
utterances that demonstrated empathy. Instead, it may have been better to use a different coding system
for MI in the group sessions.
Similarly, the nature of MOVE IT may have prevented the BCTs from being consistently captured by the
fidelity raters. For example, six of the BCTs (ii–iv and vii–ix) were intended to be delivered by the HLFs
during one-to-one portions of the group sessions when participants completed their action plans, which
were probably not captured by the recordings. Furthermore, three of the BCTs (ix–xi) were intended to be
delivered in the maintenance sessions only; hence, it is not surprising that these were among the least
captured in the fidelity analysis. And this issue is compounded by the fact that fewer maintenance sessions
were recovered after the network outage. Thus, we felt that the data loss from the outage barred us from
conducting a more robust and detailed analysis of BCT delivery by the HLFs.
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Chapter 9 Qualitative findings: the views of
participants
Background
Randomised controlled trials provide a reliable and rigorous method of assessing the effectiveness of an
intervention.125 However, owing to their complex nature there are a number of additional challenges that
may arise when reproducing the intervention. Therefore, it is important to evaluate the delivery and
processes of the intervention from the patient’s perspective.126
Focus groups give participants the opportunity to provide in-depth reflections of their experiences and
views of the intervention.127,128 Understanding the experiences of participants is vital to provide an insight
into potential barriers and improvements that often occur in lifestyle interventions.129 Therefore, the use of
focus groups can enable researchers to review the different behavioural or social processes that may not
be evident from the use of quantitative analysis only, leading to the successful implementation of an
intervention in the future.126
A recent systematic review and meta-analysis revealed the effectiveness of structured lifestyle interventions
that target both diet and PA as being successful in reducing CVD risk factors.130 Studies have found that
the delivery of MI for health-related behaviour change in lifestyle interventions to be beneficial, particularly
in the short term.49,131,132 However, few have investigated the maintenance of behaviour change in the long
term with the use of qualitative methodology.
The aim of this qualitative analysis was to explore the views of participants of MOVE IT in terms of reasons
for engagement, factors enabling behaviour change and the potential barriers to engagement.
Methods
Two groups of participants were approached for process evaluation: (1) those who attended the intensive
phase of the intervention, that is, six or more sessions (completers), and (2) those who withdrew before
the intensive phase was completed or did not attend at all (non-completers). Participants were invited,
based on a purposive sampling method to form heterogeneous groups. Only those who had completed all
three follow-up appointments were approached.
Participants were separated into six focus groups: four groups of completers (labelled as 1A–1D) and two
groups of non-completers (2A and 2B). Each group had two facilitators, who were research assistants from
the MOVE IT programme and had not met the patients before, to avoid response bias. For each group, we
aimed to include at least one female participant, an individual with an ethnic minority background and a
mix of those who attended individual and group sessions.
Focus groups using a semistructured interview schedule were carried out with the use of a topic guide
(see Appendix 4). The topic guide was informed by preliminary analysis from the HLF contribution, input
from the research team and investigators, and feedback from PPI members. It consisted of open-ended
questions relating to (1) the invitation to take part in the study, (2) lifestyle changes made since joining
the MOVE IT programme, (3) most and least helpful aspects of the sessions, (4) participant diversity and
(5) potential online interventions.
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Informed consent was obtained and each group was audiotaped. Data were anonymised and transcribed
verbatim. The transcripts were analysed using thematic analysis.133 The analysis was descriptive and
interpretative and facilitated by the use of NVivo version 10 (QSR International, Melbourne, VIC, Australia)
to code emerging themes and subthemes.
Results
A total of 74 participants were invited to attend a focus group, with 26 ultimately participating. There
were four groups of completers and two groups of non-completers. The characteristics of those who took
part are outlined in Appendix 5.
A thematic analysis of all six focus groups resulted in three generic themes. A fourth theme was generated
from only the non-completers’ responses, as shown in Table 37.
Theme 1: perceived benefits of the study
Personal behaviour changes
Participants described positive lifestyle changes they had made with regards to their diet and PA during
the study:
I found it beneficial. I took on the pedometer stuff, I took on the five a day, I took on the number of
glasses of water a day, the oily fish, all of those, you know, don’t just live a sedentary lifestyle of a
night, get up and move around, all of those things, were lessons that I took on board . . . they have
been beneficial to me.
Participant 9
I am in a habit of doing daily exercises in the morning. Although I do it at home at least half an hour
stretching and dancing. So that makes up for the lack of walking. All in all it has made quite a
positive impact.
Participant 5
TABLE 37 Summary of themes and subthemes
Themes Subthemes
1. Perceived benefits of the study l Personal behaviour changes
l Increased health awareness
2. Factors enhancing behaviour change l Social support and learning from others
l Ease of programme structure and content
l Continuity and strength of therapeutic alliance
3. Perceived risk of CVD l Perceptions of their own CVD risk
l Perceptions of the CVD risk to others
4. Potential barriers to change and overcoming these barriers l Lack of feedback
l Lack of engagement
l The role of authority
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Lifestyle changes were sustained following the completion of the sessions:
They’re in there. They’re programmed in. So on an evening, I try not to sit there plonked in front of
the television, I get up and do stuff. Make the tea, go and get some fruit. You know, just keep getting
up and doing stuff rather than just have a sedentary evening every evening.
Participant 9
I found I am counting the number of different fruits and veg that I’m having each day . . . and then
I was like ‘Ohh . . . five today,’ ‘Uh fine gosh, seven yesterday oh well’. You know, I am still doing it
every single day . . . what am I going to eat . . . when am I having it. Oh yeah . . . every day.
Participant 4
Increased health awareness
The main benefits described by the participants are the increased knowledge and health awareness from
taking part in the intervention. Primarily, individuals reported that the sessions highlighted the importance
of keeping active and making healthy lifestyle choices regarding their food intake:
I think I’ve got much more of an awareness of how . . . Oh perhaps I can leave the car behind for a
short journey. Do I need it? It’s that permanent awareness. Do I need to? Are we having enough fruit
and veg? Oh gosh. We haven’t had fish for quite a . . . quite a long time. You know . . . Just. It’s there
all the time.
Participant 2
But what MOVE IT did for me certainly did highlight that I wasn’t doing it. So it’s made me more
aware, and that’s why I ate oily fish before I came out today, not particularly because I was coming to
this focus group, but it’s ingrained in my subconscious now that I ought to eat a certain amount. I . . .
so just to reinforce . . . what this has done is benefited me in that it’s now in my consciousness. I don’t
adhere to it religiously but overall I feel it’s been beneficial.
Participant 9
More specifically, there was an increase of awareness and understanding of the use of the labels on
packaging (i.e. the traffic light system):
It wasn’t until I noted how much sugar and how much saturated fat was in food that we eat. So
when we buy things we’re more aware of what we’re buying and now and then we’ve got food
that’s got a bit of red in it [laughs] on the traffic lights . . . But as long as . . . it’s not really frequently
we don’t get too upset about it.
Participant 16
Theme 2: factors enhancing behaviour change
Social support and learning from others
Participants who had attended group sessions rather than individual sessions felt that being part of a
group had a positive impact on their ability to engage with the study. The opportunity to discuss their
achievements or setbacks and be in a positive social environment was something they appreciated and
enjoyed:
It was nice to, have other people there were going through the same experiences if you like. And you
would talk about it and bring back the same sort of problems or any success. So it’s nice to have
experience with it.
Participant 16
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I think it’s quite good really, because you know, you. People in our group you know got on quite well,
quite nice to talk to other people. Yeah . . . how you been doing, how many steps they done that
week. No . . . I think it’s quite a good social atmosphere.
Participant 13
In addition, those who had individual sessions felt that they would have benefited from having support
from others:
Whether it’s an individual session or a group session, maybe a group session more, you have to
develop a kind of . . . a group dynamic, that compels people to want to come back, because they’re a
part of that group. I think the first three groups, the first three meetings or so, if you can really get
people hooked in, they’ll come back because they’re a part of that group, or something like that.
More will come back, because they’re kind of part of that group.
Participant 21
Social support had a beneficial effect for people close to the participants. Participants had the opportunity
to share their experiences with family members and see positive effects on them too:
Yeah. I suppose so. For me the family as well. I did tell my wife about it . . . and it did have an effect
on her. You know, what she ate and stuff.
Participant 13
What was helpful – because of all the things about the diet etcetera, my son went to for blood test
and was told he was potentially diabetic, put me in the panic. So I cooked everything for him . . . I did
all the cooking and sent it round. And he lost about 3 stone in very short time and then they said he
wasn’t gonna be a diabetic at all . . . So it did for him as well as for me . . . because of what I’ve learnt.
Yeah. So that was a bonus.
Participant 15
Ease of programme structure and content
An important factor reported to enhance behaviour change was the simplicity of the techniques that
participants developed throughout the intervention. For example, setting small goals, awareness-raising
and the preparation of setbacks enabled them to achieve sustainable lifestyle changes:
And they told me the procedure was very simple once I started. I found that if I avoid snacking, then
my weight goes down. So I lost quite a bit of weight.
Participant 9
I thought personally, the pedometer was a very very good thing and it was so simple.
Participant 3
That training was excellent. You know, everybody has got a sometime or the other or you can have a
setback. So, they told us how to keep going, not to stop. So that was a very good training. There will
be step backs but those techniques help keep going.
Participant 7
You are now conditioned to be a bit more aware, and that is very important. It doesn’t mean that I do
10,000 (steps) a day, but it is that awareness, that keeps my mind going.
Participant 7
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Continuity and strength of therapeutic alliance
To sustain healthy behaviour changes, some participants felt that it was important that there was
continuity of sessions. It was reported that participants felt less motivated to continue during the later
stages of the programme because the sessions were less frequent:
I found the first six sessions really easy, because it was close together and it was just like we knew that
every Thursday you would go. It’s, when they were spread out then I felt like oh! You know, for the
last one I really did not want to go. But you know, I said it to the nice lady.
Participant 2
Participants highlighted the importance of the therapeutic relationship built with the HLFs and how this
encouraged them to return to the later sessions. During the process, there were changes to the HLFs,
which some participants found to be quite disruptive:
I found when they spread out was, so in the first six it was one and the same person and you got
almost on the one-to-one thing. So you got this rapport with someone then you hear . . . ‘Hello, she’s
left I am taking over’.
Participant 4
‘Well, she’s left, I’ve taken over.’ Well it was complete stranger, there was no rapport, and well they
thought, ‘How are you doing?’ And well . . . I don’t know . . . you don’t know . . . And it was a
complete stranger and you have no idea.
Participant 4
Maintaining continuity of staff to sustain engagement with participants was highlighted by participant 2:
I was definitely one of the lucky ones ‘cause I had the same lady all the way through . . . so I mean we
had usually an hour and a half. You know, ‘cause you know, when you to get to know somebody you
talk a lot. I mean, that was very useful.
Participant 2
Theme 3: perceived risk of cardiovascular disease
Participants’ perceptions of their own cardiovascular disease risk
Participants dismissed themselves from being at risk of CVD owing to a lack of family history or an absence
of current health problems. Some associated their risk of CVD solely with their age and discredited the
contribution of other risk factors (e.g. poor diet and lack of PA):
When I got a letter . . . from the King’s College. I was a bit . . . I was a bit surprised. I don’t have a
problem with the heart, so why they did . . . wrote letter like that, join. So I thought it might have
some benefit . . . so I joined.
Participant 14
You know . . . go to the doctor and the doctor had never said . . . oh . . . you know . . . you’re a
particularly high risk of heart disease. So it comes in the post . . . and it says, you’re in this high-risk
group. So . . . you know . . . you do a bit of a double take. I don’t know whether. But anyway . . .
you’ve got nothing to lose and do the . . . come on and do the study and find out. But I think, as
[participant 12] said, on the things they use to work out the risk factor, as soon as you put in your age
and put in you’re 70, you’re immediately in the 70% category.
Participant 13
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Perceptions of the cardiovascular disease risk to others
The participants distanced themselves from having a risk of developing CVD and projected this onto
others. Some felt that those who were selected were not appropriate for the study as they were not at risk
or had no history of being at risk of CVD:
I said the thing is, I’m old anyway, surely it’s people who are in their 30s and 40s to preclude them from
maybe getting a risk of or having an inherent risk of heart trouble or whatever. Surely, it’s the people
who drive a hundred yards, or a hundred metres to the fish and chip shop, load themselves up – mind
you I love fish and chips – every day of the week, and they are the people, surely at risk.
Participant 8
Well, I think all the people in our group. You know . . . they seemed to be reasonably fit and you
know. You know . . . you harp on about diet really. You know . . . these things . . . are kind of
self-selective aren’t they?
Participant 13
Participant 13 suggests that those who agreed to take part may not actually be the individuals who
need help:
So you wonder . . . the people that really . . . I’m not saying we didn’t benefit from it, but you know,
there weren’t really obese people there. And I think I . . . so you wonder whether the people . . . the
people who would really benefit from it. You know . . . the people who are possibly volunteering, are
the ones that need it the least.
Participant 13
Theme 4: potential barriers to change and overcoming these barriers
Lack of feedback
A recurrent subtheme for participants in both the individual intervention arm and the group intervention
arm was the lack of feedback received during the study. Particularly, participants felt that feedback seemed
to be predominantly negative throughout, without the encouragement of positive results to engage them
further with the study.
One suggestion was to provide positive feedback regarding weight loss and participants’ progress as a
means of potentially increasing motivation:
The person doing the testing didn’t want us to give feedback about the group. I understand. But we
didn’t seem to get any feedback, like ‘Oh, your weight’s gone up’ or you know . . . because that’s a
motivation in itself. You know . . . there was never that kind of discussion. Like ‘this has changed, your
cholesterol’s . . . whatever . . . or’. ‘Cause the things they test, there didn’t seem to be any feedback.
Now, I thought it would have been important to say to people ‘well, this is OK . . . but this is not
good’ you know . . . and whatever. ‘Cause that’s a motivation in itself.
Participant 21
So you’d get the negative, we would get it if it was a negative result but if you wanna keep people
more motivated they need to know about, the positive stuff as well, because that’s why they’re going.
They want to know, they’re getting better. If you’re not gonna tell me you’re getting better . . .
well why?
Participant 23
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Lack of engagement
A further barrier that was described was the lack of engagement or a relationship being developed on a
personal level during the study:
There you well ‘mm . . . you’ve been doing this for a year, it’s been bought to your mind. What are
the consequences? What’s changed in your life at all . . . that’s not enabled you to do it’ whatever . . .
you know it’s just. I think that relates to my earlier point. I think there is a lack of engagement on a
personal level. If you want to motivate people, you need to get people hooked in partly, as an
individual as well as the group . . . I think I became this name and this number without any particular
relationship being developed.
Participant 21
The role of authority
There were varying suggestions surrounding possible reasons why some individuals might not have
decided to take part and changes that may improve this in the future. A recurrent theme was the
importance of the role of authority from a health-care professional, such as a GP.
One participant suggested that their involvement may therefore be helpful to encourage those who are
more reluctant to take part:
Now . . . people tend to listen to their doctor . . . or respond to the doctor, better than the MOVE IT
study from, King’s Univ- well, who the hell are they? You know, you got to . . . there’s no
engagement there. Whereas, if the doctor sends the letter, or a covering letter . . . then . . . as a as an
intro, that’s a more powerful intro than just a letter from you know because clearly . . . well . . . if a
doctor said, we are collaborating or co-operating whatever word you choose, with this study from ah,
and from your records it would appear that you are at risk of . . . whatever. Perhaps you would be,
you’d, perhaps it would be ah, they could suggest that the study might be beneficial to you. Now,
now that would be, that would be a fairly powerful introduction I think.
Participant 21
This was also highlighted by the completers, who mentioned that their GPs were unaware of their risk:
. . . and I thought . . . oh . . . all right . . . I’ll go along with it. Then when I next saw my doctor, I said,
like you know, what’s this about high risk of heart attack and he looked at me vacantly and he says
‘I dunno’. He said probably your age. He said, that’s all I can think of.
Participant 12
Summary
This qualitative analysis explored the views of participants allocated to the intervention arms of MOVE IT.
The main themes that emerged were (1) perceived benefits of the study, (2) factors enhancing behaviour
change and (3) perceived risk of CVD. One further theme that emerged solely for the non-completers was
(4) potential barriers to change and overcoming these barriers.
We found that participants described having positive experiences during the intervention sessions, citing
the benefits of increased health awareness, positive lifestyle changes and the opportunity to learn from
others. We identified several factors that might have affected the maintenance of participant behaviour
change. Primarily, participants noted that the continuity of sessions and having the staff involved
throughout were very important. The changes to the HLFs who carried out the sessions were disruptive for
some and led to reduced engagement with the intervention. The continuity and frequency of sessions also
had an impact on participants’ motivation to take part and make healthy lifestyle changes. Owing to the
pragmatic design, duration of the intervention and short-term contracts of the HLFs, there was a natural
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staff turnover that could not be prevented, except with a vast increase in funding to potentially hire more
HLFs or offer longer contracts.
Non-completers had expressed that there was a lack of feedback and engagement throughout the
intervention. To improve this, it would be beneficial to provide more positive feedback from HLFs or to
have an alternative method of self-reflection during the sessions. This would increase motivation for
patients to continue participation and for behaviour change to be sustained. Participants’ perceptions of
their own CVD risk may be viewed as a barrier to engagement.
Most participants did not believe CVD risk to be an issue and often attributed the risk to their age rather
than their own lifestyle choices. In addition, some GPs were not aware of their patients’ risks or the study
itself, which may have altered individuals’ perceptions of CVD risks. Therefore, for future interventions, it is
important to work more closely with GPs to emphasise the benefits for patients’ health and potential to
ameliorate CVD risk. There may be other reasons why the non-completers felt a lack of engagement, as
they may have higher levels of psychological distress or social problems that were not articulated during
the focus group.
MOVE IT emphasised the importance of the use of qualitative methodology in providing detailed
experiences of participants for assessing the effectiveness of a RCT. As previously reported, studies have
supported the benefits of lifestyle interventions in the short term but few have supported them in the long
term.49,131,132
The detailed reflections from participants involved in a long-term intervention support the use of qualitative
methods for gaining greater understanding of the factors facilitating engagement and barriers to
engagement. The responses from participants highlight the benefits of lifestyle interventions and the
maintenance of behaviour changes for diet and PA levels. Finally, this study reveals areas of improvement
for the future delivery and implementation of the study, including continuity of care and duration of the
intervention. Although attendance at group sessions was lower than attendance at individual sessions,
those who attended group sessions appeared to value the peer support aspect.
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Chapter 10 Qualitative findings: the views of
healthy lifestyle facilitators and clinical psychologists
Background
The HLF team were trained by a CP to deliver MOVE IT. Training in MI involves achieving a number of core
competencies,134 and HLFs were also trained to incorporate BCTs into intervention delivery.52 There is no
fixed length for the training of MI; however, a review of 28 studies found that most training schedules
required 9–16 hours of training.135 The training methods for MI involve didactic supervision and learning
activities, such as role play, group exercises, discussions and feedback.42
The application of MI is considered helpful in working with patients towards lifestyle changes in primary
care by nurses who incorporate it into their practice.136,137 Previous studies of the application of MI in
practice have suggested that it can be demanding but rewarding and that the spirit of MI and simple
competencies are frequently achieved, but that the application of MI skills reduces over time and further
support is required for more complicated competencies.136,138 The ability to reflect on practice, continuing
to develop skills and ongoing supervision are thought to be crucial to enhancing the long-term benefits
of a MI approach.139 There is evidence that enhancing MI with CBT techniques is achievable for nurses
supporting diabetes mellitus control140 or alcohol cessation,62 and that intervention providers perceive both
positive and negative impacts of the intervention on patient care depending on the patient’s ability to
engage.141 Evaluating any novel intervention, from the perspective of stakeholders such as the intervention
providers, is important for translation to policy.142
The views and experiences of intervention providers are vital to assessing the feasibility of widespread
implementation into practice, by exploring the challenges in training and delivery. The HLF role was newly
developed for the MOVE IT trial, drawing on the promising preliminary findings of the NHS health trainer
programme, and adapted to be in line with MI, which underpins the intervention. Therefore, as the
intervention and job role are both novel, we sought to gain detailed feedback on HLF training and
intervention delivery from both the CPs who were responsible for training and supervision and the HLF
team.
Methods
A qualitative approach was adopted to study HLFs’ and CPs’ views and experiences of developing and
delivering the interventions. All 13 HLFs and two CPs were invited to interviews. Semistructured interviews
were carried out, consisting of open-ended questions relating to the training, supervision, intervention,
participants and values in psychological therapies. The topic guides used for HLFs and CPs are provided in
Appendix 6. Interviewees were invited to give their feedback and the discussion was audiotaped. To gather
meaning from the data, inductive thematic analysis explored any underlying concepts that were mentioned
regularly.
The interviews were conducted by an independent research assistant to avoid response bias, which could
exist if the interviewer was part of the MOVE IT team. Audiotapes were transcribed verbatim and the data
collected were anonymised. NVivo software was used to analyse the data. Emerging themes from the
interview transcripts were coded and categorised into themes and subthemes.
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Results
A total of nine female health-care professionals (seven HLFs and the two CPs) were interviewed. All HLFs
except one were working on the MOVE IT trial at the time of their interviews. The HLFs who no longer
worked on the trial were unavailable to participate. The characteristics of those interviewed are given in
Table 38.
A thematic analysis resulted in three generic themes:
1. challenges and suggested improvement for the training
2. supervision issues and peer support
3. challenges with delivering the intervention.
Theme 1: challenges and suggested improvement for the training
The healthy lifestyle facilitator perspective
All HLFs were required to attend training during a 6-week period, with most agreeing that all subjects
were adequately covered in this time. The HLFs appreciated the MI and CBT skills and the knowledge of
how to apply these skills gained in the sessions. Although the information was thorough and prepared the
HLFs for various situations that could occur during their sessions, the HLFs identified the 6-week training
period as intensive and time consuming:
I think towards the end people felt like ‘OK I am ready to go now’ so it could have been maybe a little
bit shorter.
HLF4
We, I say we because we have actually discussed this already, would have preferred it if it would have
actually been pushed out quicker so that we experience it rather than just continuing to do scenarios
which we kept doing every day.
HLF6
TABLE 38 Characteristics of intervention providers
Identifier
Number of months in position
at time of interview In post at time of interview?
HLF1 23 Yes
HLF2 9 No
HLF3 18 Yes
HLF4 8 Yes
HLF5 8 Yes
HLF6 8 Yes
HLF7 23 Yes
CP1 10 No
CP2 12 Yes
Note
Anonymous identifiers for the HLFs do not match those in Chapter 8.
QUALITATIVE FINDINGS: THE VIEWS OF HEALTHY LIFESTYLE FACILITATORS AND CLINICAL PSYCHOLOGISTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
At the beginning was kind of a lot of practising, it was a bit too much and it became mechanic
because we did it with each other so much.
HLF7
There was particular reference to the role-playing exercises during the training, as reflected by comments
such as:
. . . since we were role playing between ourselves we were taking it easy on each other.
HLF6
So we had training for 2 months, September and October. It was intense and it got quite repetitive
and in my opinion it got quite tedious to the point where we started overthinking everything we did.
HLF7
The HLFs reported that sessions varied considerably in terms of the participant and their motivations to
participate in the MOVE IT trial. This differed from the preparation they had undertaken in the training
period:
The patients that we had were totally opposite of what we were trained to do and that’s what threw
everyone off. Everyone was trained to talk a certain way, got to their patients but then everyone was
the total opposite.
HLF2
The clinical psychologist perspective
Both CPs were interviewed regarding their views on the training that had been developed by CP1. CP1
trained and handed over responsibilities to CP2 over an 8-week period. Within the first year, five out of
the eight HLFs that CP2 had trained had left the study, leaving three HLFs to split the workload. When CP2
was employed, three new HLFs joined the study, bringing the total number of HLFs to six. The curriculum
was adapted as the training was designed for larger groups. Despite this, CP2 felt that the HLFs managed
the situation very well despite the intensity of the curriculum and amount of material covered:
I think it was kind of split into sort of face-to-face interactive sessions . . . They were given resources to
go and self-study and some ideas of what to practice and how to practice the sessions . . . None of
them really had previous experience of actually delivering psychology-based interventions . . . I suppose
the tricky thing with something like MI, which I suppose is the key approach that is underpinning
everything in MOVE IT, is that actually there is only so much you can teach directly because a lot of it
is actually through practice and getting things wrong and reflecting on it . . . I guess that was also
another challenge, just to know which were the crucial elements to kind of teach and how to get
those across in a simplified and manageable way . . . It is quite a challenge because the concept of MI
is still quite undefined in some ways as an intervention.
CP2
They came more from a health promotion background so their thing is being much more directive,
telling people what to do, getting information, giving education, so they love all that . . . what’s
difficult is to try to pick them up into it and to try not to destroy their confidence too much so that
they do not want to come back to training . . . what we can teach people and what we can actually
take on board in my experience is quite different, so you can probably cut it [the curriculum] down by
half and they might get some of that. Maybe the content, maybe it’s more about doing less, better.
CP1
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Along with MI and CBT skills and the process of being assessed, requiring knowledge of CVD and its risk
factors contributed to the length of the training, as CP1 explains:
. . . we had been working on another trial which was training diabetes nurses also in MI and some
CBT techniques, so we were looking for a length of time which would allow them enough time to
understand the theory, enough time to get to know each other and role play with each other, and
understand a whole new curriculum and how to deliver it, plus everyone needed to be assessed which
is a really lengthy process . . . I think the additional thing is that it is also the third strand is having to
provide education about CVD.
CP1
Theme 2: supervision issues and peer support
Issues with supervision
A recurrent theme regarded the supervision received and lack of support provided, as seen in the following
excerpts:
If we had a problem it was hard to know who we should go to and sort it out quickly because they
tended to palm it off on each other quite a lot, not to be disrespectful or anything.
HLF1
But in terms of managerial supervision, we had that, but it was kind of formalities as opposed to kind
of a necessity, I don’t think they wanted to be there and we didn’t really want to be there either and
I think towards the end there was some tension between the HLFs and the supervisor.
HLF2
The project manager didn’t really come to our supervision that much, I thought they were going to be
there more to like help out with any other problems. I suppose the project manager could have been a
bit more hands on, in supervision I mean.
HLF3
In addition, the HLFs felt that there were positive and negative consequences of some of them being at
different stages of their sessions. On the one hand, a HLF further along in the training provided useful
information to listen to and learn from. However, for those HLFs who were ahead, they felt that this was
time consuming and that the time could be used to complete other tasks:
After the training, which was an intense period, you go out so it was good to constantly have that
reminder of techniques and things, and then also that other girls are at different stages in their
delivery so you can kind of hear about what’s upcoming if someone is a session or two ahead of you
. . . I think timing was probably a thing with supervision because they do seem to drag and it seemed
like talking about the same thing a lot.
HLF4
Peer support
In relation to the lack of support experienced from management, the HLFs recognised the importance of
supporting each other through difficult situations:
We, I say we because we have actually spoken about it. It’s very useful in the sense that you get to
hear what other HLFs are experiencing as well, so you might pick up on something someone else
brings up and because we are talking about it in the supervision you get to help each other.
Therefore, if that kind of situation presents itself again you know what to do.
HLF6
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If there are similar problems and successes then it’s nice to hear it but we talk about them anyway.
And it’s not nice to brag about it if someone else has an issue so I tend not to say too much, I didn’t
really participate too much.
HLF2
Once you are away from that sort of life it can be hard to come back to it, but they all encouraged me
and the clinical psychologist is really very supportive . . . They are so supportive. At the beginning I was
really slow with the IT and that sort of thing. Each other they helped with something, all of them. So
they helped me a lot.
HLF5
We were a tight family; there were eight of us and all around similar ages and personalities. We got
on so well that we were like one big team and family, we supported each other more than anyone
else did in the study.
HLF2
Healthy lifestyle facilitators 4 and 5 also expressed a lack of guidance for the administrative work that was
required. However, the situation improved after the MOVE IT administrator assisted in liaising with booking
rooms for sessions, scheduling sessions with participants and contacting potential volunteer group
facilitators:
. . . I know probably everyone is saying it, but I feel like I wasted a lot of time trying to sort that out
[administrative work] when I could have actually been doing what I am supposed to be doing.
HLF4
The administrator is helping us quite a lot and that way is fine. Even the last group invitations the
administrator helped send it and is looking for volunteers, there is help for us from there and we
are lucky in that aspect.
HLF5
One HLF was promoted to a senior position and organised meetings to discuss practicalities and
problem-solve non-clinical issues that arose. The senior HLF (HLF1) could then mediate between the
group and the CPs:
I think that’s really helped [promoting HLF] because it means that supervision with me is a bit more
protective for perhaps other more therapeutic issues or issues with the curriculum itself.
CP2
Reflective logs
It was noted that the communication and structure of fortnightly supervision meetings improved after a
senior HLF was appointed. Both CP1 and CP2 highlighted the benefits of the weekly reflective log that
each HLF completed:
Sometimes when we would start, maybe because it’s a little anxiety-provoking as well, they don’t
necessarily have issues that they would come out with then the way around that is that they have
these reflective practice logs . . . They fill in these weekly practice logs and then supervision is every
fortnight so often I would make a few notes of things that they brought up in their practice logs and
then we would talk about it in more depth.
CP2
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The supervision was in two parts, one was a face-to-face [meeting] every fortnight and the other was
weekly e-mail exchange where they would fill in a reflective practice log about what had gone well
and less well and what we needed to focus on for the following week. I would read everyone’s entry
and reply by e-mail, so they would get that support as well which worked pretty well because
everyone could read everyone else’s logs so they were all learning from each other continuously.
Everyone had to log at the end of the week.
CP1
The CPs felt that adequate support was provided, consisting of face-to-face supervision and reflective
practice logs. CP1 provided an example of the importance of a weekly log when a HLF was unable to
attend face-to-face supervision:
. . . there was one person who had a string of supervision that clashed with her running groups, that
was kind of bad because I felt like she really needed to come to supervision but again you have this
comfort with getting numbers through for the trial so we couldn’t have her abandon the group, but
thankfully she was active with the logs.
CP1
Theme 3: challenges with delivering the intervention
Challenges with patients
All HLFs mentioned enjoying interactions with patients and building a bond with them; they saw the
patients benefiting from the interventions and received positive feedback:
What I love is when they come back with the results, when they say they used to be size 20 and now
they are size 18, that’s really nice. I had someone who came off one of their medications, so they
were on medication before to control their blood pressure and cholesterol but now they are not
anymore because they have managed their diet and changed their lifestyle.
HLF6
However, challenges with delivering the intervention emerged as a common theme. Resistant patients
disputing any advice proved challenging for the HLFs, as did those who did not engage:
. . . one person walked out of the session as soon as we started with introductions the person just said
‘I’m out I’m out!’ and that scared me.
HLF7
Two of the HLFs mentioned the age of the participants as a barrier to delivering the intervention:
The participants are of an age range that aren’t used to ‘collaborative’ care and often just want to be
told/prescribed advice. This can make session delivery difficult as participants get frustrated at not
being given a straight answer.
HLF4
The patients that we had were totally opposite of what we were trained to do and that’s what threw
everyone off. Everyone was trained to talk a certain way, got to their patients but then everyone was
the total opposite.
HLF2
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Another challenge that the majority of the HLFs encountered was that participants often thought that the
HLFs were medical health experts; CP1 also noted this as a potential issue when delivering the intervention:
There are other issues that they has like their health problems, we are only trained to do the
intervention but if they come to you with other problems you are not skilled in it you don’t really
know what to do . . . I had to keep telling them that I am not in the medical profession.
HLF2
If you say that five a day is good for you then he would immediately disagree and ask where I
researched that from and how do I know if the fruit is actually good for you and not full of chemicals.
HLF6
I think other things that HLFs found challenging, especially with an older population with realistic
medical problems was when participants would say that they couldn’t exercise due to back pains, angina
or other various reasons. Then the HLFs are a bit stumped because they weren’t sure how to respond to
that because they think that it could be dangerous for them to make the participants do X, Y.
CP1
The HLFs also mentioned that the initial information sheet sent out to the participating patients was not
sufficient to prepare them for what the intervention would involve. HLF7 felt that a lot of patients would
be less reluctant to participate in the trial if they knew what each session would include:
I feel like people aren’t aware of what they are signing up to at the researcher stage, so many people
are not sure what we are talking about and I just wonder what they are told in the beginning. I
wonder if it’s been made clear that once they’ve done this then they are going to be given something,
some people are really hot on it and some have no clue what you’re talking about . . . That’s one big
thing that I feel that people aren’t aware of what they are signing up to.
HLF4
From my perspective people do not want to join the group because some expected to be weighed, or
do some physical activity because of our name like healthy lifestyle facilitators – facilitate what, is it
exercise? The name is good for using and the letter didn’t explain anything. I would expect less
dropout if you explain yourself better in the letter, because people become less nervous.
HLF7
Issues with the activity booklet
The lengths of the sessions (group and individual) were praised by the HLFs as there was adequate time to
cover the material and manage digressive conversations. A common issue referred to the provided activity
booklet being inappropriate for the age group. Participants had found the activity booklet childish or
patronising:
It’s probably the actual booklet; some people like it and some people think it’s referred to a sort of
working class. Some of the examples and case studies in there don’t particularly relate to them . . .
I guess they’ve had to write it for it to cater to different sort of educations, so some people are
obviously very well educated and it’s pretty much very basic. Some people find that a little offensive
almost so that builds up some resistance and then you are battling against that almost, so myself and
loads of the other girls have found that kind of tricky in terms of sort of putting the workbook a bit to
the side and chatting with them about things . . . There are bits in the actual goal-setting that people
don’t particularly like, which makes us feel like you almost don’t want to mention the question and
just want to put your hand over it and pretend it isn’t there.
HLF1
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Aspects of the actions plan such as rewards and reminders can be difficult to have this ‘older’ generation
understand. Often they will say ‘why do I need a reward/reminder, if I’m going to do it . . . I’ll do it’.
HLF4
People often say that this is not us but then I refer them and couple of individuals have mentioned
that this is quite patronising, the curriculum examples could be better and more age-fitting because
the patients do not relate.
HLF5
CP1 observed the struggles that the HLFs had with the activity booklet:
I think the HLFs found that difficult because they were trying to do a manualised structured worksheet
that they must fill in and the participants were just not on board, and they struggled with that.
CP1
Despite the issues with the activity booklet, CP2 highlighted the competence of the HLFs in guiding the
participants towards the booklet during an observation of a session:
They are also very good at, I suppose this is where their comfort zone is, giving the information in a
very clear way and making use of the resources in the workbook and pointing and steering people
towards those.
CP2
Summary
This qualitative analysis explored the views of HLFs and CPs regarding the process of implementing
MOVE IT. Of all 13 HLFs invited to interviews, we gained feedback from seven; we also gained feedback
from both of the CPs who trained and supervised the HLF team. The main themes that emerged were
(1) challenges faced during training and suggested improvements, (2) issues with supervision and peer
support and (3) difficulties in delivering the intervention.
The HLFs enjoyed learning how to implement MOVE IT in addition to working with the patients. The
training was described as time consuming and arduous, and HLFs felt that it could have been completed in
a shorter time allowing more time for hands-on learning. Although there was a lot of information to cover,
none of the HLFs mentioned a lack of confidence in the delivery of the intervention. With regards to the
relationship with their supervisors, many of the HLFs felt that the fortnightly sessions were not utilised
efficiently or that they could become repetitive.
The HLFs developed a strong support network between one another, and the relationship with their
superiors improved once a HLF was promoted and could mediate between them, making better use of their
time. It was noted that the activity booklets were age-inappropriate for the participants involved, which
became a barrier during some sessions. In addition, some participants assumed that the HLFs were medical
professionals who were able to discuss other health complaints and HLFs would have to reiterate that they
were not medically trained while ensuring that the participants did not lose confidence in the help that they
could provide. Both CPs noted the proficiency of the HLFs in working around these difficulties.
Enhanced MI was reported as an enriching and effective approach. The training undertaken by the HLFs
in this study could have been adapted to allow the HLFs to learn via experience as opposed to continual
rehearsal. This analysis also demonstrated the importance of effective and useful communication and
support between HLFs and those managing them. It is therefore important to consider a practical and
ongoing support structure. Furthermore, it may be useful to adapt the tools used in such an intervention
to the age of the target group to remove potential barriers to engagement.
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Chapter 11 Discussion
Summary of the clinical effectiveness of MOVE IT
This three-arm parallel RCT study tested the effectiveness of an enhanced MI intervention, delivered by
specially trained health trainers (HLFs), in a group versus individual format, versus UC for reducing weight
and increasing PA in adults at high risk (≥ 20.0%) of developing CVD in the next 10 years.
For the primary objective, the main findings were that there were no significant changes in weight or PA
24 months later between group enhanced MI or individual enhanced MI compared with UC.
For the secondary objectives, we found that MOVE IT delivered in a group format was not more effective
than when delivered in the individual format in reducing weight and increasing PA or in reducing LDL
cholesterol or CVD risk score 24 months later. There were no differences in the number of fatal or
non-fatal cardiovascular events and other recorded AEs between the three treatment arms.
The health economic results revealed that there was little difference in terms of service use and costs
between the three arms other than that resulting from the interventions themselves. Total service costs
over the follow-up period were highest for the individual intervention arm, followed by the group
intervention arm, followed by the UC arm. Differences were not statistically significant. QALYs were very
similar for each arm. The group intervention was dominated by UC in that the latter had lower costs and
produced more QALYs. The individual intervention did produce more QALYs than UC but the ICER
indicated a cost per QALY far in excess of the threshold commonly used by NICE. For this reason, neither
form of the intervention was cost-effective. There was much uncertainty around the cost and outcome
differences but the conclusions of a lack of cost-effectiveness hold.
The findings of the process evaluation were as follows.
l Mediators: we found that dietary changes did not mediate any treatment effects on the primary
outcomes. We did not conduct any further mediational analyses, as there was no change in the primary
or secondary outcomes.
l Participation bias: we found that there was significant evidence of reduced reach in that those with a
higher CVD risk, higher level of deprivation status and of African-Caribbean ethnicity were less likely to
reply to invitations to participate from their general practice.
l Fidelity analysis: there were significant methodological limitations of conducting a fidelity analysis but,
based on the much-reduced highly selected sample, there was evidence that nearly all of the HLFs had
sufficient competencies in at least one MI skillset.
l Patient experience: the main themes that emerged were (1) perceived benefits of the study (benefits
of increased health awareness, positive lifestyle changes and the opportunity to learn from others),
(2) factors enhancing behaviour change (continuity of sessions over a longer period and having
continuity of the same HLF) and (3) perceived risk of CVD (this was lower than was expected). One
further theme that emerged for the non-completers only was (4) potential barriers to change and
overcoming these barriers, such as lack of feedback and lack of engagement by their GPs.
l Therapist experience: the overall view was that the formal training period could have been shortened,
more exposure to training cases could have been provided and the HLFs had not been prepared for the
real-world challenges once in the clinical setting. They perceived themselves as competent in the MI
approach and BCTs. They observed the importance of working with patients towards their goals but
there were some common challenges, such as patients not engaging and some of the intervention
materials not being deemed age-appropriate. The HLFs felt that support from supervisors, and
administrative support, was insufficient but that they could problem-solve by supporting each other.
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Strengths and limitations
This RCT was powered to detect small effect sizes and, therefore, we can be confident that our (negative)
findings are statistically valid. We used accelerometers as the gold standard for measuring PA. However,
there may still have been a Hawthorne effect because the participants were aware of equipment and
were not blind to allocation as this was a talking therapy. If there was a Hawthorne effect of wearing
the accelerometer then it was negligible as the overall effect of the intervention was minimal on PA and
weight loss. We had greater attrition for complete PA follow-up data. Previous research has set a standard
for the amount of accelerometer wear time required per wear-day owing to variability between days of the
week.143 We found that those not providing sufficient data at follow-up were less active and more likely
to smoke, had no formal educational qualifications and had more depressive symptoms. However, in the
Health Survey for England, participants who provided sufficient accelerometer wear time did not differ
from those who did not wear their accelerometer for the requested time.144 As participants in our recruited
sample were older than the target population, the use of fewer days of accelerometer wear data may be
acceptable, as previous work has detailed that 3 consecutive wear-days accurately predicts PA levels in
older adults.145 Analysis of sedentary behaviour can require more wear-days, but this was not a main
outcome of our study.
We recruited from all 12 CCGs covering the South London region, which has > 3 million residents
representing a diverse socioeconomic and ethnically diverse community, including some inner-city London
boroughs with high rates of CVD mortality. This was a positive aspect of the study. On the other hand,
we did not include residents from the rest of the UK where there are high rates of CVD mortality, such as
the north of England, south Wales and central Scotland, and therefore this sample may not have been
representative of all people at high CVD risk.146 Another limitation is that the South London sample may
not be representative of the rest of the UK (i.e. owing to the health inequalities between the north and
south of the UK). In addition, those London CCGs with more deprivation were slower to respond to the
invitation and therefore when we were already halfway through recruitment and by the time we had
completed recruitment, less time had been spent recruiting from these CCGs. This may also have led to
under-recruitment of those most at risk, namely from deprived areas and non-white ethnic groups.
A pragmatic feature and strength of this study included using the GP QRISK2 tool, which is routinely
available on the electronic records software for calculating CVD risk. Although this was a strength because
it is an objective measure of risk, which could potentially be easily used by GPs, the limitation was that it
had a high false-positive rate, generating a very high denominator number of patients, all of whom were
invited for consent for screening for eligibility. The accuracy, completeness and age of data required for
the QRISK2 algorithm based on the data stored in medical records were variable. This resulted in inviting
and consenting many patients who turned out to have lower and therefore ineligible QRISK2 scores when
screened. We had to assess an additional 1332 patients who turned out to be ineligible to participate,
which was costly and time consuming. However, there were few other options. The NHS Health Check
programme was not appropriate as it achieved a lower-than-expected uptake across England.12
A limitation of the study was that there were delays in recruitment that had repercussions in that the
intervention delivery was delayed for some participants. The unexpected inefficiency in using the NHS
Health Check led to delaying recruitment. Switching recruitment strategy to using the QRISK2 tool
introduced another delay, which had repercussions for the delivery of the intervention. This is because the
switch from Health Checks to QRISK2 required a protocol change, ethics approval and application of a cost
extension from NIHR. The delays in recruitment and uncertainty of funding extension approval resulted in
most of the HLFs seeking jobs elsewhere as their contracts started coming to an end. At around the same
time, the co-applicant’s clinical health psychologist also resigned. We had to employ and complete the
induction of a second clinical health psychologist and train a new cohort of HLFs. This meant that when
recruitment returned once additional funding and ethics approval had been secured there was a waiting
list for delivery of the intervention. This may have contributed to some of the dropout from the
intervention.
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A strength was that our intervention was embedded and delivered in the heart of the community to
match the real-world setting and we were able to be flexible with timing of the sessions (including late
afternoons and early evenings). Our intervention focused on supporting maintenance once changes had
been made in the initial phases. However, a limitation was that we could not offer sessions immediately
and there was a waiting list for patients while HLFs were trained to competency. Approximately 50% of
participants randomised to the individual and group interventions dropped out of the intervention after the
introductory session. As most of our participants were retired, providing flexibility in the timing of sessions
around work schedules was less important. We observed that participants in both the group and individual
intervention arms generally adhered well to the intervention, based on the HLFs asking participants to set
targets at each session and record if these were achieved or not.
We developed a standardised health trainer manual that could be readily replicated and used for training
and supervision. A limitation was that the HLFs preferred practical training rather than didactic learning
and classroom-based role play. We would have preferred to have the HLFs undertake more practical
training with patients and this might have improved competencies, but this was impossible in terms of
resources and the inherent nature of delivering a complex intervention as a research study. The HLFs were
employed as NHS staff on short-term contracts; thus, we would have had to set up a CVD risk clinic very
quickly, screen patients and then offer the intervention. As this was a 12-month intervention, this was not
feasible.
We conducted a comprehensive process evaluation to understand the underlying mechanisms of action.
We ensured a long follow-up to capture both short-term and long-term, or maintenance, outcomes.
As a result of the process evaluation, we found that we did not reach those at the highest risk of CVD,
participants who did not complete the intervention expressed lack of feedback and engagement as a
reason, and participants attributed their high CVD risk to their age rather than their own lifestyle choices.
Although we did observe several participation biases (see Chapter 7), it is unclear if more specific targeting
of the intervention would have had a clinical effect, given that the absolute differences observed were
small and a large sample was recruited. In addition, participants noted a lack of engagement from their
GP concerning their high CVD risk, which may have negatively influenced any treatment effects. However,
given the large number of GPs recruited to the study, it would not have been feasible to incorporate a
larger amount of GP engagement in the study design.
Our PPI group was interactive and involved throughout. There are a number of areas in which the
methodology of the trial may be improved. For instance, the importance of the invitation process and
materials were highlighted by both PPI members and the intervention providers, and appropriate targeting
of those who may benefit most from participation in the trial may improve the reach of the study.
There were limitations in the cost-effectiveness analyses. We relied on self-report of service use information
and this may have led to recall inaccuracy. This was largely unavoidable given the range of services we wished
to include in the measure of cost. Other studies have found this approach to be reasonable and there is no
reason to suppose that any inaccuracy biased the findings.147,148 A further limitation was that the EQ-5D-3L
may not have been sensitive to change in this patient group. It is the recommended measure for such
analyses but further work on assessing its appropriateness is warranted. The lack of differences in QALYs
does support the main clinical findings of the study. Finally, we had hoped to include lost employment
costs in a societal perspective; however, data on this were not available.
Interpretation
There are several possible explanations for the results of this trial: (1) although the clinical population was
at high risk of CVD, the risk factors were not modifiable by lifestyle interventions, or (2) the psychological
theories were not the most appropriate and/or psychotherapeutic approaches are not sufficiently potent
alone.
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One explanation for the negative findings is that we may not have recruited those with high CVD risk who
had modifiable risk factors. The use of a QRISK2 score of ≥ 20.0% ensured that our study recruited those
at the highest risk of CVD in accordance with an objective risk algorithm that takes into account numerous
modifiable risk factors. However, the risk factors with the greatest weighting in the algorithm are the
non-modifiable risk factors: age, sex and ethnicity.20 It has previously been shown that risk calculators,
including the QRISK2, may not have the specificity to identify CVD risk at the individual, as opposed to
the population, level.149 Those patients of older age, male sex and South Asian ethnicity are at the highest
risk, but these individuals may be otherwise healthy in terms of their modifiable risk factors that are inputted
into the algorithm, and therefore the aims and contents of the intervention may not be applicable to them.
The use of a QRISK2 score of ≥ 20.0% may have meant that the recruitment strategy led to a sample
skewed against those with high BMIs, blood pressure and LDL cholesterol levels (exactly those participants
who were most likely to benefit as these risk factors are modifiable).
Indeed, we found that older people with a normal or underweight BMI were recruited, raising challenges
for the intervention team considering the primary aim of a reduction in weight. Previous research has
demonstrated that participants at the highest risk benefit most from preventative interventions. In Gidlow
et al.,69 an observational study based in primary care in Stoke-on-Trent, followed three groups of patients:
those with at least one modifiable CVD risk factor using the Framingham risk engine score, those with
diabetes mellitus or coronary heart disease (secondary prevention) and those who were obese and had a
CVD risk of > 15%. They received a patient-tailored, health-trainer-delivered, lifestyle intervention over
6–12 months with face-to-face and telephone/SMS (short message service) support. They observed modest
improvements in risk factors and health-related quality of life, but not in CVD risk score, except in the
subsample of patients who were at highest risk (> 20%) at baseline. In the study by Hardcastle et al.,49
the investigators focused on CVD risk factors, such as excess weight (BMI of ≥ 28 kg/m2, based on a value
used in the recruiting general practice), hypertension (systolic/diastolic blood pressure of ≥ 150/90 mmHg) or
hypercholesterolemia (≥ 5.2 mmol/l), rather than CVD risk score. They observed that the MI intervention was
particularly effective for patients with elevated numbers of CVD risk factors at baseline.
The participants in this trial had average step counts at baseline that were in line with that previously reported
for healthy older adults who were participating in exercise classes.150 Therefore, on average, the participants
recruited to MOVE IT may at baseline have been at their ceiling in terms of PA achieved, leaving little room
for improvement. Previous studies of PA interventions for older adults, using accelerometer measurement as
an outcome measure, tend to report significant increases up to a 12-month follow-up but there have been
few psychological interventions to help maintain the increased PA.151 Another explanation for the negative
findings is that patients in our sample were not obese. The association between increasing PA and decreasing
HbA1c level following behavioural intervention is stronger in those who are obese (BMI of ≥ 30 kg/m2),152 and
it may be that our sample was not at a high enough risk (the mean BMI was 28.3 kg/m2) to see significance
in outcomes.
The objective accelerometer measurement of PA provides a more reliable measure than self-report as it is
less prone to bias. However, the days for which the PA measure is collected may not represent normal PA
levels of participants; they may, for example, be elevated above the usual level owing to social desirability.153
A review of the impact of interventions combining BCTs that target diet and PA found no differences in
PA outcomes with UC when self-report PA outcome measures were used.154 These studies did find a
significant impact on BMI, suggesting that beneficial effects of the intervention had taken place and that
perhaps a change in PA levels could not be successfully captured by the self-report measure or at the
long-term follow-up. It may be that participants in our study made some initial increases in PA levels that
were not captured at the 12- and 24-month follow-ups through accelerometry or at baseline; in addition,
outcome PA measures of all participants may have been artificially raised. To further investigate the impact
of interventions on PA, studies would need to undertake continuous objective measurement throughout
participation, as opposed to the norm of 4–7 consecutive days’ wear.143 Low-cost and unobtrusive means to
monitor PA throughout participation in a RCT, such as wearable and smartphone technology, provide this
opportunity, although the reliability and validity of these methods are yet to be assessed.155,156
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A second possible explanation for the negative findings is that the intervention potency or overall dose was
suboptimal. The psychological skills were based on sound well-established psychological theories: (1) the
theory of planned behaviour for initiation of behaviour change, which states that in order to change
behaviour, people need to form an intention,53 (2) principles underpinning MI that emphasise that the
patient’s motivation to change can be used as a therapeutic tool,41 (3) CBT91 and (4) social cognitive
theory,92 which emphasises the importance of peer support in shaping behaviour, which was applied to
the group intervention arm of MOVE IT.
We used well-established and evidence-based psychotherapeutic techniques to apply the theoretical
framework for MOVE IT. MI was used to support participants in forming healthy intentions. MI is a
collaborative conversation style for strengthening a person’s own motivation, belief and commitment to
change. We used principles from CBT to support the transition from intention to action and from action to
maintenance93 by identifying and challenging unhelpful thoughts or thinking styles and promoting more
positive emotions and behaviours. Using an iterative process, we devised the intervention curriculum and a
participant workbook to support training, supervision, collaboration and replication. We had an intensive
phase and the maintenance phase consisted of four sessions delivered at 3, 6, 9 and 12 months from
intervention commencement. Those randomised to the group intervention arm were encouraged to use peer
learning and the peer-support environment to facilitate change during both the intensive and maintenance
phases. Novel methods and teaching aids were used to supplement the delivery of BCTs, such as visual aids
(food labels)/cue cards, exercise demonstrations, video/audio material of patient testimonials, activity-based
learning around meal planning and SMS/e-mail reminders. Cultural and religious awareness is built in to the
intervention.
We employed and trained health trainers with an intensive package of didactic learning, role playing and
feedback, group exercises, reading and case study discussion over 3 months. Competency in administering
the intervention was assessed through a knowledge quiz and delivering several sessions to volunteers.94–96
For HLFs that were not competent, they underwent further training until competent. HLF competency was
monitored throughout the intervention by the CP regular supervision and quality assurance by reviewing
audiotaped sessions.
This process is a standard approach to developing and evaluating a set of psychotherapeutic skills. It may
be that for this clinical setting this approach is, or components of this approach are, insufficient. The
theoretical frameworks were originally developed for mental health conditions that can remit, such as
alcohol dependence, anxiety and depressive disorders. It would seem that a clinical state such as risk of
CVD as a construct that could remit if one could develop and change one’s thinking patterns about
lifestyles has face validity for applying similar psychotherapeutic techniques. However, perhaps a
psychological model is not appropriate and intensive instruction is more apt.
Landmark studies have repeatedly shown that intensive lifestyle instruction that focuses primarily on
behaviour change, such as the diabetes prevention studies,157–159 weight reduction programmes160 and,
recently, studies on reversal of type 2 diabetes mellitus,161 does lead to significantly improved outcomes.
Even the simple behavioural act of prescribing a pedometer leads to improved PA.34 In these interventions,
the clinically active ingredients were access to intensive, highly-structured and prescribed dietary and/or PA
instruction following a counselling approach with minimal psychotherapeutic techniques. Our approach
was to use talking therapies to instigate behaviour change rather than instruction, with the philosophy that
intentions need to change before behaviours do and that changing people’s way of thinking (as opposed
to instructing them) would also be cheaper in the long term and more likely to be maintained. It could be
that with lifestyles interventions the active ingredients are intensive instruction and advice. This suggests
that the theoretical models of theory of planned behaviour and the theory that everyone has a degree of
motivation and intent may not be appropriate for lifestyle change.
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A related, but perhaps separate, explanation is that the techniques we used to apply these theories were
too weak. Secondary to factors totally outside our control, we could not assess competencies fully, but the
extremely limited evidence we had was that the competencies, although acceptable, were not highly
proficient. Assuming that this was indeed the case, then despite the intensive MI training of the HLFs this
in itself was insufficient and one needs to establish very high levels of competencies in these skills. The
health trainers did refer to this in the process evaluation; they thought that there was too much didactic
and classroom-based teaching when they would have preferred more clinical cases and more supervision
during the intervention. There have been very few studies that measure the competencies of low-intensity
psychotherapy in lifestyle-based interventions. In the field of supporting self-management in type 2
diabetes mellitus, there have been only three studies that have formally tested competencies in MI.105,162,163
The original landmark studies of MI were delivered by those who had developed the models, were leaders
in the field and specialised wholly in MI.41 As champions of MI and developers of the competency
materials, it is likely that the earlier studies of MI would have shown high competencies and that this led to
improved outcomes. It is unfortunate that although these data were collected we are not able to measure
the competencies that would allow us to examine the level of skill. It may be reasonable to assume that
the competencies delivered were probably adequate even if not excellent, in keeping with what would be
expected for a large-scale delivery of MI by NHS band 3 equivalent health trainers. The reasons are that the
health trainers were self-selected, most already had experience in this field and were given excellent
references, they received high-intensity training and supervision, and their own feedback suggested that
they were very motivated to improve their skills and seek more practical support and had insight into their
clinical needs.
Although we observed that the HLFs generally had lower than expected competency in delivering the BCTs,
it is important to note that the employed BCT coding framework was developed by us and was not validated,
potentially leading us to underestimate HLFs’ competencies in this domain. If we had the full data set of
recorded intervention sessions, we believe that we would have observed much higher levels of competency.
Anecdotes from the HLFs suggested that they were highly motivated, professional, committed, ambitious and
knew that they were being observed; these are all the key generic therapist elements often needed to be
competent in delivering talking therapies.
Finally, it is worth considering that participants in the UC arm may have received a high level of standard
care over the course of the study, which could have positively affected their PA and weight, thus obscuring
any treatment effects from MOVE IT. However, given that the UC arm did not have a significant increase
in PA or reduction in weight, this alternative is unlikely.
Clinical implications
There are a number of clinical implications to consider. These findings suggest that low-intensity
psychological intervention in the form of MI to the general population at high risk of CVD risk is not
effective. The acquisition of a workforce of health trainers who have received extensive training in MI to
a level of low-to-moderate skills in MI is probably also not indicated. If this kind of training was to be
offered, perhaps the focus should use the manual we have developed as a basis but to focus on practical
learning through case work (i.e. practical experience and case studies). There is also some consideration to
be given as to whether these findings apply to other clinical settings that require lifestyle change, such as
obesity, prediabetes, diabetes mellitus and people with CVD. Some older, male patients have a perception
that they are not at risk of CVD or that this risk is to be expected at this stage in their lives. This view may
need to be studied further to understand if it is associated with worse health outcomes.
The implication of the cost-effectiveness analyses is that introducing a generic enhanced MI-based health
trainer programme for people at high risk of CVD is not a cost-effective use of resources.
DISCUSSION
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Research implications and future directions
There are number of potential directions for the future. The first is to test whether or not this intervention
would be more successful with people at much higher risk of CVD who have modifiable risk factors. This
would involve selecting patients from primary care or community settings, and perhaps younger patients,
with higher levels of obesity, lipids and other CVD risk factors that are potentially modifiable (unlike risk
factors such as age, ethnicity and sex, which are not modifiable). One potential next step could be to model
the intervention in different populations, as we are not aware of intensive MI interventions to support
lifestyle change in which there was improved targeting.
An alternative approach would have been to increase the actual CVD risk for eligibility and to restrict the
study to a younger population, those living in deprived areas and those of non-white ethnicity. Another
improvement could be to change the format of the intervention or its delivery (i.e. being led by a practice
nurse).164 Setting BMI thresholds for recruitment would be another improvement to our methodology,
which may mean that we recruit patients at higher risk and who may have benefited more from the
intervention. However, our sensitivity analyses adjusting for different BMI thresholds did not indicate that
this factor influenced the effect of intervention.
Second, there may need to be a paradigm shift in the psychological constructs underpinning lifestyle
change in chronic disease self-management. Brief interventions for medical conditions that are chronic are
increasingly showing to be not effective and outdated. New concepts are needed that take into account
the burden, or the long haul, of living with a chronic condition. Our intervention was for 12 months but
perhaps interventions that consist of bursts of support over years need to be evaluated; the dilemma is
that these are expensive to fund and the results take a long time to be reported, and there may be a cohort
effect as medical science might move forward in that time. MOVE IT emphasised the importance of the use
of qualitative methodology in providing detailed experiences of participants for assessing the effectiveness
of a RCT. As previously reported, studies have supported the benefits of lifestyle interventions in the short
term but few have supported their benefits in the long term.49,131,132 In MOVE IT, continuity of care and
duration of the intervention was of value to those who attended. Although attendance to group sessions
was less than attendance to individual sessions, those who attended group sessions appear to value the
peer support. Future research should include more qualitative work on why those at the highest risk of CVD
or those with modifiable risk factors do not attend lifestyle interventions. It was impossible to do this in
MOVE IT as we could not gain ethics approval to contact patients who had not replied to our invitation sent
via their GPs.
Summary
An intensive lifestyle intervention using enhanced MI skills was not associated with reduced weight or
increased PA in a sample of people at risk of CVD. The reasons for this are probably attributable to the
sample having predominantly non-modifiable risk factors. Future interventions should focus on those at
high CVD risk and with modifiable risk factors and should be delivered at high levels of measured
competency.
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Appendix 1 Proficiency levels adapted for healthy
lifestyle facilitator training
Technique/skill
Proficiency levela
NotesNone Partial Moderate Full
BCTs (× 11) (% of participants) 0 50 70 100
MI (with MITI)
Global (n) < 3 3 3.5 4
Reflection-to-question ratio (n) 0 0.5 1 2
Percentage with open questions (% of participants) 10 30 50 70
Percentage with complex reflections (% of participants) 10 30 40 50
Percentage who were MI adherent (% of participants) 50 70 90 100
Group skills (adapted from AMIGOS)165 (n)
Activities 0 1 2 3 0 = none,
1 = a little,
2 = somewhat,
3 = extensively
Dynamics 0 1 2 3
Rapport 0 1 2 3
Boundaries 0 1 2 3
Time management (n) 0 1 2 3 0 = none,
1 = a little,
2 = somewhat,
3 = extensively
AMIGOS, Assessment of Motivational Interviewing Groups Observer Scale.
a Trial proficiency: BCTs = 70%; MITI = 90% MI adherent and two categories in moderate score range; group skills = three
categories in moderate score range; time management = moderate score range.
Note
Green shading denotes minimum target proficiency level.
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Appendix 2 List of participating general practices
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TABLE 39 List of participating general practices
CCG and general
practice name
General
practice
code
Date when the
first participant
was recruited
List size on
1 April 2013
Number of
patients aged
40–74 years
General
practice IMD
2010 score76
Anonymised
search saveda
Number of
potentially
eligible patients
invited
Number of patients
Who
respondedb
Who
consented Randomised
Bexley
Good Health G83630 4 December 2013 5807 1836 30.20 No 63 12 11 4
Ingleton Avenue
Surgery
G83024 20 September 2013 5038 2110 11.00 No 87 23 21 18
Lakeside Medical
Practice
G83018 8 July 2013 15,320 5253 33.50 Yes 335 38 34 15
Lyndhurst Road
Medical Centre
G83049 3 April 2014 7943 3600 14.30 No 70 – 13 5
Plas Meddyg Surgery G83029 7 October 2013 7220 3188 7.77 No 111 36 34 28
Slade Green Medical
Centre
G83062 2 August 2013 6521 2315 29.70 No 107 14 4 2
The Westwood Surgery G83002 5 August 2013 7770 3191 10.90 No 157 40 22 10
Welling Medical
Practice
G83025 5 August 2013 13,368 5984 15.00 No 85 35 17 7
Woodlands Surgery G83057 14 August 2013 10,424 4749 11.30 No 158 47 21 14
Bromley
Ballater Surgery G84040 21 August 2014 6685 2890 11.50 Yes 138 – 31 21
Bromley Common
Practice
G84024 2 December 2013 7814 3031 14.50 No 29 5 4 2
Broomwood Road
Surgery
G84019 27 August 2013 9978 3923 32.90 No 107 – 42 17
Charterhouse Surgery G84021 9 July 2013 9127 4374 8.37 Yes 150 – 49 30
Chelsfield Surgery G84020 18 July 2013 7552 3591 8.91 No 211 51 61 27
Cornerways Surgery G84018 24 June 2014 8531 3810 9.61 No 179 46 42 30
Derry Downs Surgery G84005 21 January 2014 5630 2440 26.50 No 110 35 27 15
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CCG and general
practice name
General
practice
code
Date when the
first participant
was recruited
List size on
1 April 2013
Number of
patients aged
40–74 years
General
practice IMD
2010 score76
Anonymised
search saveda
Number of
potentially
eligible patients
invited
Number of patients
Who
respondedb
Who
consented Randomised
Eden Park Surgery G84011 9 October 2013 8180 3609 11.80 No 171 31 45 24
Forge Close Surgery G84030 2 April 2014 6563 3002 6.87 Yes 113 27 32 19
Links Medical Practice G84003 27 August 2013 10,638 3974 30.60 Yes 221 23 33 14
London Lane Clinic G84016 7 August 2013 15,558 6699 15.00 No 304 20 72 47
Park Group Practice G84025 1 August 2013 8147 2983 30.10 No 126 16 15 8
Pickhurst Surgery G84033 12 December 2013 6786 3106 6.82 Yes 180 44 56 28
Poverest Medical
Centre
G84007 25 September 2013 9141 3791 23.40 Yes 199 34 53 32
Robin Hood Surgery G84029 27 February 2014 5725 2541 27.20 Yes 93 14 14 6
South View Partnership G84001 20 March 2014 6114 2647 11.70 No 195 51 69 45
Station Road Surgery G84015 23 July 2013 12,572 5873 7.80 Yes 100 – 79 47
Stock Hill Surgery G84004 31 July 2013 11,241 5386 10.40 Yes 323 – 92 55
Sundridge Medical
Centre
G84629 16 December 2013 5066 1844 16.80 Yes 112 18 15 10
Trinity Medical Centre G84022 28 July 2014 6006 2346 27.80 No 120 – 13 6
Tudor Way Surgery G84035 20 August 2014 7108 3076 7.76 No 63 – 10 8
Woodlands Practice Y00542 31 July 2014 9161 3812 19.80 Yes 202 – 31 19
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TABLE 39 List of participating general practices (continued )
CCG and general
practice name
General
practice
code
Date when the
first participant
was recruited
List size on
1 April 2013
Number of
patients aged
40–74 years
General
practice IMD
2010 score76
Anonymised
search saveda
Number of
potentially
eligible patients
invited
Number of patients
Who
respondedb
Who
consented Randomised
Croydon
Brigstock Family
Practice
H83608 21 June 2013 4211 1474 25.00 Yes 172 – 30 13
East Croydon Medical
Centre
H83044 18 November 2013 12,308 4189 17.90 Yes 287 – 63 30
Greenside Medical
Practice
H83631 16 August 2013 7833 2347 33.60 No 36 – 2 1
Keston Medical
Practice
H83016 30 January 2014 9406 3968 15.80 Yes 216 – 58 34
Leander Road Surgery H83042 25 June 2014 7035 2620 21.20 Yes 127 – 25 14
London Road Medical
Practice (Cavendish
House)
H83021 30 September 2014 5866 2240 28.10 Yes 114 – 12 6
Morland Road Surgery H83023 10 July 2013 6942 2638 23.00 Yes 193 – 24 15
Old Coulsdon Medical
Practice
H83013 27 January 2014 12,527 5526 13.20 Yes 237 – 58 32
Parchmore Medical
Centre
H83053 16 June 2014 13,878 5173 27.70 Yes 186 – 29 17
Parkside Group
Practice
H83015 2 April 2014 12,505 5020 15.40 Yes 206 – 43 31
Portland Medical
Centre
H83001 3 July 2013 12,829 4987 28.40 No 164 – 15 7
Selsdon Park Medical
Practice
H83018 22 July 2013 10,679 4759 13.10 Yes 258 – 42 23
Stovell House Surgery H83039 25 September 2013 7116 2973 18.50 Yes 250 – 61 31
Upper Norwood Group
Practice
H83005 12 September 2013 11,077 3981 27.40 No 35 – 10 5
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CCG and general
practice name
General
practice
code
Date when the
first participant
was recruited
List size on
1 April 2013
Number of
patients aged
40–74 years
General
practice IMD
2010 score76
Anonymised
search saveda
Number of
potentially
eligible patients
invited
Number of patients
Who
respondedb
Who
consented Randomised
Greenwich
All Saints Medical
Centre
G83030 27 May 2014 5006 1945 36.70 No 93 22 18 11
Burney Street G83065 6 January 2015 13,146 3594 28.50 No 55 8 10 5
Coldharbour Hill G83003 14 November 2014 4098 1706 25.10 No 141 31 23 13
New Eltham G83628 27 June 2014 5788 2188 13.40 No 125 20 15 9
Glyndon G83060 13 November 2014 7014 2466 40.80 No 66 8 4 2
Manor Brook G83001 18 June 2014 12,590 4831 27.20 Yes 276 54 47 27
Mostafa G83647 17 June 2014 5701 2050 32.50 No 96 20 12 6
Plumstead Health
Centre
G83019 18 December 2014 5445 2400 30.50 No 89 10 7 4
Royal Arsenal Medical
Centre
G83016 3 June 2014 5823 2207 36.20 No 60 9 6 2
Sherard Road Medical
Centre
G83027 19 December 2014 9790 3828 31.30 No 171 6 5 3
St Mark’s G83039 26 June 2014 7325 2662 39.00 No 55 11 8 6
Tewson Road Practice G83007 25 June 2014 4972 2073 30.60 No 102 11 10 3
Vanbrugh Group
Practice
G83021 6 March 2014 9520 3349 26.20 No 174 24 16 10
Waverley G83635 6 November 2014 5253 2103 27.60 No 77 11 7 4
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TABLE 39 List of participating general practices (continued )
CCG and general
practice name
General
practice
code
Date when the
first participant
was recruited
List size on
1 April 2013
Number of
patients aged
40–74 years
General
practice IMD
2010 score76
Anonymised
search saveda
Number of
potentially
eligible patients
invited
Number of patients
Who
respondedb
Who
consented Randomised
Kingston
Brunswick Surgery H84015 22 April 2014 6397 2594 10.40 No 73 14 13 5
Central Surgery H84030 5 August 2013 12,203 5130 10.10 No 163 51 47 26
Claremont Medical
Centre
H84619 20 June 2013 9823 3245 10.70 No 52 12 12 6
Hook Surgery H84025 16 April 2014 5957 2259 12.30 Yes 137 24 21 15
The Groves Medical
Centre
H84016 11 November 2013 11,513 4884 8.99 No 45 12 9 2
Kingston Health Centre H84061 17 December 2014 6569 2457 10.00 No 62 – 5 5
Lambeth
Brockwell Park Surgery G85137 27 November 2013 5841 1895 26.60 Yes 91 – 27 11
Crown Dale Medical
Centre
G85022 29 July 2014 10,813 4245 29.50 Yes 160 23 30 22
Hetherington Group
Practice
G85045 19 November 2013 10,094 3344 29.80 No 136 – 23 11
The Hurley Clinic G85053 27 November 2013 14,255 5235 31.90 Yes 206 – 41 19
Lambeth Walk Group
Practice
G85054 10 February 2014 7543 2988 34.10 Yes 177 – 26 12
Minet Green Health
Practice (Iveagh House)
G85135 14 January 2014 7711 2666 41.10 No 136 18 11 1
Stockwell Group
Practice
G85028 13 November 2013 13,802 5201 35.90 Yes 155 24 20 7
Streatham Common
Group Practice
G85014 11 November 2013 7496 2796 27.20 Yes 230 – 38 14
Streatham Place
Surgery
G85118 10 December 2013 4656 1710 33.60 No 54 – 4 1
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CCG and general
practice name
General
practice
code
Date when the
first participant
was recruited
List size on
1 April 2013
Number of
patients aged
40–74 years
General
practice IMD
2010 score76
Anonymised
search saveda
Number of
potentially
eligible patients
invited
Number of patients
Who
respondedb
Who
consented Randomised
Lewisham
Bellingham Green
Surgery
G85124 9 June 2014 7113 2431 38.90 No 97 – 12 6
Brockley Road Surgery G85048 30 October 2013 4561 1634 23.20 No 90 – 12 6
Grove Medical Centre G85085 26 September 2013 8101 2321 35.10 Yes 90 11 9 5
Hilly Fields Medical
Centre
G85055 17 October 2013 12,856 4696 24.90 Yes 225 – 60 32
Honour Oak Group
Practice
G85089 1 November 2013 9290 3093 30.00 No 143 10 7 2
Jenner Practice G85004 5 June 2014 15,045 5901 28.70 No 135 – 23 7
Morden Hill Surgery G85035 8 May 2014 8654 3079 32.10 Yes 112 20 19 11
Nightingale Surgery G85727 18 August 2014 5099 1628 26.60 Yes 90 – 16 11
Queens Road
Partnership
G85015 23 June 2014 11,163 4264 34.00 Yes 156 – 22 14
Rushey Green GP G85633 29 October 2013 11,332 3699 33.90 Yes 208 32 31 16
South Lewisham Group
Practice
G85005 9 October 2013 14,094 5592 33.30 Yes 250 – 44 23
St John’s Medical
Centre
G85038 29 September 2014 12,553 4621 29.30 Yes 178 – 27 16
Torridon Road Medical
Practice
G85032 11 September 2013 10,021 3982 24.30 Yes 113 – 30 11
Triangle Group Practice G85120 25 February 2014 7159 2665 31.80 Yes 86 – 12 8
Woodlands Health
Centre
G85722 11 July 2014 7091 2099 29.40 No 45 – 6 2
Woolstone Medical
Centre
G85061 11 June 2014 7133 2992 29.60 Yes 112 20 20 12
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TABLE 39 List of participating general practices (continued )
CCG and general
practice name
General
practice
code
Date when the
first participant
was recruited
List size on
1 April 2013
Number of
patients aged
40–74 years
General
practice IMD
2010 score76
Anonymised
search saveda
Number of
potentially
eligible patients
invited
Number of patients
Who
respondedb
Who
consented Randomised
Merton
Alexandra Surgery H85656 3 July 2014 5566 1928 12.10 No 106 8 13 5
Central Medical Centre H85070 6 September 2013 8271 2935 20.90 No 174 – 5 2
Grand Drive Surgery H85101 1 October 2013 9065 3204 8.39 No 170 – 33 16
Lambton Road Medical
Practice
H85051 17 September 2013 6113 2058 9.11 No 117 – 18 8
Merton Medical
Practice
H85634 5 August 2013 6740 1687 16.60 Yes 30 – 9 6
Mitcham Family
Practice (Graham Road)
H85078 27 May 2014 3074 1202 21.50 No 79 10 5 2
Morden Hall Medical
Centre
H85037 10 June 2013 13,788 5123 17.10 No 138 – 34 19
Riverhouse Medical
Practice
H85092 15 May 2014 5621 1820 15.00 No 55 11 10 10
Rowans Surgery H85035 14 June 2013 9147 3468 21.70 No 43 – 10 4
Wide Way Medical
Centre
H85029 5 November 2013 7208 2541 21.60 Yes 64 – 12 7
Richmond
Brockbank (Park Road) H84002 5 July 2013 12,339 5553 8.02 No 94 26 20 11
Flood (Essex House) H84023 5 November 2013 8919 3682 11.10 No 118 28 24 12
Jackson (Acorn) H84007 3 July 2014 7950 3488 8.94 No 83 – 21 12
O’Flynn
(Hampton Wick)
H84032 25 July 2013 8835 3885 10.30 No 103 21 17 11
Pennycook
(Hampton Hill)
H84623 22 August 2013 8819 3570 10.10 No 117 20 16 8
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CCG and general
practice name
General
practice
code
Date when the
first participant
was recruited
List size on
1 April 2013
Number of
patients aged
40–74 years
General
practice IMD
2010 score76
Anonymised
search saveda
Number of
potentially
eligible patients
invited
Number of patients
Who
respondedb
Who
consented Randomised
Southwark
Albion Street Group
Practice
G85138 13 February 2014 11,970 3536 24.30 Yes 81 5 5 5
Bermondsey and
Lansdowne Medical
Mission
G85094 8 May 2014 15,673 4527 28.80 No 112 – 17 9
Concordia Parkside G85030 7 July 2014 6634 2338 34.30 No 53 3 1 1
Lister Primary Care
Centre
G85134 11 December 2013 5824 1975 35.90 No 51 4 3 0
East Street G85721 17 March 2014 7080 2497 37.70 Yes 53 4 4 3
Acorn and Gaumont G85006 10 October 2013 11,879 3964 38.80 Yes 196 25 10 5
Camberwell Green G85013 28 March 2014 10,881 4042 33.10 Yes 61 – 11 6
Elm Lodge Surgery G85051 1 May 2014 7373 3155 16.40 Yes 96 – 30 24
Hambleden Clinic G85112 24 February 2014 3318 1093 25.00 No 34 4 3 0
Lordship Lane Surgery G85681 28 November 2013 3924 1383 26.90 Yes 69 10 8 5
Melbourne Grove G85132 27 June 2014 7158 2498 24.20 No 45 3 2 2
Nexus Health Group
(Manor Place)
G85034 18 July 2014 12,021 4003 34.70 Yes 102 6 6 4
Nunhead Surgery G85685 23 April 2014 7640 2777 33.30 Yes 130 – 24 13
Old Kent Road Surgery G85052 9 January 2014 5920 1869 36.90 No 57 6 5 1
Queens Road Surgery G85040 12 February 2014 3672 1519 38.90 No 56 3 2 1
Sir John Kirk Close
Surgery
G85050 11 July 2014 3894 1343 32.60 Yes 60 2 2 2
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TABLE 39 List of participating general practices (continued )
CCG and general
practice name
General
practice
code
Date when the
first participant
was recruited
List size on
1 April 2013
Number of
patients aged
40–74 years
General
practice IMD
2010 score76
Anonymised
search saveda
Number of
potentially
eligible patients
invited
Number of patients
Who
respondedb
Who
consented Randomised
Sutton
The Beeches Surgery H85662 24 June 2014 5593 2671 9.89 No 46 – 19 15
The GP Centre H85019 25 July 2013 5066 2270 8.76 No 273 – 34 16
Cheam GP Centre H85054 9 June 2014 5065 2196 9.02 No 116 30 28 20
Dr Scott and partners H85063 26 July 2013 5088 2236 8.61 No 73 – 17 8
The Health Centre
(Robin Hood Lane)
H85095 21 June 2013 10,017 3528 15.90 Yes 180 – 26 12
Manor Practice H85116 7 June 2013 8583 3159 20.60 No 114 – 16 8
Shotfield Medical
Practice
H85115 16 July 2014 10,370 4466 15.20 Yes 209 52 50 28
Wallington Family
Practice
H85653 11 September 2014 11,081 4772 16.00 Yes 264 – 75 44
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CCG and general
practice name
General
practice
code
Date when the
first participant
was recruited
List size on
1 April 2013
Number of
patients aged
40–74 years
General
practice IMD
2010 score76
Anonymised
search saveda
Number of
potentially
eligible patients
invited
Number of patients
Who
respondedb
Who
consented Randomised
Wandsworth
Brocklebank Group
Practice
H85048 9 January 2014 16,781 5046 19.90 Yes 248 35 29 17
Chartfield Surgery Y01132 17 December 2013 11,662 3946 18.90 Yes 212 33 31 12
Elborough Street
Surgery
H85057 5 March 2014 6008 1973 11.30 Yes 120 31 31 10
Mayfield Surgery H85006 28 November 2013 5521 1874 29.90 No 139 20 16 4
Open Door Surgery H85087 17 April 2014 9312 3823 24.70 No 179 10 8 6
Wandsworth Medical
Centre
H85001 22 October 2013 14,145 2860 19.30 Yes 168 30 24 12
Total 1,154,963 439,100 17,775 3515 3183 1742
a Anonymised data of all patients invited to participate saved on medical records by practice. Data subsequently extracted for participation bias analyses.
b The number of patients who responded was not accurately recorded for all practices, and is missing in some cases. Total numbers of responses were reported accurately. Therefore, total
numbers of responses equal the sum of available response data and missing response data.
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Appendix 3 Behaviour change technique coding
framework for the fidelity analysis
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BCT code BCT label BCT description
Score (0= not
delivered,
1= delivered)
Line/page
numbers
(transcript) Sample quotations
Total number
and frequency
1 Provide information on
the consequences
(elicit-provide-elicit)
Give, or make salient, information about
the risk factors of CVD and how a
healthier diet and/or more PA could
lower risk
There are a number of risk factors
associated with CVD, some are non-
modifiable which include . . . and some
are modifiable which include . . .
By following national guidelines of
healthy eating and physical activity,
you can reduce your risk of CVD and
therefore your overall health
2 Prompt intention formation Support patient to form a specific
statement about what they intend to do
this week (i.e. ‘I will . . . for X times per
day/week’)
So you have identified that you would
like to . . . What would you like to focus
on in the week ahead?
What do you intend to do this week?
3 Prompt barrier
identification
Support patient to think in advance of
the barriers to achieving their goal and
how they can be managed
What barriers might occur to you
achieving this goal?
4 Prompt specific goal-setting Support patient to list specific
behavioural actions that will support
their goal. Ensures goal and action steps
are realistic and meaningful. Offer ‘other’
option if prompts are not relevant
How will you go about achieving
this goal?
How many times a week will you
do that?
How realistic do you think this goal is?
5 Prompt review of
behavioural goals
Use neutral, open questions to review
past progress with goals set in previous
sessions
I am interested to hear how you got on
with your goals set in our last session
Please tell me how you got on . . .
6 Prompt self-monitoring of
behaviour
Support patient to use diary sheet and
e-monitoring to record progress
I would encourage you to use this diary
to monitor how you get on with your
goal by ticking each day that you
achieve it
I would encourage you to use the
pedometer to keep track of your number
of steps
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BCT code BCT label BCT description
Score (0= not
delivered,
1= delivered)
Line/page
numbers
(transcript) Sample quotations
Total number
and frequency
7 Teach to use prompts or
cues
Support patient to use reminder prompts What might help to remind you?
8 Agree on behavioural
contract
Support patient to complete action plan
and talk through with HLF or another
group member
Let’s complete this action plan together
Would you like to complete this
action plan?
9 Plan social support or social
change
Support patient to consider who can
support them at home. If no one,
suggest buddying
Who might be able to support you with
this goal, e.g. someone at home or a
friend or another group member?
10 Prompt self-talk Explain/elicit CBT lapse–relapse model.
Support patient to find their own
cheerleading statements when they have
a setback
One way of helping to prevent a relapse
is to think of some cheerleading
statements you can say to yourself when
you have a setback, what might these be
for you?
11 Relapse prevention Elicit common barriers to diet/exercise
changes and ways to manage/minimise.
Support patient to identify lapse triggers
and ‘if . . . then’ statements
What situations would you be most likely
to relapse?
If that occurs, let’s think about what you
could do now to avoid a relapse
Comments Please list any necessary comments or points of clarification
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Appendix 4 Participant focus group topic guides
Focus group 1: participants who received six or more intervention sessions
Invitation/information received
Our first set of questions are about the invitation you received from your GP informing you of the study
and inviting you to take part. This letter would have informed you of your high risk of heart disease, who
was running the study and the motivational interviewing that would be used. In order to participate you
would have had to send back a reply slip expressing your interest.
Q1) What made you volunteer to take part?
How did the following influence your decision to take part?
l Finding out that you were at high risk of heart disease (according to the NHS screening)
l Potential health benefits of a healthy lifestyle intervention
l Potential for helping others prevent heart disease in the future
l The researcher appointment, which included clinical tests and questionnaires about your lifestyle.
Sessions
You would have received sessions with a healthy lifestyle facilitator. You may have had different experiences of
this – different HLFs, different number of sessions, different types of session (one-to-one or in a group). We
want to hear about all of your thoughts and experiences. The weekly sessions consisted of an introduction to
the concept of heart disease and its risk factors, followed by two sessions on exercise, two on diet and two on
maintaining healthy habits. After which there were follow-up meetings once every 3 months.
Q2) Did you change any aspects of your lifestyle as a result of the treatment?
l If there were changes, could you give some examples?
l If there were no changes, why do you think that was?
Q3) How did the treatment impact on your lifestyle?
l Could you tell us more about how effective you thought the following aspects of the intervention were
in helping you change your lifestyle?
¢ Content of sessions (information given, tools, workbook)
¢ Format/structure (length, number, spacing of sessions)
¢ Behaviour change techniques (action plans, reminders, talking about setbacks)
¢ Conversation style (including relationship with HLF)
¢ Social support (other group members, family and friends).
Q4) The study aimed to invite a diverse range of people from different cultural, social and
ethnic minority backgrounds. Based on the treatment you received, what aspects of the
treatment made it suitable or unsuitable for a wide range of populations to participate?
Were any of the following aspects of the treatment a help or a hindrance?
l The materials used.
l What was it about the HLF that helped/did not help?
¢ Did you feel you had something in common with the HLF?
¢ Or the opposite, having nothing in common (e.g. did not come from your world/culture/age group).
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l The other members of your group (if applicable).
¢ Did you feel you had something in common with the other group members?
¢ Or the opposite, having nothing in common (e.g. did not come from your world/culture/age group).
Q5) Is there anything I have not mentioned that you would like to add?
l Is there anything you would change about MOVE IT?
Focus group 2: participants who received fewer than two
intervention sessions
Invitation/information received
Our first set of questions are about the invitation you received from your GP informing you of the study
and inviting you to take part. This letter would have informed you of your high risk of heart disease, who
was running the study and the motivational interviewing that would be used. In order to participate you
would have had to send back a reply slip expressing your interest.
Q1) What made you volunteer to take part?
How did the following influence your decision to take part?
l Finding out that you were at high risk of heart disease (according to the NHS screening)
l Potential health benefits of a healthy lifestyle intervention
l Potential for helping others prevent heart disease in the future
l The researcher appointment, which included clinical tests and questionnaires about your lifestyle.
Sessions
You were allocated to receive either one-to-one or individual sessions with a healthy lifestyle facilitator.
However, you either did not attend any sessions or attended only the first session. We think that it is
important for us to find out why this may be.
Q2) What were the key reasons that made you drop out?
Examples of reasons we thought some people might drop out are:
l Lack of time to take part. If time was an issue for you, can you tell us more specifically about what
resulted in time being a problem?
l The MOVE IT workbook/documents you may have received from the HLF in session 0; if this was a
reason for dropping out, can you tell us what things you didn’t like?
l Participants not necessarily feeling that the treatment relates to them or would not be useful. If this
influenced your reason for dropping out, can you tell us what aspects of the treatment you felt did not
relate to you?
l The allocation (group or individual) you were assigned to. Would you have been more likely to take part
if allocated to the other condition?
l The duration of each session, the number of sessions and the intervention duration as a whole
(12-month period)? If this relates to you, can you tell us more about how this affected your participation?
l Ill health or illness within your family. If this relates to you, can you tell us more about how this affected
your participation?
l Not wanting to share personal information, with either the HLF or other group members. If this relates
to you, can you tell us more about how this affected your participation?
l Can you tell us more about what influenced your decision to drop out?
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Q3) The study aimed to invite a diverse range of people from different cultural, social
and ethnic minority backgrounds. Based on the treatment you received, what aspects
of the treatment made it suitable or unsuitable for a wide range of populations to
participate?
Were any of the following aspects of the treatment a help or a hindrance?
l The materials used.
l What was it about the HLF that helped/did not help?
¢ Did you feel you had something in common with the HLF?
l Or the opposite, having nothing in common (e.g. did not come from your world/culture/age group).
l The other members of your group (if applicable).
l Did you feel you had something in common with the other group members?
l Or the opposite, having nothing in common (e.g. did not come from your world/culture/age group).
Q4) What would have helped you to continue with the treatment?
Q5) Is there anything I have not mentioned that you would like to add?
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Appendix 5 Characteristics of focus group
attendees
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TABLE 40 Characteristics of focus group attendees
Group and
participant Borough Trial arm
Number of
sessions
attendeda Age (years) Sex Ethnicity
Deprivation
quintileb Educational attainment
Relationship
status
Occupational
status
QRISK2
score
1A
P1 Bexley Group 10 74 Male White 3 No formal qualifications Married Retired 19.9
P2 Bromley Individual 9 75 Female White 2 A level or above Divorced Retired 22.7
P3 Lewisham Individual 10 70 Male White 2 A level or above Married Retired 20.0
P4 Croydon Individual 10 72 Female White 5 A level or above Married Retired 21.3
P5 Croydon Group 6 69 Male Asian 2 A level or above Married Employed 22.3
P6 Sutton Individual 10 69 Male Asian 4 A level or above Married Employed 20.4
P7 Merton Individual 10 73 Male White 5 A level or above Married Retired 20.4
1B
P8 Bromley Individual 7 76 Male White 4 No formal qualifications Married Retired 20.5
P9 Croydon Individual 8 71 Male Mixed 4 O level/GCSE Married Retired 19.4
P10 Kingston Group 7 68 Female Asian 5 A level or above Married Retired 22.1
1C
P11 Bromley Group 7 73 Female Asian 4 O level/GCSE Married Retired 22.9
P12 Merton Group 8 76 Male White 4 No formal qualifications Widowed Retired 21.4
P13 Lambeth Group 8 73 Male White 3 A level or above Married Retired 18.7
P14 Lambeth Individual 10 76 Male Asian 3 A level or above Married Retired 39.9
A
PPEN
D
IX
5
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
140
Group and
participant Borough Trial arm
Number of
sessions
attendeda Age (years) Sex Ethnicity
Deprivation
quintileb Educational attainment
Relationship
status
Occupational
status
QRISK2
score
1D
P15 Bexley Individual 10 74 Female White 2 A level or above Married Retired 28.9
P16 Bexley Group 10 69 Male White 4 O level/GCSE Married Retired 20.3
P17 Bromley Individual 10 75 Female White 5 O level/GCSE Divorced Retired 21.3
P18 Southwark Individual 10 67 Male White 1 No formal qualifications Married Retired 22.0
P19 Croydon Individual 6 73 Female White 2 O level/GCSE Single Retired 26.4
P20 Croydon Individual 10 71 Male White 5 A level or above Married Employed 25.1
2A
P21 Richmond Group 1 71 Male White 5 A level or above Married Retired 21.6
P22 Sutton Individual 2 71 Male Asian 5 A level or above Married Retired 33.4
P23 Kingston Group 0 66 Male White 5 A level or above Married Employed 36.6
2B
P24 Southwark Individual 0 74 Male White 3 A level or above Cohabiting Employed 21.2
P25 Merton Group 1 71 Male Asian 4 A level or above Married Retired 32.6
P26 Sutton Group 0 63 Male White 5 A level or above Divorced Employed 22.8
A level, Advanced level; GCSE, General Certificate of Secondary Education; O level, Ordinary level; P, participant.
a Excluding session 0.
b Calculated from the IMD 2015 score (1 is most deprived).111
D
O
I:10.3310/hta23690
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.69
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.
This
w
ork
w
as
produced
by
Ism
ailet
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
141

Appendix 6 Health-care professional feedback
topic guides
Healthy lifestyle facilitator interview topic guides
**Some content has not been reproduced here**
Training
You attended the training and supervision at King’s.
l What were your views on the supervision?
l Can you tell me any ways in which you think the supervision could have been improved?
l Have you had any previous supervision in facilitating psychological therapies?
Supervision
l What are your views about the supervision you received throughout the study?
l What are your views about the support you received from the research team in general?
l How did other members of staff at your practice feel about you taking part in the study?
¢ Were they supportive/not supportive? How so?
l What would have made it easier for you to participate?
Intervention
Now I’d like to ask you about delivering the intervention.
l What went well, could you give me some examples?
l What went less well?
l How did you find the sessions with patients?
¢ How did you find the length of the sessions?
l What are your views about the admin time involved in the study?
Self-awareness
l How confident did you feel about delivering the group intervention?
l How confident did you feel delivering the individual intervention?
l How confident did you feel about managing the caseload?
Patients
l Can you tell me about any difficulties you experienced in getting patients to attend the sessions?
¢ Was there any difference in response between the individual and group sessions?
¢ Which method (group or individual) do you feel is more effective?
¢ Did you book the patients in yourself?
l What were the challenges that you faced in using CBT skills with these patients?
l What other challenges were there when delivering the intervention?
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Clinical psychologist interview topic guides
Training
You delivered the training and supervision to the HLFs.
l What were your views on the supervision?
¢ HLF engagement?
¢ Frequency?
¢ Length?
l Can you tell me about any problems you experienced with the supervision?
¢ What would have made it easier for you?
¢ What were the challenges that you faced when teaching CBT skills to the HLFs?
l Can you tell me any ways in which you think the supervision could have been improved?
l Have you had any previous experience in facilitating psychological therapies?
l What are your views about the support you received from the trial manager and your team (NDZ)
in general?
¢ Were they supportive/not supportive? How so?
¢ What would have made it easier for you to participate more?
Supervision (fortnightly)
What are your views about the supervision you have delivered throughout the study?
l Can you tell me about any difficulties you experienced in getting HLFs to attend the supervision?
l Do the HLFs find it useful/helpful?
l Have you had any negative feedback about the supervision from the HLFs, if so could you give me
some examples?
l Have you had any positive feedback about the supervision from the HLFs, if so could you give me
some examples?
Intervention
Now I’d like to ask you about your views on delivery of the intervention. You sometimes shadow the HLFs
at their surgeries, from your perspective:
l What goes well, could you give me some examples?
l What goes less well, could you give me some examples?
l What are your views about the HLF admin time involved in the study?
l Which method (group or individual) do you feel is more effective?
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